<?xml version="1.0"?>
<!DOCTYPE pmc-articleset PUBLIC "-//PMC//DTD ARTICLE SET 2.0//EN" "http://www.pubmedcentral.nih.gov/pmcdoc/dtd/nlm_lib/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset>

<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><!--The publisher of this article does not allow downloading of the full text in XML form.--><?properties manuscript?><?origin nihpa?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">9107782</journal-id><journal-id journal-id-type="pubmed-jr-id">8548</journal-id><journal-id journal-id-type="nlm-ta">Curr Biol</journal-id><journal-title>Current biology : CB</journal-title><issn pub-type="ppub">0960-9822</issn><issn pub-type="epub">1879-0445</issn></journal-meta><article-meta><article-id pub-id-type="pmc">2730174</article-id><article-id pub-id-type="pmid">19559617</article-id><article-id pub-id-type="manuscript">nihpa124328</article-id><article-id pub-id-type="doi">10.1016/j.cub.2009.05.062</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Synergistic interactions of red and blue light in the control of Arabidopsis gene expression and development</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sellaro</surname><given-names>Romina</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hoecker</surname><given-names>Ute</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yanovsky</surname><given-names>Marcelo</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chory</surname><given-names>Joanne</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Casal</surname><given-names>Jorge J.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>IFEVA, Facultad de Agronom&#x000ed;a, Universidad de Buenos Aires, and CONICET, Av. San Mart&#x000ed;n 4453, 1417-Buenos Aires, Argentina.</aff><aff id="A2"><label>2</label>Botanical Institute, University of Cologne, D-50931 Koeln, Germany</aff><aff id="A3"><label>3</label>Plant Biology Laboratory and Howard Hughes Medical Institute, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA</aff><author-notes><corresp id="cor1"><label>*</label>Correspondence: <email>casal@ifeva.edu.ar</email>, Fax: 5411- 4514-8730</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>9</day><month>7</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>25</day><month>6</month><year>2009</year></pub-date><pub-date pub-type="ppub"><day>28</day><month>7</month><year>2009</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>7</month><year>2010</year></pub-date><volume>19</volume><issue>14</issue><fpage>1216</fpage><lpage>1220</lpage><permissions><copyright-statement>&#x000a9; 2009 Elsevier Inc. All rights reserved.</copyright-statement><copyright-year>2009</copyright-year></permissions><abstract><title>Summary</title><p id="P1">The synergism between red and blue light in the control of plant growth and development [<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R2">2</xref>] requires the co-action of the red/far-red light photoreceptor phytochrome B (phyB) and the blue/UV-A receptors, cryptochromes (cry) [<xref ref-type="bibr" rid="R3">3</xref>]. Here we describe the mechanism for the co-action of these photoreceptors in controlling both development and physiology. In seedlings grown under red light, a transient supplement with blue light induced persistent changes in the transcriptome and growth patterns. Blue light enhanced the expression of the transcription factors <italic>LONG HYPOCOTYL 5 (HY5)</italic> and <italic>HOMOLOG OF HY5</italic> (<italic>HYH</italic>) [<xref ref-type="bibr" rid="R4">4</xref>] and of <italic>SUPPRESSOR OF PHYA 1</italic> (<italic>SPA1</italic>) and <italic>SPA4</italic> [<xref ref-type="bibr" rid="R5">5</xref>]. HY5 and HYH enhanced phyB signalling output beyond the duration of the blue-light signal and, contrary to their known role as repressors of phyA signalling [<xref ref-type="bibr" rid="R5">5</xref>], SPA1 and SPA4 also enhanced phyB signalling. These observations demonstrate that the mechanism of synergism involves the promotion by cry of positive regulators of phyB signalling. The persistence of the light-derived signal into the night commits the seedling to a morphogenetic and physiological program consistent with a photosynthetic lifestyle.</p></abstract><contract-num rid="TW1">R03 TW006836-03</contract-num><contract-num rid="TW1">R03 TW006836-02</contract-num><contract-num rid="TW1">R03 TW006836-01A1</contract-num><contract-sponsor id="TW1">Fogarty International Center : FIC</contract-sponsor></article-meta></front></article>





<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Inform</journal-id><journal-id journal-id-type="publisher-id">101258149</journal-id><journal-title-group><journal-title>Cancer Informatics</journal-title></journal-title-group><issn pub-type="epub">1176-9351</issn><publisher><publisher-name>Libertas Academica</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">2730175</article-id><article-id pub-id-type="pmid">19718446</article-id><article-id pub-id-type="publisher-id">cin-2009-217</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>New Advanced Technologies to Provide Decentralised and Secure Access to Medical Records: Case Studies in Oncology</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Quantin</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="af1-cin-2009-217">1</xref></contrib><contrib contrib-type="author"><name><surname>Coatrieux</surname><given-names>Gouenou</given-names></name><xref ref-type="aff" rid="af2-cin-2009-217">2</xref></contrib><contrib contrib-type="author"><name><surname>Allaert</surname><given-names>Fran&#x000e7;ois Andr&#x000e9;</given-names></name><xref ref-type="aff" rid="af3-cin-2009-217">3</xref></contrib><contrib contrib-type="author"><name><surname>Fassa</surname><given-names>Maniane</given-names></name><xref ref-type="aff" rid="af1-cin-2009-217">1</xref></contrib><contrib contrib-type="author"><name><surname>Bourquard</surname><given-names>Karima</given-names></name><xref ref-type="aff" rid="af4-cin-2009-217">4</xref></contrib><contrib contrib-type="author"><name><surname>Boire</surname><given-names>Jean-Yves</given-names></name><xref ref-type="aff" rid="af5-cin-2009-217">5</xref></contrib><contrib contrib-type="author"><name><surname>de Vlieger</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="af5-cin-2009-217">5</xref><xref ref-type="aff" rid="af6-cin-2009-217">6</xref></contrib><contrib contrib-type="author"><name><surname>Maigne</surname><given-names>Lydia</given-names></name><xref ref-type="aff" rid="af6-cin-2009-217">6</xref></contrib><contrib contrib-type="author"><name><surname>Breton</surname><given-names>Vincent</given-names></name><xref ref-type="aff" rid="af6-cin-2009-217">6</xref></contrib></contrib-group><aff id="af1-cin-2009-217"><label>1</label> Inserm, U866, Dijon, F-21000, France; Univ de Bourgogne, Dijon, F-21000, France; CHRU Dijon, Dpt. of Biostatistics and Medical Informatics, Dijon, F-21000, France</aff><aff id="af2-cin-2009-217"><label>2</label> Institut Telecom; Telecom Bretagne; Unite INSERM 650 Latim, Brest</aff><aff id="af3-cin-2009-217"><label>3</label> Ceren Esc Dijon and Department of Public Health University of Liege</aff><aff id="af4-cin-2009-217"><label>4</label> GMSIH, Paris, France</aff><aff id="af5-cin-2009-217"><label>5</label> ERIM-ERI 14 INSERM, Facult&#x000e9; de M&#x000e9;decine, Clermont Ferrand</aff><aff id="af6-cin-2009-217"><label>6</label> LPC, UMR CNRS-IN2P3 Universit&#x000e9; Blaise Pascal, Clermont Ferrand</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>7</day><month>8</month><year>2009</year></pub-date><volume>7</volume><fpage>217</fpage><lpage>229</lpage><permissions><copyright-statement>&#x000a9; 2009 The authors.</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p><!--CREATIVE COMMONS-->This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>).</license-p></license></permissions><abstract><p>The main problem for health professionals and patients in accessing information is that this information is very often distributed over many medical records and locations. This problem is particularly acute in cancerology because patients may be treated for many years and undergo a variety of examinations. Recent advances in technology make it feasible to gain access to medical records anywhere and anytime, allowing the physician or the patient to gather information from an &#x0201c;ephemeral electronic patient record&#x0201d;. However, this easy access to data is accompanied by the requirement for improved security (confidentiality, traceability, integrity, ...) and this issue needs to be addressed. In this paper we propose and discuss a decentralised approach based on recent advances in information sharing and protection: Grid technologies and watermarking methodologies. The potential impact of these technologies for oncology is illustrated by the examples of two experimental cases: a cancer surveillance network and a radiotherapy treatment plan. It is expected that the proposed approach will constitute the basis of a future secure &#x0201c;google-like&#x0201d; access to medical records.</p></abstract><kwd-group><kwd>data security</kwd><kwd>electronic signature</kwd><kwd>direct access</kwd><kwd>medical record</kwd><kwd>patient identifier</kwd><kwd>watermarking</kwd><kwd>grid</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>1. Introduction</title><p>Throughout Europe, patients are entitled to have direct access to their medical records. For example, in France, this has been true since 2002; previously, only indirect access via a physician was allowed. At present, the simplest solution consists in giving to the patient a paper copy of his/her medical record or, if it has been computerized and if the function is available, a digital copy on a readable storage medium. This communication process can be carried out &#x0201c;without constraint at reasonable intervals and without excessive delay or expense&#x0201d; as required by article 12 of the Directive &#x0201c;On the Protection of Individuals with regard to the Processing of Personal Data and on the Free Movement of Such Data&#x0201d;.<xref ref-type="bibr" rid="b1-cin-2009-217">1</xref> Such a delay is needed, however, to ensure that the identity of the individual making the request can be properly checked and that any additional conditions on access, such as those provided for in article 13 section 1(g) of the same directive<xref ref-type="bibr" rid="b1-cin-2009-217">1</xref> &#x0201c;for the protection of the Data Subject or the rights and freedoms of others&#x0201d;, are correctly fulfilled. This current approach does not involve any particular risk to the information system, but there are already pressing demands from patients with their increasingly powerful computing facilities to speed up these processes and to have direct access to medical record systems. These pressures will be difficult to resist in the present, fast moving, electronic environment, and it is difficult to imagine that the traditional, delayed, process will be accepted for much longer. Soon, patients will be expecting to have direct access to their medical files via the internet or its equivalent. Instead of trying to resist this inescapable evolution, it is preferable to seek solutions that provide security for both patients and health professionals while allowing this valuable development in the area of personal freedom and human rights.</p><p>However, one on the main problems of direct access is that patient&#x02019;s medical records, especially in oncology (as several health practitioners of different specialties have to participate in patient care), may be split into different parts and recorded in the information system of different healthcare centres. It is not reasonable to expect patients suffering from cancer to deal with the dispersion of their medical information themselves; they should be provided with a secure way to consult it.</p><p>For more than 20 years, Research and Development teams have been working on standardised, centralised, secure and reliable Medical Record (MR) systems. The French DMP project to implement personal MRs for each patient that are accessible to the patient is an illustrative example.<xref ref-type="bibr" rid="b2-cin-2009-217">2</xref> The DMP has raised many difficulties regarding ethical and legal aspects, the definition of a common identifier and the creation of a central storage system for all records. As far as we are aware no country has managed to reach these goals at a national level. An alternative is to develop a strategy based on a pragmatic, secure, distributed, unstructured MR system which could be operational in the very short term. This article promotes a non-centralised and non-standardised MR system based on original search and access to distributed medical data like the one that exists in Israel (Clalit HMO and government hospitals), Pittsburgh (Pennsylvania&#x02014;UPMC) [1] and is being implemented in Brussels (IRIS hospitals)<xref ref-type="bibr" rid="b3-cin-2009-217">3</xref> and Franche Comte, France (EMOSYST).<xref ref-type="bibr" rid="b4-cin-2009-217">4</xref></p><p>Grid technology, which has evolved quickly over the last 10 years, has enabled such an MR system. Today, it has reached a level of maturity in the field of distributed computing and data management, which makes it a natural choice to handle distributed medical data. It allows distributed data sources to be brought together, to be queried remotely and on demand, which mobilizes large CPU (Central Processing Unit) resources to analyse them.</p><p>In this paper, we discuss opportunities provided by grid technology to enable secure access to medical records through a google-like interface providing professionals and patients with permanent access to their medical information wherever it has been stored. The advantage of grid technology compared with other existing methods is that no movement of data is needed as they are queried where they are produced. We also discuss security issues beyond information access control (e.g. users&#x02019; authentication and assessments of users&#x02019; rights) and focus on the need to trace distributed data in order to know where they have come from, to know the last user to consult them and to make sure the data have not been damaged or tampered with. For this purpose, watermarking technologies provide a new way to protect data without interfering with the medical practice.</p><p>The paper is organized as follows:</p><list list-type="simple"><list-item><p>&#x02013; in section 2, we describe a proposal for a secure access to medical records through a &#x0201c;google-like&#x0201d; interface.</p></list-item><list-item><p>&#x02013; in section 3, we present grid technology in more detail and provide examples of how it is being used currently to address specific medical needs in oncology.</p></list-item><list-item><p>&#x02013; in section 4, we discuss a number of issues to be addressed to enable the proposed access to medical records.</p></list-item><list-item><p>&#x02013; section 5 provides a conclusion and some perspectives.</p></list-item></list></sec><sec><title>2. Proposal for a Secure &#x000ab; Google Like &#x000bb; Access</title><p>Today, the main problem for health professionals or patients who want to have full access to medical information, particularly in oncology, is that this information is very often spread over many medical records kept by different health structures or professionals. Therefore, it would be convenient for the patient suffering from cancer, after identification and authentication, to be able to use a medical search engine to gain access to the medical information that has been selected by the medical practitioner (i.e. suitable for viewing by the patient) wherever it has been stored. The patient can also authorize other medical practitioners (for example if they meet for the first time) to consult his/her information.</p><p>First, generally speaking, in industrialised countries each health-care structure whatever the type (public or private) has an information system that gathers structured or unstructured computerised medical records. Secondly, information contained in the routine daily MR is sufficient for the needs of health professionals. Thus, the additional work a doctor needs to do to reconstitute a patient&#x02019;s medical history (MH) is limited even if the patient frequently consults in different places, as is the case in cancerology. Doctors therefore have this extra workload only occasionally. Given the two previous points, and the dangers and complexity of a centralised system, it seems reasonable to us to set up a system that allows each doctor, once the consent of the patient has been obtained, to collect information on that patient from the different health structures. The doctor will then have to synthesise the patient&#x02019;s MH for his personal use, save it in his personal information system site, and update it regularly. This effort to synthesise MRs will be reduced because one doctor can pass on information about his patients to other doctors in case the patient moves. For example, the General Practitioner could summarize the patient&#x02019;s MH which could be accessed by his/her colleagues when necessary, and with the patient&#x02019;s consent.</p><p>The main organisational advantage is that it could be operational rapidly because problems of harmonisation will be reduced and information will be more secure. The decentralised management principle supposes that the saved MR will remain in its unmodified form in terms of content and structure in hospitals and clinics, and will remain identifiable by certain elements that exist in all patients&#x02019; MRs such as first names, last names and dates of birth, and require no complementary indexation. When patients or doctors want to gain access to medical data that are distributed among the servers of various hospitals or clinics, they have to be connected to an electronic server on which they identify themselves. In the case of access by a doctor, at the first connection, the patient must be present so as to give his/her consent. This first connection will be made using the doctor&#x02019;s professional card with a password. In the future, authentication could be ensured by using a professional identity or national identity card based on cryptographic methods. The system would transform the patient&#x02019;s identity using a cryptographic algorithm. The aim of this algorithm is to obtain a strictly anonymous code, but always the same one for a given individual in order to link all the information concerning the same patient. It would not be possible for the management system to read directly in the memories of the local information system. All of the information would be gathered at the level of the decentralised management system which transfers it to the doctor. The interest of this approach is that it protects the confidentiality of the patient&#x02019;s identity, particularly during transfer in the network. Only encrypted medical information would be moved. However, to go further about data security, questions must be answered on how to verify that information is reliable and on how to trace data after several copies have been made or when the data come from outside the system. Data reliability relies on proof of information integrity, of its origins and that it belongs to one patient. Though most standards provide for such proof for one transmission, continuity of protection through several transactions is not guaranteed. Hackers who disrupt the confidentiality chain have to be identified and prosecuted.</p></sec><sec sec-type="methods"><title>3. Grid Technology for Distributed Medical Data Management</title><p>Providing patients with &#x0201c;google-like&#x0201d; secure access to their medical records requires the information to be available for querying and retrieval. Google is able to query and search for any data published on the Internet. However, it will be absolutely necessary to ensure the security of this Internet environment before storing any medical data on it. An alternative is provided by grid technology which allows distributed data to be queried securely according to personal access rights. Grids are defined as fully distributed, dynamically reconfigurable, scalable and autonomous infrastructures to provide location independent, pervasive, reliable, secure and efficient access to a coordinated set of services encapsulating and virtualising resource. Their relevance for managing medical information has been investigated within the framework of the HealthGrid initiative.<xref ref-type="bibr" rid="b5-cin-2009-217">5</xref>&#x02013;<xref ref-type="bibr" rid="b8-cin-2009-217">8</xref> Some platforms in medical data management,<xref ref-type="bibr" rid="b9-cin-2009-217">9</xref> management of paediatric data<xref ref-type="bibr" rid="b10-cin-2009-217">10</xref> or medical radiography data<xref ref-type="bibr" rid="b11-cin-2009-217">11</xref> already benefit from grid technologies to manage medical data securely thanks to dedicated grid middleware services such as MDM<xref ref-type="bibr" rid="b8-cin-2009-217">8</xref> or Globus Medicus.<xref ref-type="bibr" rid="b9-cin-2009-217">9</xref> The use of grids overcomes the difficulties inherent in a centralized storage system, especially high cost and complexity. Grids also make it possible to store data where or very close to where they are produced. Through grid authentication, authorization and accounting, only duly authorized persons can gain access to data which are encrypted and made anonymous when they are transmitted.<xref ref-type="bibr" rid="b12-cin-2009-217">12</xref></p><p>Well-identified areas of relevance of the grid paradigm are epidemiology and computer-intensive analysis of geographically distributed medical images. Epidemiology focused on population-level research requires access to distributed, critically sensitive and heterogeneous data, resulting in overall costly computing processes. Users ought to be able to take it for granted that the security mechanisms are sufficient to protect their data; that the results of their research will be private and available to third parties only if designated; that the system will meet the concerns of the ethical and legal committees of their research institutions; that the services are reliable, efficient and permanent; that they do not have to change significantly their current procedures; protocols or workflow, and finally that the data is somehow automatically organised and gathered, and thus available for further exploitation. Early attempts at epidemiological applications of grids<xref ref-type="bibr" rid="b13-cin-2009-217">13</xref> have demonstrated their relevance for patient customized research. In the next chapter, we will present an epidemiological application of grids for cancer surveillance which is currently being used in France.</p><p>Another attractive field of application for grid technology is computer-intensive analysis of distributed medical images. The impact of grid technology comes from the secure management of distributed images together with the capacity to gain access to large computing resources on demand to analyze them. In the field of oncology, the use of Computer-Aided Detection (CAD) for the analysis of mammograms was addressed by the MammoGrid project as early as 2005.<xref ref-type="bibr" rid="b11-cin-2009-217">11</xref> Other efforts focus on using grid computing resources to plan radiotherapy treatment:<xref ref-type="bibr" rid="b14-cin-2009-217">14</xref> a case of the use of this technology currently exploited in collaboration with a French Cancer Treatment Centre will be further documented in chapter 4.</p><sec sec-type="methods"><title>3.1. Case study 1: cancer surveillance network</title><p>Cancer screening programs aim at the early detection of the malignant tumors in order to improve the prognosis. Most EU countries have launched a national program for breast cancer screening.<xref ref-type="bibr" rid="b15-cin-2009-217">15</xref> In France, when a woman is positively diagnosed with a risk of tumour, cancer associations are responsible for providing a second diagnosis on the mammograms and have to follow-up the pathology data about the tumour, which are stored by the laboratories. At present, the patient&#x02019;s data are faxed on request or carried physically by the patient to the associations where they are recorded again. This process is costly and error prone as data has to be typed and reinterpreted twice.</p><p>The cytopathology data are also relevant for epidemiological analysis. The INVS (Sanitary Surveillance Institute), the French equivalent of the (E)CDC in the USA, is in charge of publishing indicators about global health and particularly about cancer. To produce its indicators, the INVS relies on regional cancer registries (CRISAPs) set up to collect relevant information to support statistical and epidemiological studies about cancer incidence, mortality, prevalence or screening. CRISAPs (Centre de Regroupement Informatique et Statistique en Anatomie et cytologie Pathologiques) are like regional data warehouses collecting anonymous data from pathology laboratories or from healthcare establishments involved in cancer treatment. Healthcare professionals in laboratories are reluctant to release data because of cost and also because they lose some control over the data they have produced.</p><p>An alternative is for clients to query databases of the pathology laboratories. A grid, federating the laboratories, (see <xref ref-type="fig" rid="f1-cin-2009-217">Fig. 1</xref>) would provide a secure framework enabling the screening associations to query databases and fill their local patient files.<xref ref-type="bibr" rid="b16-cin-2009-217">16</xref> No action is required by physicians to put their data on the network. Thanks to the grid security architecture, the cytopathologists are able to define and modify the access rights of the users querying their data.</p><p>Several projects in Europe have studied or are currently exploring the advantages of grid technology with regard to breast cancer, particularly computer-aided diagnosis of mammograms (e-Diamond<xref ref-type="bibr" rid="b17-cin-2009-217">17</xref> and MammoGrid projects).<xref ref-type="bibr" rid="b11-cin-2009-217">11</xref></p><p>If a sentinel network is able to federate pathology databases, it can be used by the epidemiological services of the National Institute for Health Surveillance (Institut National de Veille Sanitaire) and the regional epidemiological observatory.</p><p>In the present case, it means that women could consult their own data in the pathology laboratories as well as see mammographic images stored in the radiology services through the proposed network.</p><p>A cancer surveillance network is presently being implemented in the Auvergne region in France within the framework of the AuverGrid regional grid initiative (<ext-link ext-link-type="uri" xlink:href="http://www.auvergrid.fr">http://www.auvergrid.fr</ext-link>) using grid technology developed by the EGEE<xref ref-type="bibr" rid="b18-cin-2009-217">18</xref> (AMGA metadata catalogue<xref ref-type="bibr" rid="b19-cin-2009-217">19</xref> and MDM Medical Data Manager<xref ref-type="bibr" rid="b8-cin-2009-217">8</xref> and Health-e-Child projects<xref ref-type="bibr" rid="b20-cin-2009-217">20</xref> (Pandora Gateway).</p></sec><sec sec-type="methods"><title>3.2. Case study 2: application to radiotherapy</title><p>Radiotherapy is one of the three major treatments for cancer. It has demonstrated its efficacy in curing cancer and is also the most cost effective strategy. From a technology point of view, radiotherapy is a highly complex procedure, involving many computational operations for data gathering, processing and control. The treatment process requires large amounts of data from different sources that vary in nature (physics, mathematics, biostatistics, biology and medicine), which makes it an ideal candidate for healthgrid applications.</p><p>Nowadays, in radiotherapy and brachytherapy, commercial treatment planning systems (TPS), use an analytical calculation to determine dose distributions near the tumor and organs at risk. Such codes are very fast (execution time below one minute to give the dose distribution of a treatment), which makes them suitable for use in medical centres. For some specific treatments using very thin pencil beams (IMRT) and/or in the presence of heterogeneous tissues such as the air-tissue, lung-tissue and bone-tissue interfaces, it appears that Monte Carlo simulations are the best way to compute complex cancer treatment by keeping errors in the dose calculation below 2%. The accuracy of Monte Carlo (MC) dose computation is excellent, provided that the computing power is sufficient to allow for extreme reduction of statistical noise. In order to finish MC computations within an acceptable time period for interactive use, parallel computing over very many CPUs has to be available. In this way, MC dose computations could become standard for radiotherapy quality assurance, planning and plan optimisation years before individual departments could afford local investment that is able to support MC.</p><p>With the objective of making Monte Carlo dose computations the standard method for radiotherapy quality assurance, planning and plan optimisation, we are participating in the development of a Monte Carlo platform dedicated to SPECT, TEP, radiotherapy and brachytherapy simulations together with 21 other research laboratories which are involved in the international collaboration OpenGATE (<ext-link ext-link-type="uri" xlink:href="http://www.opengatecollaboration.org">http://www.opengatecollaboration.org</ext-link>).<xref ref-type="bibr" rid="b21-cin-2009-217">21</xref> This GATE software with its accuracy and flexibility was made available to the public in 2004 and now has a community of over 1000 users worldwide. The limiting issue of GATE right now is its time consuming simulations for modelling realistic scans or treatment planning.</p><p>A secured web platform enabling medical physicists and physicians to use grid technology to compute treatment planning using GATE Monte Carlo simulations and share medical data has been developed. This platform, named HOPE (Hospital Platform for E-health),<xref ref-type="bibr" rid="b22-cin-2009-217">22</xref> provides quick, secure and easy to use tools to physicians or medical physicists to perform treatment planning on the Grid infrastructure. When the user is logged in, he/she has the possibility to upload or access medical data located on the hospital&#x02019;s PACS (Picture Archiving and Communication System) server In the case of medical imaging for radiotherapy, the metadata server (AMGA)<xref ref-type="bibr" rid="b19-cin-2009-217">19</xref> services located at the hospital collect metadata as attributes like the name of the patient, the characteristics of the disease, etc. SSL (Secure Socket Layer) connections in addition to encryption systems are used for the transfer of data. Authentication using ACLs (Access Control Lists) are used for the access to metadata in the database. The metadata server provides a replication layer which makes databases locally available to user jobs and replicates the changes between the different participating databases.</p><p>Information contained in electronic patient sheets is also registered as parameters in the metadata server. The anonymized medical images are registered on the grid. GridFTP (File Transfer Protocol) is used to enable advanced security transfers. Medical images are associated with patient sheets and the user can automatically visualize them.</p><p>By visualizing the tumour, the physician can choose what kind of device is the most appropriate to treat the patient using ionizing particles (field size, type of particle, energy, brachytherapy sources, ...). The treatment plans can be directly visualized from the HOPE portal and downloaded onto the personal computer of the user.</p><p>The web portal offers to the user a transparent and secure way to create, submit and manage GATE simulations using realistic scans in a grid environment. The conviviality of the web portal and the Grid performances could make it possible, in the near future, to use Monte Carlo simulations from clinical centres or hospitals to treat patients in routine clinical practice for specific radiotherapy treatments. In addition, the web platform functionalities enable direct access to medical data (patient sheets, images...) and secure sharing between two users located in different hospitals.</p></sec></sec><sec><title>4. Conditions of Implementation</title><p>In the previous section, we have shown how grid technology could provide the services needed to handle and analyze distributed medical data and images securely. In this section, we discuss additional issues that need to be addressed in order to implement the proposed &#x0201c;Google Like&#x0201d; access to medical records.</p><sec><title>4.1. The implication of assembling medical records in a grid environment: towards an Ephemeral Electronic Health Record (E-EHR)</title><p>Storing all heath information in one place was the dream of centralisation proponents, who were certain that it was the only way to deal with the complexity. However, for many years, the public authorities have understood the danger of a centralised system, notably the considerable risk of losing all of the data if the centralised organisation is destroyed. After realising the weaknesses of a centralised system, the USA ministry of defence created in 1969 the ARPANET, a network system that would continue to function in the case of a catastrophe. Considering health data, hackers may see a centralised system as a challenge and try to gain access to the central patient MR system and modify patients&#x02019; medical information. Moreover a centralised information system may discourage doctors from providing health information; they may feel less responsible for the information than they do when they hold the information themselves. It may also be difficult for a centralised system to manage and store the huge quantity of information generated. Moreover, any breakdown, however short it may be, would have considerable repercussions given the number of people managed. It would be then safer to store information in different places to ensure protection and privacy.</p><p>As a consequence, our proposal for a secure system that allows the patient to gather the different parts of his medical record which may be spread in different healthcare systems may provide an interesting &#x000ab; alternative &#x000bb; to the classical proposal of a centralized medical record. With such a system, during the consultation, the oncologist will have the complete history of the patient thanks to the documents that the medical practitioner has declared as communicable and validated.</p><p>It is important to underline the fact that in such a system the medical information of the patients stays in the different hospital or practitioner information systems under the responsibility of the hospital or of the practitioner. This provides better guarantees against attacks than does a centralized system. Moreover, information will be provided to other medical practitioners directly by the patients by transferring the right of access to the practitioner.</p></sec><sec sec-type="subjects"><title>4.2. Authentication of patients and health professionals before access to medical records on line</title><p>Direct access to medical files via electronic media gives rise to many difficulties, and very strict access control and authentication measures are therefore essential, particularly in oncology. The principal difficulty in this field is to ensure that only the holder of the access rights will be able to gain access to the Personal Data.</p><p>A brief consideration of the risks associated with unlawful access to Medical Record systems for patients and for healthcare organizations makes it clear that a very reliable authentication system will be required before allowing any public access to such systems. The traditional approach for the authentication of individuals has two components: assertion of identity, followed by proof of the identity.<xref ref-type="bibr" rid="b1-cin-2009-217">1</xref> Generally, this proof can be in terms of something that the individual knows or something that the individual has or something that the individual is. Technical solutions are available to cover any degree of proof in authenticating individuals, but many of them would require a substantial organization system to be set up before they could become effective.</p><p>Biometric technologies are sometimes proposed as a way to associate a patient with his or her medical data, as they do not require the patient to bring any documents or remember any information. Though this technology represents real progress both in the identification and in the authentication of the patient, there are still many questions<xref ref-type="bibr" rid="b4-cin-2009-217">4</xref> regarding the accuracy and reliability of each biometric technology and the associated costs. But the main problem lies in the acceptability of such systems by organizations concerned with ethical considerations such as patients&#x02019; associations, national ethics committees, human rights associations, and national committees for data protection. For example, in France, the use of biometric solutions for identification in the field of health has not been approved by the National Ethics Committee.</p><p>Even today, after extensive computerization of Medical Record systems, the simplest and most common authentication mechanism is still that of an &#x0201c;Identifier&#x0201d; together with a &#x0201c;Password&#x0201d;. This approach combines simplicity of use and management, but it is the weakest and the most unsatisfactory mechanism.<xref ref-type="bibr" rid="b23-cin-2009-217">23</xref> The most satisfactory approach would lie in the creation of an individual chip card including electronic signature cryptographic algorithms,<xref ref-type="bibr" rid="b24-cin-2009-217">24</xref> both for patients and health professionals. Generated signatures will have the value of legal proof in front of a court, as they are legally recognised, and would provide access follow up. It must be noticed that the availability of such a chip card will take some time and will generate considerable expenditure before becoming the accepted standard. As this more satisfactory electronic solution cannot be implemented now and everywhere, only inferior less safe solutions can be considered.</p><p>A possible solution is a smart card,<xref ref-type="bibr" rid="b25-cin-2009-217">25</xref>&#x02013;<xref ref-type="bibr" rid="b27-cin-2009-217">27</xref> associated with the provision of a secret PIN code with 8 characters, like the one proposed for use in France for the DMP project. This solution would require hospitals to be equipped with powerful firewall-type data-processing devices to filter access. In such a system, patients provide a list of medical practitioners who are authorized to have permanent access to their medical data. The access rights given to the medical practitioners can be erased at any time by the patient (for example, if he/she moves to another town), who can also authorize temporary access for other medical practitioners he/she has to consult.</p><p>In emergency cases, when the patient is unable to express his/her will, the easiest solution is to provide access through a specific procedure (breaking the glass procedure), under the responsibility of the medical practitioner in charge of the patient, with immediate notification to an official security supervisor. This partial solution represents a compromise between security rules and the patient&#x02019;s health care and ensures that collected data are made available when necessary. It is a general principle of penal law to consider that citizens generally act in accordance with social rules and that penalties are imposed as a deterrent and to punish those who break the law.</p><p>Medical records transmitted to patients must be electronically signed by the practitioner to be sure that he/she has agreed to this transfer and that no unauthorized modifications have been made, which is essential in oncology, particularly for pathological descriptions of the disease. Here also, the recognition of the legal value of the electronic signature permits controlled electronic transmission of the medical record to the patient. This electronic signature also makes it possible to ensure that any modifications of the medical record, for example, adding new medical information, are made by the medical practitioner. However, such signatures are ancillary data that can be easily removed.</p></sec><sec sec-type="methods"><title>4.3. Verifiying data reliability and tracing outsourced data</title><p>As stated previously in section 1, questions arise about how to trace information and verify its reliability. For example, once data are decrypted, they are not protected any more; they can be copied exactly, routed away from the initial use, tampered with, and so on.</p><p>Recently, watermarking has been proposed for the protection of medical information.<xref ref-type="bibr" rid="b28-cin-2009-217">28</xref> Basically, watermarking is defined as the invisible embedding or insertion of a message in a host document, for example an image, like XML structured data. Watermarking provides an original way to share a document with some ancillary data like protection data or meta-data, in a way that is a priori independent of the information file storage format. For example, with regard to images, security elements are introduced in the signal by imperceptible modification. Watermarked data thus remain attached at the signal level independently of the image file format. It means that embedded data can be recovered after file format conversion; for example, conversion which occurs when data are outsourced from the system or when they have been screen captured.</p><p>Most of the work on watermarking for medical images has been related to the need to verify image integrity (embedding a digital signature inf the image) or improve confidentiality,<xref ref-type="bibr" rid="b28-cin-2009-217">28</xref> as it is often considered that embedding information makes it more difficult for unauthorized persons to gain access to this information. Watermarking is complementary to other security mechanisms. It gives access to a kind of communication channel that is transparent to non-compliant systems, as it does not add extra-header information, while compliant systems will be able to read embedded data.</p><p>In the considered framework, before an isolated medical document can be accessed or shared it has to be identified. A watermarked authentication code may allow identification of the health professional who consulted the patient data for the purpose of traceability, or the identification of the patient. To go further, if the embedded identity is rendered anonymous,<xref ref-type="bibr" rid="b29-cin-2009-217">29</xref> then it is possible to gain access to and to link information concerning the same patient without knowing his or her identity so as to guarantee both privacy and interoperability. These patient privacy issues may appear during the verification process, which is necessary to reduce the risk of errors when identifying documents in everyday practice or when sending a patient&#x02019;s Electronic Health Record. For example, the verifier may be able to gain access to patient data without authorization. This method may also provide a solution to the problem of the identification of lost medical documents. However, further research and development are necessary to extend watermarking methodology to text.</p></sec><sec><title>4.4. Integration profiles and standards</title><p>In the last few years, access to medical data in a distributed or centralized model has been the object of several studies which led to the specification of integration profiles.<xref ref-type="bibr" rid="b30-cin-2009-217">30</xref> Several EHRs projects based on these integration profiles are currently in progress. The main profiles that support the EHRs system are the following:</p><list list-type="bullet"><list-item><p>The integration profile XDS (cross referencing document sharing) which defines a communication infrastructure based on metadata and using structured (based on standards such as HL7 CDAv2 for documents and DICOM for images) or unstructured data (pdf documents);</p></list-item><list-item><p>PIX (patient identity cross referencing) and PDQ (patient demographic query) profiles for management of the identity of the patient, which defines how to link the identity of the patient when registered in different organizations or domains);</p></list-item><list-item><p>BPPC profile for patient consent, which defines the rights attached to a document</p></list-item><list-item><p>And other security profiles such as ATNA profiles for security of nodes and audit trails.</p></list-item></list></sec><sec><title>4.5. <italic>Technology against ethics</italic> and <italic>law: the limits of liability</italic></title><p>Even though watermarking methodology allows us to solve the most important part of the problem concerning secure access of the patient to his or her medical record by embedding a strong identification marker in the document, two main dangers still exist. The first lies in the fact that this process of &#x0201c;automatic&#x0201d; access is not accompanied by any medical explanation and even more importantly, there will be no medical warning about the contents that the patient will read. It is by no means certain that providing patients with routine direct access to their medical records automatically extracted from the database is a very satisfactory solution from a medical point of view. If the medical records contain information (like the diagnosis of the cancer) which may cause serious psychological distress (possibly leading to suicide), the hospital or the medical practitioner could be held responsible from a legal point of view or at least from an ethical or deontological point of view. In oncology, the contents of the medical record need to be carefully reviewed (updated or validated) before being delivered to patients. In other cases, information contained in a medical record may refer to third persons (in cases of hereditary diseases, or in cases of divorce), and providing access to such information may be considered a breach of confidentiality. Once again, the hospital or the practitioner may be held legally responsible. Therefore, even though providing patients with automatic access to their medical records appears to be satisfactory from a technical and data-security point of view, it may not fulfil the quality requirements for the security of healthcare information. No transmission should be allowed without the consent of the medical practitioner who takes care of the patient, or the practitioner&#x02019;s representative. As the practitioner is legally responsible, his/her formal agreement to the transmission is required, and the transmitted document should be electronically signed by him/her.</p><p>The second point lies in the use of the medical record by the patient. As patients are deemed to be responsible adults, we will not consider the possible unexpected effects of communicating their medical records to their insurance company or bank, which may have required it officially or unofficially. From a medical point of view, the main problem could come from modifications of the medical record by patients themselves to erase information that prevents them from obtaining certain advantages. If such modifications were possible, imagine what could happen if patients erased the fact that they had cancer in order to get a job. Thus, it does not seem desirable to give to everybody direct access to the system that manages the files, even to authenticated users. However, it seems reasonable to verify integrity and authenticity of outsourced data, especially when they are used in a healthcare framework. The original medical record, which is the means to bring evidence in case of litigation, should be protected from any kind of attempt by unauthorised persons to modify the information. It will then be preferable to envisage a request procedure for access, including the search for the file and the extraction of the communicable documents authorized by the law. This approach, in which a special access file is created, could happen much faster than the time delay allowed in some European countries (in the UK the authorities have 40 days to comply with a Subject&#x02019;s Access request, whereas in France, the delay is 8 days).</p></sec></sec><sec><title>5. Conclusion</title><p>The idea that every citizen will have direct access to his medical records anywhere is no longer a utopia, as this situation can be considered the logical outcome of much of the work that is going on world-wide in e-Government, e-Health and e-Shopping. With the constant progress of technology, it is now possible to envisage the possibility of &#x0201c;reassembling&#x0201d; personal health records anywhere and anytime. But security measures need to be much stronger, necessitating mechanisms to provide continuous data protection.</p><p>In this paper we have illustrated the potential of grid technology for medical data record sharing through its use in two experimental cases. The deployment of such technology needs to be coupled with relevant security measures and mechanisms. Strict identity checks for both the patient and healthcare professionals are necessary and can be based on cryptographic techniques as those planned for the electronic signature. They can also be used to ensure the confidentiality and integrity of files, authentication of the applicant&#x02019;s identity and access follow-up. In addition, watermarking technology can provide ultimate protection once access control is bypassed. This would ensure the reliability and traceability of data inside and outside the system. With regard to search engines, who could have imagined ten years ago that a system would be able to retrieve everything you have ever published and list all the people who have made a reference to it in a matter of seconds!</p></sec></body><back><ack><title>Acknowledgements</title><p>This research was supported by The French National Agency for Research (ANR). The authors thank Audrey Bellisario for valuable comments and assistance. The authors thank P. Bouchet, Dr. A. Gaillot, Dr. M-A Grondin, Dr. P. Lonchambon, C. Mestre for valuable inputs to the list of requirements for the cancer surveillance network in the Auvergne region.</p><p>The work described in this article was partly supported by grants from the European Commission (EGEE-III, Embrace), the French Ministry of Research (GWENDIA) and a number of regional authorities (Conseil R&#x000e9;gional d&#x02019;Auvergne, Conseil G&#x000e9;n&#x000e9;ral du Puy-de-D&#x000f4;me, Conseil G&#x000e9;n&#x000e9;ral de l&#x02019;Allier).</p><p>The Enabling Grids for the E-sciencE (EGEE-III) project is co-funded by the European Commission under contract INFSO-RI-031688. The EMBRACE project is co-funded by the European Commission under the thematic area &#x0201c;Life sciences, genomics and biotechnology for health&#x0201d;, contract number LHSG-CT- 2004-512092. Auvergrid is a project funded by the Conseil Regional d&#x02019;Auvergne. The French ministry of Research supports the GWENDIA project.</p></ack><fn-group><fn><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-cin-2009-217"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allaert</surname><given-names>FA</given-names></name><name><surname>Le Teuff</surname><given-names>G</given-names></name><name><surname>Quantin</surname><given-names>C</given-names></name></person-group><article-title>Law and standards faced to market rules in health information security</article-title><source>Stud Health Technol Inform</source><year>2003</year><volume>95</volume><fpage>125</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">14663974</pub-id></mixed-citation></ref><ref id="b2-cin-2009-217"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quantin</surname><given-names>C</given-names></name><name><surname>Guinot</surname><given-names>C</given-names></name><name><surname>Tursz</surname><given-names>A</given-names></name><name><surname>Salomez</surname><given-names>JL</given-names></name><name><surname>Rogier</surname><given-names>C</given-names></name><name><surname>Salamon</surname><given-names>R</given-names></name></person-group><article-title>Le traitement &#x000e9;pid&#x000e9;miologique du Dossier M&#x000e9;dical Personnel au service des malades?</article-title><source>Rev Epid&#x000e9;miol Sant&#x000e9; Publique</source><year>2006</year><comment>n&#x000b0; 2</comment><volume>54</volume><fpage>177</fpage><lpage>84</lpage></mixed-citation></ref><ref id="b3-cin-2009-217"><label>3</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Sood</surname><given-names>SP</given-names></name><name><surname>Nwabueze</surname><given-names>SN</given-names></name><name><surname>Mbarika</surname><given-names>VWA</given-names></name><etal/></person-group><article-title>Electronic Medical Records: A Review Comparing the Challenges in Developed and Developing Countries</article-title><conf-name>Proceedings of Hawaii International Conference on System Sciences</conf-name><year>2008</year><fpage>248</fpage><lpage>57</lpage></mixed-citation></ref><ref id="b4-cin-2009-217"><label>4</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Vaclav</surname><given-names>M</given-names></name><name><surname>Zdenek</surname><given-names>R</given-names></name></person-group><article-title>Biometric authentication systems</article-title><source>A technical report</source><comment>Retrieved April 15, 2006 from ecom-monitor.com web site: <ext-link ext-link-type="uri" xlink:href="http://www.ecom-monitor.com/papers/biometricsTR2000.pdf">http://www.ecom-monitor.com/papers/biometricsTR2000.pdf</ext-link></comment></mixed-citation></ref><ref id="b5-cin-2009-217"><label>5</label><mixed-citation publication-type="confproc"><person-group person-group-type="editor"><name><surname>Breton</surname><given-names>V</given-names></name><name><surname>Dean</surname><given-names>K</given-names></name><name><surname>Solomonides</surname><given-names>T</given-names></name></person-group><collab>on behalf of the Healthgrid White Paper collaboration</collab><article-title>The Healthgrid White Paper</article-title><conf-name>Proceedings of Healthgrid conference, Studies in Health Technology and Informatics</conf-name><publisher-name>IOS Press</publisher-name><year>2005</year><fpage>112</fpage></mixed-citation></ref><ref id="b6-cin-2009-217"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breton</surname><given-names>V</given-names></name><name><surname>Dean</surname><given-names>K</given-names></name><name><surname>Solomonides</surname><given-names>T</given-names></name></person-group><source>The Healthgrid White Paper, Studies in Health Technology and Informatics</source><year>2005</year><volume>112</volume><fpage>249</fpage><lpage>321</lpage></mixed-citation></ref><ref id="b7-cin-2009-217"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olive</surname><given-names>M</given-names></name><name><surname>Rahmouni</surname><given-names>H</given-names></name><name><surname>Solomonides</surname><given-names>T</given-names></name><etal/></person-group><article-title>SHARE, from vision to road map: technical steps</article-title><source>Medinfo</source><year>2007</year><volume>12</volume><issue>Pt 2</issue><fpage>1149</fpage><lpage>53</lpage></mixed-citation></ref><ref id="b8-cin-2009-217"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montagnat</surname><given-names>J</given-names></name><name><surname>Jouvenot</surname><given-names>D</given-names></name><name><surname>Pera</surname><given-names>C</given-names></name><etal/></person-group><article-title>Bridging clinical information systems and grid middleware: a Medical Data Manager</article-title><source>Stud Health Technol Inform</source><year>2006</year><volume>120</volume><fpage>14</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">16823119</pub-id></mixed-citation></ref><ref id="b9-cin-2009-217"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erberich</surname><given-names>SG</given-names></name><name><surname>Silverstein</surname><given-names>JC</given-names></name><name><surname>Chervenak</surname><given-names>A</given-names></name><name><surname>Schuler</surname><given-names>R</given-names></name><name><surname>Nelson</surname><given-names>MD</given-names></name><name><surname>Kesselman</surname><given-names>C</given-names></name></person-group><article-title>Globus MEDICUS&#x02014;federation of DICOM medical imaging devices into healthcare Grids</article-title><source>Stud Health Technol Inform</source><year>2007</year><volume>126</volume><fpage>269</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">17476069</pub-id></mixed-citation></ref><ref id="b10-cin-2009-217"><label>10</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Freund</surname><given-names>J</given-names></name><name><surname>Comaniciu</surname><given-names>D</given-names></name><name><surname>Ioannis</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Health-e-child: an integrated biomedical platform for grid-based paediatrics</article-title><source>Studies in Health Technology Informatics</source><year>2007</year><volume>120</volume><fpage>259</fpage><lpage>70</lpage><conf-name>Proceedings the 4th HealthGrid Int. Conference (HG&#x02019;06)</conf-name><conf-loc>Valencia, Spain</conf-loc></mixed-citation></ref><ref id="b11-cin-2009-217"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>R</given-names></name><name><surname>Solomonides</surname><given-names>T</given-names></name><name><surname>del Frate</surname><given-names>C</given-names></name><etal/></person-group><source>Mammogrid&#x02014;A Prototype Distributed Mammographic Database for Europe Clinical Radiology</source><year>2007</year><month>6</month><volume>62</volume><issue>11</issue><fpage>1044</fpage><lpage>51</lpage></mixed-citation></ref><ref id="b12-cin-2009-217"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammed</surname><given-names>Y</given-names></name><name><surname>Sax</surname><given-names>U</given-names></name><name><surname>Viezens</surname><given-names>F</given-names></name><name><surname>Rienhoff</surname><given-names>O</given-names></name></person-group><article-title>Shortcomings of current grid middlewares regarding privacy in HealthGrids</article-title><source>Stud Health Technol Inform</source><year>2007</year><volume>126</volume><fpage>322</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17476075</pub-id></mixed-citation></ref><ref id="b13-cin-2009-217"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanquer</surname><given-names>I</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>V</given-names></name></person-group><article-title>The Grid as a Healthcare Provision Tool</article-title><source>Methods of Information in Medicine</source><year>2005</year><volume>44</volume><fpage>144</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15924164</pub-id></mixed-citation></ref><ref id="b14-cin-2009-217"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benkner</surname><given-names>S</given-names></name><name><surname>Berti</surname><given-names>G</given-names></name><name><surname>Engelbrecht</surname><given-names>G</given-names></name><etal/></person-group><article-title>GEMSS: Grid-infrastructure for Medical Service Provision</article-title><source>International J. Supercomputer Applications</source><year>2001</year><volume>15</volume><issue>3</issue></mixed-citation></ref><ref id="b15-cin-2009-217"><label>15</label><note><p>Cancer Screening in the European Union; Report on the implementation of the Council Recommendation on cancer screening. 2007.</p></note></ref><ref id="b16-cin-2009-217"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Vlieger</surname><given-names>P</given-names></name><name><surname>Boire</surname><given-names>JY</given-names></name><name><surname>Breton</surname><given-names>V</given-names></name><etal/></person-group><source>Grid-enabled Sentinel Network for Cancer Surveillance, to be published in Studies in Health Technologies and Informatics</source></mixed-citation></ref><ref id="b17-cin-2009-217"><label>17</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Brady</surname><given-names>M</given-names></name><etal/></person-group><person-group person-group-type="editor"><name><surname>Berman</surname><given-names>F</given-names></name><name><surname>Fox</surname><given-names>G</given-names></name><name><surname>Hey</surname><given-names>T</given-names></name></person-group><article-title>eDiamond: a grid-enabled federated database of annotated mammograms</article-title><source>Grid Computing: Making the Global Infrastructure a Reality</source><publisher-name>Wiley</publisher-name><year>2003</year></mixed-citation></ref><ref id="b18-cin-2009-217"><label>18</label><mixed-citation publication-type="webpage"><collab>EGEE</collab><comment><ext-link ext-link-type="uri" xlink:href="http://www.eu-egee.org">http://www.eu-egee.org</ext-link></comment></mixed-citation></ref><ref id="b19-cin-2009-217"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koblitz</surname><given-names>B</given-names></name><name><surname>Santos</surname><given-names>N</given-names></name><name><surname>Pose</surname><given-names>V</given-names></name></person-group><article-title>The AMGA Metadata Service</article-title><source>Journal of Grid Computing</source><year>2008</year><volume>6</volume><fpage>61</fpage><lpage>76</lpage></mixed-citation></ref><ref id="b20-cin-2009-217"><label>20</label><note><p>The Health-e-Child project: <ext-link ext-link-type="uri" xlink:href="http://www.health-e-child.org/">http://www.health-e-child.org/</ext-link>.</p></note></ref><ref id="b21-cin-2009-217"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jan</surname><given-names>S</given-names></name><etal/></person-group><article-title>GATE: a simulation toolkit for PET and SPECT</article-title><source>Phys Med Biol</source><year>2004</year><volume>49</volume><fpage>4543</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">15552416</pub-id></mixed-citation></ref><ref id="b22-cin-2009-217"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diarena</surname><given-names>M</given-names></name><etal/></person-group><article-title>HOPE, an open platform for medical data management on the grid</article-title><source>Stud Health Technol Inform</source><year>2008</year><volume>138</volume><fpage>34</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">18560106</pub-id></mixed-citation></ref><ref id="b23-cin-2009-217"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>HM</given-names></name><name><surname>Twu</surname><given-names>SH</given-names></name><name><surname>Hsu</surname><given-names>CM</given-names></name></person-group><article-title>A patient-identity security mechanism for electronic medical records during transit and a rest</article-title><source>Medical Informatics and the Internet in Medicine</source><month>9</month><year>2005</year><volume>30</volume><issue>3</issue><fpage>227</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">16403711</pub-id></mixed-citation></ref><ref id="b24-cin-2009-217"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allaert</surname><given-names>FA</given-names></name><name><surname>Le Teuff</surname><given-names>G</given-names></name><name><surname>Quantin</surname><given-names>C</given-names></name><name><surname>Barber</surname><given-names>B</given-names></name></person-group><article-title>The legal acknowledgement of the electronic signature : a key for a secure direct access of patients to heir computerised medical record</article-title><source>International Journal of Medical Informatics</source><year>2004</year><volume>73</volume><fpage>239</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">15066553</pub-id></mixed-citation></ref><ref id="b25-cin-2009-217"><label>25</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Roger France</surname><given-names>FH</given-names></name><name><surname>De Clercq</surname><given-names>E</given-names></name><name><surname>Bangels</surname><given-names>SM</given-names></name></person-group><source>Purposes of health identification cards in Belgium&#x02014;EFMI, European Federation for Medical Informatics</source><publisher-name>IOS Press</publisher-name><year>2005</year><comment>Connecting Medical Informatics and Bio-Informatics</comment></mixed-citation></ref><ref id="b26-cin-2009-217"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pharow</surname><given-names>P</given-names></name><name><surname>Blobel</surname><given-names>B</given-names></name></person-group><article-title>eHealth Competence Center, Regensburg, Germany.<email>peter.pharow@ehealth-cc.de</email> Benefits and weaknesses of health cards used in health information systems</article-title><source>Stud Health Technol Inform</source><year>2006</year><volume>124</volume><fpage>320</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">17108543</pub-id></mixed-citation></ref><ref id="b27-cin-2009-217"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pharow</surname><given-names>P</given-names></name><name><surname>Blobel</surname><given-names>B</given-names></name></person-group><article-title>Fraunhofer Institute for Integrated Circuits IIS, Erlangen, Germany. Security infrastructure requirements for electronic health cards communication</article-title><source>Stud Health Technol Inform</source><year>2005</year><volume>116</volume><fpage>403</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16160291</pub-id></mixed-citation></ref><ref id="b28-cin-2009-217"><label>28</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Coatrieux</surname><given-names>G</given-names></name><name><surname>Lecornu</surname><given-names>L</given-names></name><name><surname>Sankur</surname><given-names>B</given-names></name><name><surname>Roux</surname><given-names>C</given-names></name></person-group><source>A Review of Image Watermarking Applications in Healthcare</source><comment>IEEE-EMBC06</comment><month>9</month><year>2006</year><publisher-loc>New York, USA</publisher-loc></mixed-citation></ref><ref id="b29-cin-2009-217"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quantin</surname><given-names>C</given-names></name><name><surname>Cohen</surname><given-names>O</given-names></name><name><surname>Riandey</surname><given-names>B</given-names></name><name><surname>Allaert</surname><given-names>FA</given-names></name></person-group><article-title>Unique patient concept: a key choice for European epidemiology</article-title><source>International Journal of Medical Informatics</source><year>2007</year><volume>76</volume><fpage>419</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">17085069</pub-id></mixed-citation></ref><ref id="b30-cin-2009-217"><label>30</label><note><p>Vol. 1 (ITI-TF-1). Integration Profiles. <ext-link ext-link-type="uri" xlink:href="http://www.ihe.net/Technical_Framework/upload/IHE_ITI_TF_5-0_Vol1_FT_2008-12-12.pdf">http://www.ihe.net/Technical_Framework/upload/IHE_ITI_TF_5-0_Vol1_FT_2008-12-12.pdf</ext-link>.</p></note></ref></ref-list></back><floats-group><fig id="f1-cin-2009-217" position="float"><label>Figure 1</label><caption><p>Cancer surveillance network architecture.</p></caption><graphic xlink:href="cin-2009-217f1"/></fig><fig id="f2-cin-2009-217" position="float"><label>Figure 2</label><caption><p>Examples of GATE Monte Carlo simulations for radiotherapy treatment.</p></caption><graphic xlink:href="cin-2009-217f2"/></fig><fig id="f3-cin-2009-217" position="float"><label>Figure 3</label><caption><p>HOPE (Hospital Platform for E-health) web platform.</p></caption><graphic xlink:href="cin-2009-217f3"/></fig></floats-group></article>


<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Inform</journal-id><journal-id journal-id-type="publisher-id">101258149</journal-id><journal-title-group><journal-title>Cancer Informatics</journal-title></journal-title-group><issn pub-type="epub">1176-9351</issn><publisher><publisher-name>Libertas Academica</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">2730176</article-id><article-id pub-id-type="pmid">19718447</article-id><article-id pub-id-type="publisher-id">cin-2009-159</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Linguistic Processing and Classification of Semi Structured Bibliographic Data on Complementary Medicine</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ostermann</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="af1-cin-2009-159">1</xref><xref ref-type="aff" rid="af2-cin-2009-159">2</xref></contrib><contrib contrib-type="author"><name><surname>Raak</surname><given-names>Christa K.</given-names></name><xref ref-type="aff" rid="af1-cin-2009-159">1</xref><xref ref-type="aff" rid="af2-cin-2009-159">2</xref></contrib><contrib contrib-type="author"><name><surname>Matthiessen</surname><given-names>Peter F.</given-names></name><xref ref-type="aff" rid="af1-cin-2009-159">1</xref></contrib><contrib contrib-type="author"><name><surname>B&#x000fc;ssing</surname><given-names>Arndt</given-names></name><xref ref-type="aff" rid="af1-cin-2009-159">1</xref></contrib><contrib contrib-type="author"><name><surname>Zillmann</surname><given-names>Hartmut</given-names></name><xref ref-type="aff" rid="af3-cin-2009-159">3</xref></contrib></contrib-group><aff id="af1-cin-2009-159"><label>1</label> Chair of Medical Theory and Complementary Medicine, Faculty of Medicine, University of Witten/Herdecke, Gerhard-Kienle-Weg 4, 58313 Herdecke, Germany</aff><aff id="af2-cin-2009-159"><label>2</label> Specialist Library for Complementary Medicine, University of Witten/Herdecke, Gerhard-Kienle-Weg 4, 58313 Herdecke, Germany</aff><aff id="af3-cin-2009-159"><label>3</label> IDM&#x02014;Intelligent Data Management, Osnabrueck, Germany</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>6</day><month>7</month><year>2009</year></pub-date><volume>7</volume><fpage>159</fpage><lpage>169</lpage><permissions><copyright-statement>&#x000a9; 2009 The authors.</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p><!--CREATIVE COMMONS-->This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>).</license-p></license></permissions><abstract><p>Complementary and alternative therapies and medicines (CAM) such as acupuncture or mistletoe treatment are much asked for by cancer patients. With a growing interest in such therapies, physicians need a simple tool with which to get an overview of the scientific publications on CAM, particularly those that are not listed in common bibliographic databases like MEDLINE. CAMbase is an XML-based bibliographical database on CAM which serves to address this need. A custom front end search engine performs semantic analysis of textual input enabling users to quickly find information relevant to the search queries. This article describes the technical background and the architecture behind CAMbase, a free online database on CAM (<ext-link ext-link-type="uri" xlink:href="www.cambase.de">www.cambase.de</ext-link>). We give examples on its use, describe the underlying algorithms and present recent statistics for search terms related to complementary therapies in oncology.</p></abstract><kwd-group><kwd>cancer</kwd><kwd>complementary medicine</kwd><kwd>database</kwd><kwd>semantic web</kwd><kwd>literature</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>In 1999, Zollmann and Vickers defined complementary and alternative medicine (CAM) as &#x0201c;a group of therapeutic and diagnostic disciplines that exist largely outside the institutions where conventional health care is taught and provided&#x0201d;).<xref ref-type="bibr" rid="b1-cin-2009-159">1</xref> In the last decade however, complementary medicine has not only succeeded in establishing itself in the academic context, with an increasing number of institutions at European universities working on CAM, it has also expanded its activities in all fields of research.<xref ref-type="bibr" rid="b2-cin-2009-159">2</xref></p><p>The growing academic development of CAM accompanies the increasing demand for complementary therapies in the public domain. All surveys of this field show that, depending on the country, between 20% and 65% of people use CAM,<xref ref-type="bibr" rid="b3-cin-2009-159">3</xref> and that patients often request to be updated on CAM options. Although the family physician is in most cases regarded as the first choice for such inquires, a growing number of patients also use the internet as a resource for CAM information. In one survey, the Pew Internet and American Life Project found that 48% of health seekers have looked for information about CAM on the internet.<xref ref-type="bibr" rid="b4-cin-2009-159">4</xref></p><p>In particular, there is an increasing demand for information on CAM among cancer patients.<xref ref-type="bibr" rid="b5-cin-2009-159">5</xref> Patients are actively seeking treatments and are thus aiming at utilizing coping strategies which might be helpful to extend survival time, gain a better quality of life or to relieve pain.<xref ref-type="bibr" rid="b6-cin-2009-159">6</xref>,<xref ref-type="bibr" rid="b7-cin-2009-159">7</xref> While many patients have discovered the World Wide Web as a resource for information on CAM,<xref ref-type="bibr" rid="b8-cin-2009-159">8</xref> modest empirical research has been conducted into the kind of sources of CAM information and search tools used by cancer patients. Some observations suggest that cancer patients increasingly search professional sources of clinical evidence in the internet, such as patient guidelines or databases.<xref ref-type="bibr" rid="b9-cin-2009-159">9</xref> Our own experience with CAMbase, a bibliographic database on CAM, revealed a strong interest from cancer patients in evidence based information on complementary therapies.<xref ref-type="bibr" rid="b10-cin-2009-159">10</xref></p><p>The increasing interest of cancer patients in the internet and the diversity of information resources has led to difficulties in identifying, filtering and implementing new and appropriate medical knowledge. <xref ref-type="fig" rid="f1-cin-2009-159">Figure 1</xref> illustrates the growth of information in various bibliographic databases using the example of the search term &#x0201c;cancer&#x0201d;. Between 1996&#x02013;2006, there was an increase in information in resources such as PubMed of 66% (CAM-Subset: 120%), Allied and Complementary Medicine Database (AMED) 238% and &#x0201c;Cumulative Index to Nursing and Allied Health (CINAHL) 454%.</p><p>The expansion of the internet in the last ten years has made information retrieval challenging not only for patients but also for health care providers and physicians who wish to separate &#x0201c;important/meaningful&#x0201d; from &#x0201c;unimportant/meaningless&#x0201d; information.<xref ref-type="bibr" rid="b11-cin-2009-159">11</xref> Thus, with the growing interest in CAM, there is an urgent need by users of online databases for tools to assist in reviewing the scientific information on CAM in cancer.</p><p>Despite the development of CAM research and application in recent decades, a large proportion of the publications reporting on CAM cannot be easily found in digital bibliographic databases like MEDLINE. This is mostly due to two problems:</p><list list-type="order"><list-item><p>A broadly accepted thesaurus for CAM in total does not exist: With respect to heterogeneity, CAM has not developed a strong tradition for a controlled vocabulary to classify CAM literature<xref ref-type="bibr" rid="b12-cin-2009-159">12</xref> and despite some promising efforts,<xref ref-type="bibr" rid="b13-cin-2009-159">13</xref> this is still an unsolved problem. In addition, the conventional MESH-Keywords of MEDLINE do not adequately map the contents of CAM-Literature.</p></list-item><list-item><p>Despite the existence of semi-structured bibliographic data on CAM in electronic databases, a researcher might use misleading or ambiguous keywords in his search strategy and hence cannot find the relevant data. This problem is also known as the so called &#x0201c;vocabulary problem&#x0201d;.<xref ref-type="bibr" rid="b14-cin-2009-159">14</xref></p></list-item></list><p>While the first problem is a result of the diverse composition of CAM itself, the second also arises in other biomedical contexts and is a problem on the client&#x02019;s side.</p><p>In our work, we have sought to provide search options suitable for (i) experienced users who want to employ a specific search strategy, e.g. for systematic reviews, as well as for (ii) casual users who want to inform themselves on a topic which at that moment of query issue might not be paraphrased very precisely.<xref ref-type="bibr" rid="b15-cin-2009-159">15</xref></p><p>This article describes the linguistic processing and classification of semi-structured bibliographical data on complementary and alternative medicine in CAMbase, a free bibliographic database on CAM realized with the semantic web standard XML and accessible online at the URL <ext-link ext-link-type="uri" xlink:href="www.cambase.de">www.cambase.de</ext-link>.</p></sec><sec><title>Technical Realization</title><p>In situations where there is no concise repertoire of controlled vocabulary, there is a necessity to build tools which guide the user through the bibliographical landscape. Based on the inverted file structure and the implementation of XML together with the linguistic algorithms, we are able to offer such a search-tool of CAM-landscapes, which are created for every single search query based on elementary bibliographic data (i.e. keywords or authors).</p><p>The basic idea behind this approach is to guide the user through the mass of resulting datasets, which in the case of the search query &#x02018;cancer&#x02019; in conventional databases like MEDLINE might lead to a large volume of results as can be seen in <xref ref-type="fig" rid="f1-cin-2009-159">Figure 1</xref>.&#x0201d;</p><p>In the following section we focus on the specific topics of processing and classification of semi-structured bibliographical data.</p></sec><sec sec-type="methods"><title>Search Procedures and Strategies</title><p>Search strategies in medical research, e.g. for systematic reviews, are nowadays targeted towards identifying relevant articles in bibliographical databases such as MEDLINE and are commonplace.<xref ref-type="bibr" rid="b16-cin-2009-159">16</xref> Users are primarily scientists or specially trained library professionals, who are consulted by domain experts. On the other hand, an increasing number of physicians are embracing the internet to gather information about the latest guidelines or to deepen their education in web-based medical training and seminars.<xref ref-type="bibr" rid="b17-cin-2009-159">17</xref> When the structure of CAMbase was initially planned, we intended to develop search options which suit both of these user-groups. Therefore, in addition to conventional search options (Author, title, keywords, publication year, etc.), we implemented a natural language interface with linguistic algorithms designed to facilitate enhanced query capture before issuing to the search process.</p><p>Apart from conventional techniques of natural language processing (NLP) like stemming, text segmentation and the analysis of punctuation and normalisation (see Brants<xref ref-type="bibr" rid="b18-cin-2009-159">18</xref> for a review of common methods of NLP), we have developed special features, which are quite unique with respect to their decomposition of search phrases into their linguistic and grammatical entities. In the following we illustrate these features using two examples:</p><sec><title>Example 1: Modification and restriction of a subject, explicitly formulated by the user</title><p>In the search term &#x0201c;<italic>European mistletoe for the treatment of cancer</italic>&#x0201d;, the phrase &#x0201c;mistletoe&#x0201d; is the subject modified by &#x0201c;treatment of cancer&#x0201d; and restricted by &#x0201c;Europ~ean&#x0201d;, whereas in the search term &#x0201c;<italic>mistletoe treatment of cancer in Europe</italic>&#x0201d;, the term &#x0201c;cancer&#x0201d; is the central subject modified by &#x0201c;Europe&#x0201d; and restricted by &#x0201c;mistletoe treatment&#x0201d; (<xref ref-type="fig" rid="f2-cin-2009-159">Fig. 2</xref>). Thus, even though the textual phrase consists of the same words, the ranking of the search results will be different<xref ref-type="bibr" rid="b19-cin-2009-159">19</xref>&#x02013;<xref ref-type="bibr" rid="b21-cin-2009-159">21</xref> because of the grammatical relation between the words. Note that most of these language processing features are quite unique for German.</p><p>As can be seen in this example, linguistic procedures like automated morphological reduction and decomposition algorithms also help in the processing of search queries: the search query &#x0201c;european&#x0201d; will also lead to hits on &#x0201c;europe&#x0201d; and the German search query &#x0201c;Krebstherapie&#x0201d; (cancer therapy) also finds &#x0201c;Therapie des Krebses&#x0201d; (therapy of cancer) and vice versa. <xref ref-type="table" rid="t1-cin-2009-159">Table 1</xref> gives an overview of the implemented NLP-techniques.</p></sec></sec><sec><title>Ranking Algorithm</title><p>Based on a mathematical analysis of how the search phrase is conceptually represented in the dataset, a numerical distance value between 0 (=no relevance) to 100 (identical) is computed, which helps the user to decide which documents fit to his/her search query, i.e. datasets with a higher ranking will be placed in a higher position than those with a lower ranking. The underlying algorithm can be described as follows:</p><p>Let <italic>C</italic> = {<italic>d|d =</italic> 1 <italic>&#x02026; D</italic>} denote the <italic>corpus</italic> containing a total of D datasets <italic>d</italic> and let <italic>W</italic><italic><sub>d</sub></italic> = {<italic>w</italic><italic><sub>i</sub></italic><italic><sup>d</sup></italic>|<italic>w</italic><italic><sub>i</sub></italic><italic><sup>d</sup></italic> &#x02208; <italic>d; i</italic> = 1 . . .<italic>n</italic>} denote the set of all words <italic>w</italic><italic><sub>i</sub></italic><italic><sup>d</sup></italic> of the dataset <italic>d.</italic> The inclusion of words depends on the given record structure and the decision of the database owner. In our case we included all words of bibliographical fields (i.e. title, keywords, abstract) and excluded content notes such as page numbers and stopwords such as &#x0201c;the&#x0201d;,&#x0201c;an&#x0201d; or &#x0201c;and&#x0201d;, which were filtered out prior to the processing. Based on the <italic>w</italic><italic><sub>i</sub></italic><italic><sup>d</sup></italic> an address vector <italic>&#x00077;&#x020d7;</italic><italic><sub>i</sub></italic><italic><sup>d</sup></italic> = (<italic>w</italic><italic><sub>i</sub></italic><italic><sup>d</sup></italic>, <italic>a</italic><sub>1</sub>, <italic>a</italic><sub>2</sub>, . . ., <italic>a</italic><italic><sub>k</sub></italic>) is defined where <italic>a</italic><sub>1</sub>, <italic>a</italic><sub>2</sub>, <italic>&#x02026;</italic>, <italic>a</italic><italic><sub>k</sub></italic> denote additional coded information about syntactical and morphological attributes of the word <italic>w</italic><italic><sub>i</sub></italic><italic><sup>d</sup></italic> (See <xref ref-type="table" rid="t1-cin-2009-159">Table 1</xref> for an overview of these additional informations). Then <italic>&#x00057;&#x00303;</italic><italic><sub>d</sub></italic> = {<italic>&#x00077;&#x020d7;</italic><italic><sub>j</sub></italic><italic><sup>d</sup></italic>|; <italic>i</italic> = 1 . . . <italic>&#x000f1;</italic>} is called the <italic>index</italic> of the dataset <italic>d</italic> and <italic>&#x00057;&#x00303;</italic> = &#x0222a; <italic>&#x00057;&#x00303;</italic><italic><sub>d</sub></italic> is called the <italic>index</italic> of the whole database. Finally the terms <italic>S</italic><italic><sub>j</sub></italic> of the search query <italic>S</italic> are defined by <italic>S</italic>={<italic>s</italic><italic><sub>j</sub></italic>|<italic>s</italic><italic><sub>j</sub></italic>; <italic>j</italic> = 1 . . .<italic>m</italic>} Again, according to the construction of the <italic>&#x00077;&#x020d7;</italic><italic><sub>i</sub></italic><italic><sup>d</sup></italic> a search vector <italic>&#x00073;&#x020d7;</italic><italic><sub>j</sub></italic> = (<italic>s</italic><italic><sub>j</sub></italic>, <italic>a</italic><sub>1</sub>, <italic>a</italic><sub>2</sub>, . . ., <italic>a</italic><italic><sub>k</sub></italic>) is defined. The search query <italic>S</italic> and all algorithms are processed on the index <italic>&#x00057;&#x00303;</italic>.</p><p>Independent of the location of the terms <italic>s</italic><italic><sub>j</sub></italic> &#x02208; <italic>&#x00057;&#x00303;</italic><italic><sub>d</sub></italic>&#x02200;<italic>j</italic> = 1 . . . <italic>&#x0006d;&#x00303;, &#x0006d;&#x00303;</italic> &#x02264; <italic>m</italic> we define a parameter 0 &#x0003c; <italic>Q</italic><italic><sub>&#x0006d;&#x00303;</sub></italic>&#x02264;100 for these datasets. Note that <italic>s</italic><italic><sub>j</sub></italic> &#x02208; <italic>&#x00057;&#x00303;</italic><italic><sub>d</sub></italic> also is fulfilled if <italic>S</italic><italic><sub>j</sub></italic> is &#x02018;part&#x02019; of a word <italic>w</italic><italic><sub>i</sub></italic><italic><sup>d</sup></italic> (i.e. the German term &#x0201c;<italic>Therap~ie</italic>&#x0201d; in &#x0201c;<italic>Misteltherap~ie</italic>&#x0201d; or the English term &#x0201c;<italic>therap~y</italic>&#x0201d; <italic>in</italic> &#x0201c;<italic>therap~eutic</italic>&#x0201d;). In the case of a normally distributed heterogeneity of <italic>C</italic>, <italic>Q</italic><italic><sub>m</sub></italic> like in our case this value is set to 50 and <italic>Q</italic><italic><sub>&#x0006d;&#x00303;</sub></italic> are defined accordingly as <italic>Q</italic><italic><sub>m</sub></italic>&#x000b7; <italic>&#x0006d;&#x00303;/m.</italic></p><p>Based on <italic>Q</italic><italic><sub>&#x0006d;&#x00303;</sub></italic> the quality function 

<inline-formula><mml:math id="M1"><mml:mrow><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mi>d</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>S</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>Q</mml:mi></mml:mrow><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>&#x0223c;</mml:mo></mml:mover></mml:msub><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>m</mml:mi></mml:munderover></mml:mstyle><mml:mrow><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover></mml:mstyle><mml:mrow><mml:msub><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mrow><mml:mover accent="true"><mml:mi>w</mml:mi><mml:mo>&#x02192;</mml:mo></mml:mover></mml:mrow><mml:mi>i</mml:mi><mml:mi>d</mml:mi></mml:msubsup><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mover accent="true"><mml:mi>s</mml:mi><mml:mo>&#x02192;</mml:mo></mml:mover></mml:mrow><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x02264;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula> is calculated, where <italic>q</italic><italic><sub>i</sub></italic>(<italic>&#x00077;&#x020d7;</italic><italic><sub>i</sub></italic><italic><sup>d</sup></italic> <italic>&#x00073;&#x020d7;</italic><italic><sub>j</sub></italic>) denote additional quality criteria functions (i.e. correct flexion, correct position and order of the words, containment in a compound word, irregular plurals) which are given by the <italic>a</italic><sub>1</sub>, <italic>a</italic><sub>2</sub>, . . ., <italic>a</italic><italic><sub>k</sub></italic>. Depending on their weightings, the <italic>q</italic><italic><sub>i</sub></italic>(<italic>&#x00077;&#x020d7;</italic><italic><sub>i</sub></italic><italic><sup>d</sup></italic> <italic>&#x00073;&#x020d7;</italic><italic><sub>j</sub></italic>) add a significant amount to the value of <italic>Q</italic><italic><sub>&#x0006d;&#x00303;</sub></italic> Finally the quality threshold <italic>Q</italic><italic><sub>t</sub></italic> = <italic>Q</italic><italic><sub>m</sub></italic>&#x02212;<italic>&#x003b4;</italic><italic><sub>m</sub></italic>;<italic>&#x003b4;</italic>&#x0003e; 0 is defined as the lower bound for the quality of a dataset. In other words, every dataset <italic>d</italic> with a value <italic>Q</italic><italic><sub>d</sub></italic>(<italic>S</italic>) &#x02265; <italic>Q</italic><italic><sub>t</sub></italic> is presented as a result of the search query <italic>S.</italic> Note that all datasets with <italic>s</italic><italic><sub>j</sub></italic> &#x02208; <italic>&#x00057;&#x00303;</italic><italic><sub>d</sub></italic>&#x02200;<italic>j</italic> = 1 . . . <italic>m</italic> by definition are above the threshold of <italic>Q</italic><italic><sub>t</sub></italic>. If wanted, both the threshold value and the sensitivity of the <italic>q</italic><italic><sub>i</sub></italic>(<italic>&#x00077;&#x020d7;</italic><italic><sub>i</sub></italic><italic><sup>d</sup></italic> <italic>&#x00073;&#x020d7;</italic><italic><sub>j</sub></italic>) may be adjusted by the user of the database. In the case of CAMbase, <italic>Q</italic><italic><sub>t</sub></italic> is set to the value of 45.</p><p><xref ref-type="fig" rid="f3-cin-2009-159">Figure 3</xref> illustrates the behaviour of the search algorithm for the threshold values <italic>Q</italic><italic><sub>t</sub></italic> = 35 and <italic>Q</italic><italic><sub>t</sub></italic> = 45 and a high (+) versus a low (&#x02212;) sensitivity. Note that the threshold values <italic>Q</italic><italic><sub>t</sub></italic> = 35 together with a low sensitivity results in a total of 54 hits whereas <italic>Q</italic><italic><sub>t</sub></italic> = 45 with a high sensitivity delivers only 10 hits. The remaining two combinations <italic>Q</italic><italic><sub>t</sub></italic> = 45 with low sensitivity and <italic>Q</italic><italic><sub>t</sub></italic> = 35 with a high sensitivity each achieve about 20 hits. Also note that in these cases the decrease in quality of the hits develops slightly differently.</p></sec><sec><title>Inverted File Structure</title><p>In our context, along with the linguistic processing of the bibliographical metadata of documents, data volume and query processing loads increase continually and thus it is of great importance to have an efficient information retrieval system which is able to process the search queries in an appropriate run time. We therefore decided to use an indexing mechanism based on inverted file structure.<xref ref-type="bibr" rid="b22-cin-2009-159">22</xref> All bibliographical datasets (including sentences if an abstract is available) are processed into an index by the above mentioned linguistic algorithms, and together with additional discriminating information (ADIs) for example, the logical subset that a bibliographical record belongs to, an inverted file structure is created (<xref ref-type="fig" rid="f4-cin-2009-159">Fig. 4</xref>).</p><p>Within the context of linguistic indexing, one new feature has been developed to enhance the speed of search algorithms operating on conventional inverted file structures: words are no longer regarded as textual &#x02018;atoms&#x02019;, but are recognized in their syntactic-semantic interrelation. Based on a 6-byte coding, the above mentioned mathematical algorithms produce a &#x02018;word-map&#x02019; of the documents which provides the information on whether or not a word appears in certain documents. This information is used as a filter when more than two search terms are entered in the query. Thus, matching-algorithms may abstain from processing a document from the outset if the word-map provides this information, which increases the speed of processing the search query.</p><sec><title>Example 2: Search-query &#x02018;mistletoe in oncology&#x02019;</title><p>When searching for the phrase &#x0201c;adverse effects of mistletoe preparations&#x0201d;, our matching algorithms, based on the mathematical calculation of Q (adverse, effects, mistletoe, preparations), together with the inverse file coding, are able to detect whether the term &#x0201c;preparation~s&#x0201d; occurs in a dataset or not. Thus, documents found in the search for &#x02018;mistletoe&#x02019; without the words &#x0201c;preparation~s&#x0201d; or &#x0201c;adverse effect~s&#x0201d; are not processed any further because no match for the combined search term emerges. This has quite a dramatic effect on the processing speed of the search query. In the search query example given above, the single term &#x0201c;adverse&#x0201d; results in a performance of 0.05 seconds based on the average of 20 subsequent entries on a conventional notebook with a DSL-6Mbit data rate. For the terms &#x0201c;adverse&#x0201d; and &#x0201c;effects&#x0201d;, the database responds with a mean of 0.06 seconds. Adding the search term &#x0201c;mistletoe&#x0201d; increases the speed by a factor of 6 to 0.01 seconds and finally the complete phrase is processed in 0.005 seconds on average.</p><p>As shown in the example, our method is more efficient when more search terms are entered in the search query, in contrast to conventional data structures which at first sight shows a paradoxical search time behaviour as illustrated in <xref ref-type="fig" rid="f5-cin-2009-159">Figure 5</xref>. This procedure becomes more important with larger data volumes and is also used for keyword landscapes described below.</p></sec></sec><sec><title>Semantic Web Standard: XML</title><p>As bibliographical data, in the case of CAM, does contain several heterogeneous elements arising from the different sources from which the datasets originate (i.e. publishers, libraries, authors entries, offline collections of datasets of research institutes), we decided to use the innovative technological web-standard XML (eXtended Markup Language)<xref ref-type="bibr" rid="b23-cin-2009-159">23</xref> to receive capture the output in a homogeneous structure. We constructed XML-based import interfaces to process incoming documents of varying document type definitions (DTDs), to extract structural and descriptive metadata from these documents and to deliver special document output styles on demand. As an additional feature, we also implemented XML-interfaces for the standards given by the Open&#x02014; Archives&#x02014;Initiative (OAI). With this XML&#x02014;based document-management, CAMbase can be easily connected with national and international electronic databases and other digital libraries.<xref ref-type="bibr" rid="b24-cin-2009-159">24</xref>,<xref ref-type="bibr" rid="b25-cin-2009-159">25</xref> In addition, connections with other metadata, e.g. semantic web standard ontologies, can be established.</p><p>The basic idea behind this approach is to guide the user through the bibliographical landscape. The following figure illustrates this approach with the example of the search query for &#x0201c;Krebs&#x0201d; (German for &#x0201c;cancer&#x0201d;).</p><p>Given the German language search term &#x0201c;Krebs&#x0201d;, the search algorithm which is similar to other conventional databases displays a listing of articles which includes this search term or compositions like &#x0201c;Krebstherapie&#x0201d; (Engl: &#x0201c;cancer therapy&#x0201d;). Additionally, a keyword-landscape on the right side (German Title: &#x0201c;Themenlandkarte&#x0201d;) is also given which describes the resulting dataset more precisely. Keywords occurring more often are displayed in the landscape with a bigger font size and at least one dataset behind every keyword displayed in the landscape is guaranteed.</p><p>By clicking on a term displayed in the landscape, the system again displays the results. In our case, clicking on the term &#x0201c;Hyperthermie&#x0201d; leads to 243 hits which are equivalent to a boolean AND-relation &#x0201c;Krebs AND Hyperthermie&#x0201d;). Naturally, the results of this search query are also linked to another landscape (see <xref ref-type="fig" rid="f6-cin-2009-159">Fig. 6</xref>). With each navigation step, the user might choose another keyword for narrowing the result set even further. An additional feature is available after the nth step (n &#x0003e; 2) offering the user permutations of the search terms of the (n&#x02212;1)th step: For the query &#x0201c;Krebs AND Hyperthermie AND Immunstimulation&#x0201d; (2 hits), the system also asks whether the user might want to switch to the search query &#x0201c;Krebs AND Immunstimulation&#x0201d; without the term &#x0201c;Hyperthermie&#x0201d; (19 hits).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>The next generation of the Web is often characterized as the &#x0201c;Semantic Web&#x0201d;<xref ref-type="bibr" rid="b26-cin-2009-159">26</xref> in which information processing is no longer the task for human users, but rather handled by machines and algorithms giving rise to semantically empowered search engines such as the one described above. Semantic processing, however, requires standards for the syntactic form and for the semantic content of documents. One important technology for this purpose is already in place: eXtensible Markup Language (XML).</p><p>There are other semantic web standards used for indexing bibliographic resources, like Web Ontology Language (OWL) and Resource Description Framework (RDF), that can facilitate data integration i.e. for genomic data<xref ref-type="bibr" rid="b27-cin-2009-159">27</xref> and applications that employ ontologies such as indexes and query models, e.g. GoPubMed,<xref ref-type="bibr" rid="b28-cin-2009-159">28</xref> Knowlegator<xref ref-type="bibr" rid="b29-cin-2009-159">29</xref> and Textpresso).<xref ref-type="bibr" rid="b30-cin-2009-159">30</xref>,<xref ref-type="bibr" rid="b31-cin-2009-159">31</xref> These systems show sophisticated use of of bibliographic metadata for indexing literature abstracts or full texts according to domain content. All of these approaches are domain specific and the approach presented here is likewise a first for the field of CAM.</p><p>A first evaluation of the vocabulary used in more than 28,000 search queries applied to CAMbase between 2003 and 2006 found that 12.2% were regarding authors publishing primarily in CAM, 10.9% on general terms, 30.3% on diseases, disorders and symptoms, 25.2% on therapies and procedures and 10.2% on plants and ingredients.<xref ref-type="bibr" rid="b32-cin-2009-159">32</xref> However, according to the recently conducted review of Kim et al<xref ref-type="bibr" rid="b33-cin-2009-159">33</xref> of tag ontologies for semantically linked data, a reorientation in evaluation strategies seems to be necessary to develop appropriate metrics, particularly if the results of this evaluation shall be used for the creation of a CAM-ontology.</p><p>In particular, a precise identification of entities is essential for the creation of an ontology-driven document indexing and data integration.<xref ref-type="bibr" rid="b34-cin-2009-159">34</xref> In addition, most of our data can be considered to be &#x0201c;old data&#x0201d;, which means, there is only limited information for the creation of a valid ontology and changes in underlying ontologies might have far-reaching side effects for more recent data as the old scheme might not be compatible with the new results.<xref ref-type="bibr" rid="b35-cin-2009-159">35</xref> Nevertheless, if one looks closely at the CAM-landscapes created for every search query they implicitly indicate the presence of some underlying ontology. Thus, according to Vatant<xref ref-type="bibr" rid="b36-cin-2009-159">36</xref> a closer analysis of our CAM landscapes would be a first step to establish an ontological framework of CAM. Within this context the use of RDFs as interchange formats and the OWL as a formal description of the underlying concepts, terms, and relationships seem promising.</p><p>Taking into consideration the high amount of German language articles on CAM, our features and algorithms even today are of direct relevance. Whilst we have addressed the technical specifications in the construction of CAMbase, the issue of generating semantic ontologies in CAM is even more challenging than in other disciplines. This is because a catalogue of homogeneous synonyms for medical terms (which is valid for all CAM-disciplines) remains intangible (i.e. the term &#x0201c;liver&#x0201d; has a quite different meaning in traditional Chinese medicine than in homeopathy).</p><p>Mertz<xref ref-type="bibr" rid="b37-cin-2009-159">37</xref> also pointed out that one of the important future tasks for research in CAM is to build CAM vocabularies and make them available to the public domain. In doing so, one has to be aware that even if some values are shared with traditional biomedicine, axiological differences have to be considered as well. Although our examples are based on CAM bibliographical records in &#x0201c;CAMbase&#x0201d;, the underlying algorithms we have developed are generic and work for other contexts as well. For example, a user might not only want to access the scientific literature, but also wants to look for a research institution or an expert involved in a distinct search topic (i.e. for a unique cancer treatment). In the same way as described above, this can be realized with an XML-based content management system, in which such information is stored<xref ref-type="bibr" rid="b24-cin-2009-159">24</xref> and a multi-dimensional web-portal is the next logical step.</p><p>Another example where deployments of semantic ontologies can be found within the field of CAM is the use of these features and tools for electronic lexicography.<xref ref-type="bibr" rid="b38-cin-2009-159">38</xref>,<xref ref-type="bibr" rid="b39-cin-2009-159">39</xref> In particular, machine readable lexicons or dictionaries with a codification of domain knowledge and literature metadata in accordance with a generic and extendible XML scheme model are more suitable in this context. One open problem in complementary medicine in this context is the semantic processing of the many resources of homeopathic remedies, <italic>Materia Medicia</italic>. Such repositories contain structured data on medical symptoms and the corresponding homeopathic remedies. Natural language processing of and ontology creation for such vast resources would be beneficial in the complex process of homeopathic prescribing.<xref ref-type="bibr" rid="b40-cin-2009-159">40</xref></p></sec><sec><title>Conclusion</title><p>Although the internet has brought a &#x02018;revolution to information technology&#x02019;, most of the current forms of web content remain incomprehensible for intelligent analysis by computers. The semantic web standard XML can be used to unite structural properties of databases, web requirements and the demands of end users. In this publication we were able to show how XML together with other algorithmic features like linguistic processing may aid the user to find his/her way through incomplete and often only semi-structured data in the field of CAM. On a long term, our approach may lead to a creation of a CAM ontology as currently described for other areas of biomedical research.<xref ref-type="bibr" rid="b41-cin-2009-159">41</xref></p></sec></body><back><fn-group><fn><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-cin-2009-159"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zollman</surname><given-names>C</given-names></name><name><surname>Vickers</surname><given-names>A</given-names></name></person-group><article-title>ABC of complementary medicine. What is complementary medicine?</article-title><source>British Medical Journal</source><year>1999</year><volume>319</volume><fpage>693</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10480829</pub-id></mixed-citation></ref><ref id="b2-cin-2009-159"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varga</surname><given-names>O</given-names></name><name><surname>M&#x000e1;rton</surname><given-names>S</given-names></name><name><surname>Moln&#x000e1;r</surname><given-names>P</given-names></name></person-group><article-title>Status of Complementary and Alternative Medicine in European Medical Schools</article-title><source>Forsch Komplement&#x000e4;rmed</source><year>2006</year><volume>13</volume><fpage>41</fpage><lpage>5</lpage></mixed-citation></ref><ref id="b3-cin-2009-159"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernst</surname><given-names>E</given-names></name></person-group><article-title>The role of complementary and alternative medicine</article-title><source>British Medical Journal</source><year>2000</year><volume>321</volume><fpage>1133</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">11061738</pub-id></mixed-citation></ref><ref id="b4-cin-2009-159"><label>4</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>S</given-names></name><name><surname>Rainie</surname><given-names>L</given-names></name></person-group><source>Vital decisions: how Internet users decide what information to trust when they or their loved ones are sick</source><publisher-loc>Washington, DC</publisher-loc><publisher-name>The Pew Internet and American Life project</publisher-name><year>2002</year></mixed-citation></ref><ref id="b5-cin-2009-159"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molatossiotis</surname><given-names>A</given-names></name><name><surname>Fernandez-Ortega</surname><given-names>P</given-names></name><name><surname>Pud</surname><given-names>D</given-names></name><name><surname>Ozden</surname><given-names>G</given-names></name><name><surname>Scott</surname><given-names>JA</given-names></name><name><surname>Panteli</surname><given-names>V</given-names></name></person-group><article-title>Use of CAM in cancer patients: A European survey</article-title><source>Ann Oncol</source><year>2005</year><volume>16</volume><fpage>655</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">15699021</pub-id></mixed-citation></ref><ref id="b6-cin-2009-159"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leydon</surname><given-names>GM</given-names></name><name><surname>Boulton</surname><given-names>M</given-names></name><name><surname>Moynihan</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cancer patients&#x02019; information needs and information seeking behaviour: in depth interview study</article-title><source>British Medical Journal</source><year>2000</year><volume>320</volume><issue>7239</issue><fpage>909</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">10742000</pub-id></mixed-citation></ref><ref id="b7-cin-2009-159"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000fc;ssing</surname><given-names>A</given-names></name><name><surname>Ostermann</surname><given-names>T</given-names></name><name><surname>Matthiessen</surname><given-names>PF</given-names></name></person-group><article-title>Search for meaningful support and the meaning of illness in German cancer patients</article-title><source>Anticancer Res</source><year>2005</year><volume>25</volume><issue>2B</issue><fpage>1449</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">15865104</pub-id></mixed-citation></ref><ref id="b8-cin-2009-159"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziebland</surname><given-names>S</given-names></name><name><surname>Chapple</surname><given-names>A</given-names></name><name><surname>Dumelow</surname><given-names>C</given-names></name><name><surname>Evans</surname><given-names>J</given-names></name><name><surname>Prinjha</surname><given-names>S</given-names></name><name><surname>Rozmovits</surname><given-names>L</given-names></name></person-group><article-title>How the internet affects patients&#x02019; experience of cancer: a qualitative study</article-title><source>British Medical Journal</source><year>2004</year><volume>328</volume><fpage>564</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">15001506</pub-id></mixed-citation></ref><ref id="b9-cin-2009-159"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>SK</given-names></name><name><surname>Pandey</surname><given-names>GS</given-names></name><name><surname>Kesari</surname><given-names>A</given-names></name><name><surname>Choudhuri</surname><given-names>G</given-names></name><name><surname>Mittal</surname><given-names>B</given-names></name></person-group><article-title>Fighting cancer in the information age: the role of Internet</article-title><source>Indian J Exp Biol</source><year>2003</year><volume>41</volume><issue>3</issue><fpage>189</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">15267146</pub-id></mixed-citation></ref><ref id="b10-cin-2009-159"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostermann</surname><given-names>T</given-names></name><name><surname>Zillmann</surname><given-names>H</given-names></name><name><surname>Matthiessen</surname><given-names>PF</given-names></name></person-group><article-title>Literatur zur Komplement&#x000e4;rmedizin bei Krebs&#x02014;Recherchem&#x000f6;glichkeit im Internet mit der CAMbase-Datenbank</article-title><source>Dt Zs Onkol</source><year>2004</year><volume>36</volume><fpage>165</fpage><lpage>9</lpage></mixed-citation></ref><ref id="b11-cin-2009-159"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt Ernst</surname><given-names>E</given-names></name></person-group><article-title>Assessing websites on complementary and alternative medicine for cancer</article-title><source>Ann Oncot</source><year>2004</year><volume>15</volume><issue>5</issue><fpage>733</fpage><lpage>42</lpage></mixed-citation></ref><ref id="b12-cin-2009-159"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>LS</given-names></name><name><surname>Reinsch</surname><given-names>S</given-names></name><name><surname>Najm</surname><given-names>WI</given-names></name><etal/></person-group><article-title>Searching biomedical databases on complementary medicine: the use of controlled vocabulary among authors, indexers and investigators</article-title><source>BMC Complementary and Alternative Medicine</source><year>2003</year><volume>3</volume><fpage>3</fpage><pub-id pub-id-type="pmid">12846931</pub-id></mixed-citation></ref><ref id="b13-cin-2009-159"><label>13</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Shahar</surname><given-names>T</given-names></name><name><surname>Yitzhaki</surname><given-names>M</given-names></name></person-group><article-title>Entwurf eines kontrollierten Thesaurus f&#x000fc;r das schnell wachsende Fach alternative Medizin</article-title><conf-name>Proceedings of the 66th IFLA Council and General Conference</conf-name><conf-loc>Jerusalem</conf-loc><year>2000</year></mixed-citation></ref><ref id="b14-cin-2009-159"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furnas</surname><given-names>GW</given-names></name></person-group><article-title>Statistical semantics: How can a computer use what people name things to guess what things people mean when they name things</article-title><source>Proceedings of the Human Factors in Computer Systems Conference</source><year>1982</year><fpage>251</fpage><lpage>3</lpage></mixed-citation></ref><ref id="b15-cin-2009-159"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostermann</surname><given-names>T</given-names></name><name><surname>Zillmann</surname><given-names>H</given-names></name><name><surname>Matthiessen</surname><given-names>PF</given-names></name></person-group><article-title>The CAMbase literature database-an XML-based approach towards published evidence in CM</article-title><source>Focus Altern Complement Ther</source><year>2004</year><volume>9</volume><fpage>37</fpage></mixed-citation></ref><ref id="b16-cin-2009-159"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickersin</surname><given-names>K</given-names></name><name><surname>Scherer</surname><given-names>R</given-names></name><name><surname>Lefebvre</surname><given-names>C</given-names></name></person-group><article-title>Systematic Reviews: Identifying relevant studies for systematic reviews</article-title><source>British Medical Journal</source><year>1994</year><volume>309</volume><fpage>1286</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">7718048</pub-id></mixed-citation></ref><ref id="b17-cin-2009-159"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flanagan</surname><given-names>A</given-names></name><name><surname>Guy</surname><given-names>P</given-names></name><name><surname>Larsson</surname><given-names>S</given-names></name><name><surname>Saussois</surname><given-names>C</given-names></name></person-group><article-title>European Physicians and the Internet</article-title><source>The Boston Consultig Group Report</source><year>2003</year></mixed-citation></ref><ref id="b18-cin-2009-159"><label>18</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Brants</surname><given-names>T</given-names></name></person-group><article-title>Natural Language Processing in Information Retrieval</article-title><conf-name>Proceedings of the 14th Meeting of Computational Linguistics in the Netherlands</conf-name><conf-loc>Antwerp, Belgium</conf-loc><year>2004</year><fpage>1</fpage><lpage>13</lpage></mixed-citation></ref><ref id="b19-cin-2009-159"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zillmann</surname><given-names>H</given-names></name></person-group><article-title>Information Retrieval and Search Engines in Full-Text-Databases</article-title><source>Liber Quarterely</source><year>2000</year><volume>10</volume><fpage>335</fpage><lpage>41</lpage></mixed-citation></ref><ref id="b20-cin-2009-159"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loth</surname><given-names>K</given-names></name></person-group><article-title>Thematische Abfrage einer dreisprachigen Datenbank mit computerlinguistischen Komponenten</article-title><source>ABI Technik</source><year>2004</year><volume>24</volume><issue>4</issue><fpage>294</fpage><lpage>300</lpage></mixed-citation></ref><ref id="b21-cin-2009-159"><label>21</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Siegm&#x000fc;ller</surname><given-names>R</given-names></name></person-group><article-title>Verfahren der automatischen Indexierung in bibliotheksbezogenen Anwendungen</article-title><source>Berliner Handreichungen zur Bibliotheksund Informationswissenschaft 214</source><publisher-loc>Berlin</publisher-loc><year>2007</year></mixed-citation></ref><ref id="b22-cin-2009-159"><label>22</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Harman</surname><given-names>D</given-names></name><name><surname>Fox</surname><given-names>E</given-names></name><name><surname>Baeta-Yates</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Frakes</surname><given-names>WB</given-names></name><name><surname>Baeza-Yates</surname><given-names>R</given-names></name></person-group><article-title>Inverted Files</article-title><source>Information Retrieval: Data Structures and Algorithms</source><publisher-name>Prentice Hall</publisher-name><year>1992</year><fpage>28</fpage><lpage>44</lpage></mixed-citation></ref><ref id="b23-cin-2009-159"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>DA</given-names></name><name><surname>Mahoney</surname><given-names>A</given-names></name><name><surname>Rydberg-Cox</surname><given-names>JA</given-names></name></person-group><article-title>Management of XML documents in an integrated digital library</article-title><source>Markup Languages: Theory and Practice</source><year>2000</year><volume>2</volume><issue>3</issue><fpage>205</fpage><lpage>14</lpage></mixed-citation></ref><ref id="b24-cin-2009-159"><label>24</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ostermann</surname><given-names>T</given-names></name><name><surname>Zillmann</surname><given-names>H</given-names></name><name><surname>Matthiessen</surname><given-names>PF</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Lasker</surname><given-names>GE</given-names></name><name><surname>Kratky</surname><given-names>KW</given-names></name></person-group><article-title>The CAMbase-Literature-Database&#x02014;A XML-based Approach towards Published Evidence in Complementary Medicine</article-title><source>Health, Healing and Medicine. Volume XI. Comparative and Integrative Medicine</source><publisher-name>The International Institute for Advanced Studies in Systems Research and Cybernetics</publisher-name><publisher-loc>Windsor, Ontario</publisher-loc><year>2005</year><fpage>29</fpage><lpage>34</lpage></mixed-citation></ref><ref id="b25-cin-2009-159"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostermann</surname><given-names>T</given-names></name><name><surname>Zillmann</surname><given-names>H</given-names></name><name><surname>Matthiessen</surname><given-names>PF</given-names></name></person-group><article-title>Die CAMbase-Literaturdatenbank&#x02014;Realisierung eines komplement&#x000e4;rmedizinischen Datenbankverbundes</article-title><source>Zeitschrift f&#x000fc;r &#x000e4;rztliche Fortbildung und Qualit&#x000e4;tssicherung</source><year>2004</year><volume>98</volume><fpage>501</fpage><lpage>8</lpage></mixed-citation></ref><ref id="b26-cin-2009-159"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decker</surname><given-names>S</given-names></name><name><surname>van Harmelen</surname><given-names>F</given-names></name><name><surname>Broekstra</surname><given-names>J</given-names></name><name><surname>Erdmann</surname><given-names>M</given-names></name><name><surname>Fensel</surname><given-names>D</given-names></name><name><surname>Horrocks</surname><given-names>I</given-names></name></person-group><article-title>The semantic web&#x02014;on the respective roles of XML and RDF</article-title><source>IEEE Internet Computing</source><year>2000</year></mixed-citation></ref><ref id="b27-cin-2009-159"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Post</surname><given-names>LJ</given-names></name><name><surname>Roos</surname><given-names>M</given-names></name><name><surname>Marshall</surname><given-names>MS</given-names></name><name><surname>van Driel</surname><given-names>R</given-names></name><name><surname>Breit</surname><given-names>TM</given-names></name></person-group><article-title>A semantic web approach applied to integrative bioinformatics experimentation: a biological use case with genomics data</article-title><source>Bioinformatics</source><year>2007</year><volume>23</volume><issue>22</issue><fpage>3080</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17881406</pub-id></mixed-citation></ref><ref id="b28-cin-2009-159"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doms</surname><given-names>A</given-names></name><name><surname>Schroeder</surname><given-names>M</given-names></name></person-group><article-title>GoPubMed: exploring PubMed with the Gene Ontology</article-title><source>Nucleic Acids Res</source><year>2005</year><volume>33</volume><issue>Web Server issue</issue><fpage>W783</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15980585</pub-id></mixed-citation></ref><ref id="b29-cin-2009-159"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>C</given-names></name><name><surname>Kanagasabai</surname><given-names>R</given-names></name><name><surname>Ang</surname><given-names>W</given-names></name><name><surname>Veeramani</surname><given-names>A</given-names></name><name><surname>Low</surname><given-names>H</given-names></name><name><surname>Wenk</surname><given-names>M</given-names></name></person-group><article-title>Towards ontology-driven navigation of the lipid bibliosphere</article-title><source>BMC bioinformatics</source><year>2008</year><volume>9</volume><issue>Suppl 1</issue><fpage>S5</fpage><pub-id pub-id-type="pmid">18315858</pub-id></mixed-citation></ref><ref id="b30-cin-2009-159"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>HM</given-names></name><name><surname>Sternberg</surname><given-names>PW</given-names></name></person-group><article-title>Automatic document classification of biological literature</article-title><source>BMC Bioinformatics</source><year>2006</year><volume>7</volume><fpage>370</fpage><pub-id pub-id-type="pmid">16893465</pub-id></mixed-citation></ref><ref id="b31-cin-2009-159"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;ller</surname><given-names>HM</given-names></name><name><surname>Rangarajan</surname><given-names>A</given-names></name><name><surname>Teal</surname><given-names>TK</given-names></name><name><surname>Sternberg</surname><given-names>PW</given-names></name></person-group><article-title>2008. Textpresso for neuroscience: searching the full text of thousands of neuroscience research papers</article-title><source>Neuroinformatics</source><year>2005</year><volume>6</volume><issue>3</issue><fpage>195</fpage><lpage>204</lpage></mixed-citation></ref><ref id="b32-cin-2009-159"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostermann</surname><given-names>T</given-names></name><name><surname>Zillmann</surname><given-names>H</given-names></name><name><surname>Raak</surname><given-names>CK</given-names></name><name><surname>B&#x000fc;ssing</surname><given-names>A</given-names></name><name><surname>Matthiessen</surname><given-names>PF</given-names></name></person-group><article-title>CAMbase&#x02014;A XML-based bibliographical database on Complementary and Alternative Medicine (CAM)</article-title><source>Biomedical Digital Libraries</source><year>2007</year><volume>4</volume><fpage>2</fpage><pub-id pub-id-type="pmid">17407592</pub-id></mixed-citation></ref><ref id="b33-cin-2009-159"><label>33</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HL</given-names></name><name><surname>Passant</surname><given-names>A</given-names></name><name><surname>Breslin</surname><given-names>JG</given-names></name><name><surname>Scerri</surname><given-names>S</given-names></name><name><surname>Decker</surname><given-names>S</given-names></name></person-group><article-title>Review and Alignment of Tag Ontologies for Semantically-Linked Data in Collaborative Tagging Spaces</article-title><conf-name>The 2nd IEEE International Conference on Semantic Computing</conf-name><conf-loc>Santa Clara, USA</conf-loc><year>2008</year></mixed-citation></ref><ref id="b34-cin-2009-159"><label>34</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Hassell</surname><given-names>J</given-names></name><name><surname>Aleman-Meza</surname><given-names>B</given-names></name><name><surname>Arpinar</surname><given-names>IB</given-names></name></person-group><article-title>Ontology-driven automatic entity disambiguation in unstructured text</article-title><conf-name>Proceedings of the 5th International Semantic Web Conference</conf-name><conf-loc>Athens, GA</conf-loc><year>2006</year></mixed-citation></ref><ref id="b35-cin-2009-159"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckingham</surname><given-names>S</given-names></name></person-group><article-title>Data&#x02019;s future shock</article-title><source>Nature</source><year>2004</year><volume>428</volume><fpage>774</fpage><lpage>7</lpage></mixed-citation></ref><ref id="b36-cin-2009-159"><label>36</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Vatant</surname><given-names>B</given-names></name></person-group><year>2004</year><article-title>Ontology-Driven Topic Maps</article-title><source>Proc. XML Europe (2004)</source><comment><ext-link ext-link-type="uri" xlink:href="http://www.idealliance.org/europe/04/call/xmlpapers/03-03-03.91/.03-03-03.html">http://www.idealliance.org/europe/04/call/xmlpapers/03-03-03.91/.03-03-03.html</ext-link></comment></mixed-citation></ref><ref id="b37-cin-2009-159"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertz</surname><given-names>M</given-names></name></person-group><article-title>Complementary and alternative medicine: the challenges of ethical justification. A philosophical analysis and evaluation of ethical reasons for the offer, use and promotion of complementary and alternative medicine</article-title><source>Med Health Care Philos</source><year>2007</year><volume>10</volume><issue>3</issue><fpage>329</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">17318364</pub-id></mixed-citation></ref><ref id="b38-cin-2009-159"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Logan</surname><given-names>HM</given-names></name></person-group><article-title>Electronic lexicography</article-title><source>Computers and the Humanities</source><year>1991</year><volume>25</volume><issue>6</issue><fpage>351</fpage><lpage>61</lpage></mixed-citation></ref><ref id="b39-cin-2009-159"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santana</surname><given-names>O</given-names></name><name><surname>Carreras</surname><given-names>F</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>Z</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>A</given-names></name></person-group><article-title>Integration of an XML electronic dictionary with linguistic tools for natural language processing</article-title><source>Information Processing and Management</source><year>2007</year><volume>43</volume><issue>4</issue><fpage>946</fpage><lpage>57</lpage></mixed-citation></ref><ref id="b40-cin-2009-159"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitmarsh</surname><given-names>T</given-names></name></person-group><article-title>The complexities of homeopathic prescribing or how do we decide to do what we do?</article-title><source>Homeopathy</source><year>2007</year><volume>96</volume><issue>2</issue><fpage>71</fpage><pub-id pub-id-type="pmid">17437930</pub-id></mixed-citation></ref><ref id="b41-cin-2009-159"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bug</surname><given-names>WJ</given-names></name><name><surname>Ascoli</surname><given-names>GA</given-names></name><name><surname>Grethe</surname><given-names>JS</given-names></name><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Fennema-Notestine</surname><given-names>C</given-names></name><name><surname>Laird</surname><given-names>AR</given-names></name></person-group><article-title>The NIFSTD and BIRNLex Vocabularies: Building Comprehensive Ontologies for Neuroscience</article-title><source>Neuroinformatics</source><year>2008</year><volume>6</volume><issue>3</issue><fpage>175</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">18975148</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig id="f1-cin-2009-159" position="float"><label>Figure 1</label><caption><p>Relative growth of bibliographical datasets in various online-sources of information on the search query term &#x0201c;cancer&#x0201d; from 1996 to 2006. Absolute number of hits for &#x0201c;cancer&#x0201d; in 1996: Pubmed: 56070; CAM-Subset of Pubmed: 2611; EMBase: 290; Cinahl: 451; AMED: 208.</p></caption><graphic xlink:href="cin-2009-159f1"/></fig><fig id="f2-cin-2009-159" position="float"><label>Figure 2</label><caption><p>Linguistic processing of natural language queries: Subject Search of &#x0201c;European mistletoe for the treatment of cancer&#x0201d; leads to different results than &#x0201c;mistletoe treatment of cancer in Europe.&#x0201d;</p></caption><graphic xlink:href="cin-2009-159f2"/></fig><fig id="f3-cin-2009-159" position="float"><label>Figure 3</label><caption><p>Behaviour of the search algorithms for the threshold values <italic>Q</italic><italic><sub>t</sub></italic> = 35 and <italic>Q</italic><italic><sub>t</sub></italic> = 45 and high (+) versus low (&#x02212;) sensitivity. The quality index <italic>Q</italic>(<italic>s</italic>) &#x02212;<italic>Q</italic><italic><sub>t</sub></italic> is plotted against the number of hits and produces different survival curves for the datasets searched with the query &#x0201c;adverse effects of mistletoe preparations&#x0201d; depending on the setting of the parameters.</p></caption><graphic xlink:href="cin-2009-159f3"/></fig><fig id="f4-cin-2009-159" position="float"><label>Figure 4</label><caption><p>Schematic description of an inverted file structure of a bibliographical dataset with linguistic processing information in the front and additional discriminant information (ADIs) in the back of the coding. &#x0201c;*stem$mr&#x0201d; denotes the decomposition of a search term i.e. &#x0201c;oncology&#x0201d; leads to &#x0201c;oncolog$~y&#x0201d;. Note that front truncation information (marked with a &#x0201c;*&#x0201d;) and umlauting are features specially designed for German language (i.e. for composition terms like &#x0201c;Krebstherapie&#x0201d; (engl. &#x0201c;therapy of cancer&#x0201d;).</p></caption><graphic xlink:href="cin-2009-159f4"/></fig><fig id="f5-cin-2009-159" position="float"><label>Figure 5</label><caption><p>Illustration of seeking time <italic>t</italic> behaviour in relation to the number of search terms for search queries processed by conventional search algorithms without IFS (no IFS), conventional search algorithms operating on inverted file structures (IFS) and special algorithms given in CAMbase operating on inverted file structures (IFS+). Whilst conventional structures without IFS increase exponentially in their seeking time, IFS has a more or less logistic curve, and IFS+ decreases in its searching time the more search terms are included in the query.</p></caption><graphic xlink:href="cin-2009-159f5"/></fig><fig id="f6-cin-2009-159" position="float"><label>Figure 6</label><caption><p>Search tree and respective screen shots of CAM-landscapes on the search query &#x0201c;Krebs&#x0201d; (engl.: cancer).</p></caption><graphic xlink:href="cin-2009-159f6"/></fig><table-wrap id="t1-cin-2009-159" position="float"><label>Table 1</label><caption><p>Description and Examples of NLP-techniques applied in CAMbase.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">NLP-Technique</th><th align="left" rowspan="1" colspan="1">Description</th><th align="left" rowspan="1" colspan="1">Examples</th></tr></thead><tbody><tr><td colspan="3" align="left" rowspan="1"><bold>Morphological analysis of</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02022; Flexions</td><td align="left" rowspan="1" colspan="1">Change of word form which does not change the part-of-speech category, such as conjugation</td><td align="left" rowspan="1" colspan="1">Treat/-ing/-ed; assess/-ment</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02022; Compound words</td><td align="left" rowspan="1" colspan="1">Rule based decomposition of a word into its base forms; base form compounding</td><td align="left" rowspan="1" colspan="1">Krebstherapie (engl.: cancer therapy) is decomposed into &#x0201c;Krebs&#x0201d; and &#x0201c;Therapie&#x0201d;; &#x0201c;Lektine&#x0201d; (engl.: lectins) also finds &#x0201c;Mistellektine&#x0201d; (engl.: &#x0201c;mistletoe lectins&#x0201d;)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02022; Irregular plurals</td><td align="left" rowspan="1" colspan="1">Rule based analysis of German</td><td align="left" rowspan="1" colspan="1">&#x0201c;Fragebogen&#x0201d; (engl.: questionnaire) finds &#x0201c;Frageb&#x000f6;gen&#x0201d; and vice versa</td></tr><tr><td colspan="3" align="left" rowspan="1"><bold>Stemming and Lemmatisation</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02022; Stemming</td><td align="left" rowspan="1" colspan="1">Rule based stripping off affixes to get the stem (root) of the word</td><td align="left" rowspan="1" colspan="1">German: Chemotherap/-ie/-n; English: filter/-s</td></tr><tr><td colspan="3" align="left" rowspan="1"><bold>Grammatical analysis</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02022; Subject-Object relations</td><td align="left" rowspan="1" colspan="1">Grammatical dissolution and analysis of the search phrase</td><td align="left" rowspan="1" colspan="1">See <xref ref-type="fig" rid="f2-cin-2009-159">Figure 2</xref></td></tr><tr><td colspan="3" align="left" rowspan="1"><bold>Tokenisation/Text Segmentation</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02022; Punctuation</td><td align="left" rowspan="1" colspan="1">Splitting the character sequence at white space positions.</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02022; Normalisation</td><td align="left" rowspan="1" colspan="1">Analysis of capitalised words.</td><td align="left" rowspan="1" colspan="1">MIT (Massachusetts Institute of Technology) is different from the German &#x0201c;mit&#x0201d; (engl: &#x0201c;with&#x0201d;)</td></tr><tr><td colspan="3" align="left" rowspan="1"><bold>Word Distributions</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02022; Analysing word frequencies and collocations</td><td align="left" rowspan="1" colspan="1">Comparing different uses and occurrences of the same word/stem</td><td align="left" rowspan="1" colspan="1">Thematic landscapes; Tag clouds (see <xref ref-type="fig" rid="f6-cin-2009-159">Fig. 6</xref>)</td></tr></tbody></table></table-wrap></floats-group></article>


<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Inform</journal-id><journal-id journal-id-type="publisher-id">101258149</journal-id><journal-title-group><journal-title>Cancer Informatics</journal-title></journal-title-group><issn pub-type="epub">1176-9351</issn><publisher><publisher-name>Libertas Academica</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">2730177</article-id><article-id pub-id-type="pmid">19718448</article-id><article-id pub-id-type="publisher-id">cin-2009-123</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Microarray-Based Cancer Prediction Using Soft Computing Approach</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xiaosheng</given-names></name><xref ref-type="aff" rid="af1-cin-2009-123">1</xref><xref ref-type="corresp" rid="c1-cin-2009-123"/></contrib><contrib contrib-type="author"><name><surname>Gotoh</surname><given-names>Osamu</given-names></name><xref ref-type="aff" rid="af1-cin-2009-123">1</xref><xref ref-type="aff" rid="af2-cin-2009-123">2</xref></contrib></contrib-group><aff id="af1-cin-2009-123"><label>1</label> Department of Intelligence Science and Technology, Graduate School of Informatics, Kyoto University, Kyoto 606&#x02013;8501, Japan</aff><aff id="af2-cin-2009-123"><label>2</label> National Institute of Advanced Industrial Science and Technology, Computational Biology Research Center, Tokyo 135-0064, Japan</aff><author-notes><corresp id="c1-cin-2009-123">Correspondence: Xiaosheng Wang, Department of Intelligence Science and Technology, Graduate School of Informatics, Kyoto University, Kyoto 606-8501, Japan. Email:

<email>david@genome.ist.i.kyoto-u.ac.jp</email></corresp></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>26</day><month>5</month><year>2009</year></pub-date><volume>7</volume><fpage>123</fpage><lpage>139</lpage><permissions><copyright-statement>&#x000a9; 2009 The authors.</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p><!--CREATIVE COMMONS-->This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>).</license-p></license></permissions><abstract><p>One of the difficulties in using gene expression profiles to predict cancer is how to effectively select a few informative genes to construct accurate prediction models from thousands or ten thousands of genes. We screen highly discriminative genes and gene pairs to create simple prediction models involved in single genes or gene pairs on the basis of soft computing approach and rough set theory. Accurate cancerous prediction is obtained when we apply the simple prediction models for four cancerous gene expression datasets: CNS tumor, colon tumor, lung cancer and DLBCL. Some genes closely correlated with the pathogenesis of specific or general cancers are identified. In contrast with other models, our models are simple, effective and robust. Meanwhile, our models are interpretable for they are based on decision rules. Our results demonstrate that very simple models may perform well on cancerous molecular prediction and important gene markers of cancer can be detected if the gene selection approach is chosen reasonably.</p></abstract><kwd-group><kwd>gene expression profiles</kwd><kwd>cancer prediction</kwd><kwd>soft computing</kwd><kwd>rough set theory</kwd><kwd>feature selection</kwd><kwd>decision rules</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Conventional tumor diagnostic methods based on the morphological appearance of tumors are not always effective as misdiagnoses often occur. On the other hand, a wide variety of studies have revealed cancer to be a disease involving dynamic changes in the genome. Therefore, using molecular markers of cancers might be an alternative approach to the diagnosis of tumors. The rapid advances in gene expression microarray technology that enable simultaneously measuring the expression levels for tens of thousands of genes in a single experiment, make the detection of cancerous molecular markers possible.<xref ref-type="bibr" rid="b1-cin-2009-123">1</xref> Since the pioneering work of Golub et al in applying gene expression monitoring by DNA microarray to cancer classification,<xref ref-type="bibr" rid="b2-cin-2009-123">2</xref> many investigations of using microarray technology to build cancer diagnosis, prognosis or prediction classifiers have been conducted. In general, the major difficulty in this topic is how to effectively identify the genes pertaining to the pathogenesis of specific cancers from the extremely high-dimensionality gene expression data, which often contain a large amount of noise caused by irrelevant genes. On the other hand, compared with the measured quantities of gene expression levels in experiments, the numbers of samples are severely limited. That often influences prediction accuracy. In this extreme of very few observations on very many features, it is natural and perhaps essential to investigate feature selection and regularization methods.<xref ref-type="bibr" rid="b3-cin-2009-123">3</xref> Feature selection, i.e. gene filtering, is particularly crucial for microarray-based cancer prediction since the number of irrelevant genes for prediction may be huge, and as long as feature selection is performed reasonably, accurate prediction is achieved with even the simplest of predictive models.<xref ref-type="bibr" rid="b4-cin-2009-123">4</xref></p><p>Various methods of building cancer predictors have been proposed such as Clustering, SVMs (Support Vector Machines), k-NNs (k-Nearest Neighbours), ANNs (Artificial Neural Networks), GAs (Genetic Algorithms), Naive Bayes (NB), DTs (Decision Trees), RSs (Rough Sets), EPs (Emerging Patterns), et al. In this article, we explore the use of rule-based pipelines to construct cancer predictors as the rule-based methods are more likely to be accepted by biologists and clinicians for they are easily understood. This kind of approaches like DTs,<xref ref-type="bibr" rid="b5-cin-2009-123">5</xref> RSs,<xref ref-type="bibr" rid="b6-cin-2009-123">6</xref> EPs<xref ref-type="bibr" rid="b7-cin-2009-123">7</xref> etc. have been commonly utilized to produce cancer predictors by many investigators.<xref ref-type="bibr" rid="b7-cin-2009-123">7</xref>&#x02013;<xref ref-type="bibr" rid="b14-cin-2009-123">14</xref> In addition, we attempt to employ one or two genes to conduct cancer prediction. The same problem also has been addressed by some investigators.<xref ref-type="bibr" rid="b15-cin-2009-123">15</xref>,<xref ref-type="bibr" rid="b16-cin-2009-123">16</xref></p><p>Our method is based on rough set theory, originally proposed by Pawlak in the early 1980s,<xref ref-type="bibr" rid="b6-cin-2009-123">6</xref> which can be applied for analysis of both precise and imprecise data.<xref ref-type="bibr" rid="b17-cin-2009-123">17</xref> In,<xref ref-type="bibr" rid="b8-cin-2009-123">8</xref>&#x02013;<xref ref-type="bibr" rid="b11-cin-2009-123">11</xref> rough set theory is applied for cancer classification and prediction. A majority of these studies conduct feature selection by the attribute reduction approach, one core idea of rough set theory. However, to our knowledge, rough sets attribute reductions are computationally expensive, and the resultant reducts maybe are not unique. Moreover, the reducts cannot ensure high prediction performance because there maybe exists redundancy between the attributes in one reduct.<xref ref-type="bibr" rid="b18-cin-2009-123">18</xref> To avoid expensive cost in computing attribute reductions, we select the features (genes) with perfect <italic>attribute depended degree</italic>, a concept from rough set theory, and then create rule classifiers by the chosen genes instead of running attribute reductions. As it is very difficult to find the single genes or gene pairs with perfect attribute depended degree in terms of the canonical definition, we extend the concept of attribute depended degree to the more flexible soft computing framework. Using the extended definition of attribute depended degree, we can detect some single genes or gene pairs with indeed strong class discriminatory power while they will be ignored if the conventional attribute depended degree standard is employed. Consequently, although the rules derived from the detected genes or gene pairs might not be absolutely true, they are comparatively reliable and able to perform effective prediction.</p><p>We apply our algorithm to the four noted gene expression datasets: central nervous system (CNS) tumor, colon tumor, lung cancer, and diffuse large B-cell lymphoma (DLBCL). They are available from the Kent Ridge Bio-medical Data Set Repository (<ext-link ext-link-type="uri" xlink:href="http://datam.i2r.a-star.edu.sg/datasets/krbd/">http://datam.i2r.a-star.edu.sg/datasets/krbd/</ext-link>). We validate the efficacy of our method by leave-one-out cross-validation (LOOCV), and compare our results with other already published research outcomes. Furthermore, we examine and analyze the biological relevance of the selected genes.</p></sec><sec sec-type="results"><title>Results</title><sec sec-type="methods"><title>CNS tumor dataset</title><p>In the dataset, we first try to find the single genes with high class discriminative power. When <italic>&#x003b1;</italic> is set to 0.9 or 0.85, there is no gene with <italic>&#x003b1;</italic> depended degree equal to 1 occurring in all the 60 training sets; when <italic>&#x003b1;</italic> is set to 0.8, gene U28963_at occurs in 59 out of the 60 training sets; when <italic>&#x003b1;</italic> is set to 0.75 and 0.7, there are two and six genes occurring in all the 60 training sets, respectively. In every training set, each of the six genes results to two decision rules, which are used to predict the test sample. The final prediction estimate is the average of 60 test results. <xref ref-type="table" rid="t1-cin-2009-123">Table 1</xref> shows the prediction results by the six genes. Subsequently, we attempt to seek for the gene pairs with strong class discriminative ability. When <italic>&#x003b1;</italic> is set to 0.9, no gene pair is detected; when <italic>&#x003b1;</italic> is set to 0.85, only one gene pair is detected; when <italic>&#x003b1;</italic> is reduced to 0.8, eleven gene pairs are found. In general, each gene pair produces four decision rules. Then we apply the four decision rules to classify the test sample and the average of 60 test results is the prediction estimate of the gene pair. <xref ref-type="table" rid="t2-cin-2009-123">Table 2</xref> shows the prediction results by the eleven gene pairs.</p><p>Here we denote the expression level of gene <italic>G</italic> by g(<italic>G</italic>). When the first sample is left out as the test set, and the remaining samples set is trained by the learning algorithm, the selected gene U28963_at will give rise to two decision rules:</p><list list-type="bullet"><list-item><p>If g(U28963_at) &#x02264; 431, then Class 1;</p></list-item><list-item><p>If g(U28963_at) &#x0003e;431, then Class 0.</p></list-item></list><p>The two rules have 81% and 84% confidence, respectively. One can use the two rules to classify the test set. When another sample instead of the first one is left out, gene U28963_at will result to two similar decision rules:</p><list list-type="bullet"><list-item><p>If g(U28963_at) &#x02264; <italic>x</italic>, then Class 1;</p></list-item><list-item><p>If g(U28963_at) &#x0003e; <italic>x</italic>, then Class 0.</p></list-item></list><p><italic>x</italic> equals to 431 or is close to it. Anyway, the rules imply that if gene U28963_at is up-regulated in one CNS tumor patient, the patient will be more inclined to succumb to the disease. The other chosen genes give rise to similar form of rules.</p><p>Likewise, when the first sample is left out for test while the remaining samples are retained for training, the selected gene pair D83542_ at&#x02014;S71824_at will generate four decision rules:</p><list list-type="bullet"><list-item><p>if g(D83542_at) &#x02264; 280.5 and g(S71824_at) &#x02264; 434, then Class 1;</p></list-item><list-item><p>if g(D83542_at) &#x02264; 280.5 and g(S71824_at) &#x0003e; 434, then Class 1;</p></list-item><list-item><p>if g(D83542_at) &#x0003e; 280.5 and g(S71824_at) &#x02264; 434, then Class 1;</p></list-item><list-item><p>if g(D83542_at) &#x0003e; 280.5 and g(S71824_at) &#x0003e; 434, then Class 0.</p></list-item></list><p>The four rules possess 100%, 100%, 89% and 88% confidence, respectively. They can be simplified into equivalent three rules:</p><list list-type="bullet"><list-item><p>if g(D83542_at) &#x02264; 280.5 , then Class 1;</p></list-item><list-item><p>if g(S71824_at) &#x02264; 434, then Class 1;</p></list-item><list-item><p>if g(D83542_at) &#x0003e; 280.5 and g(S71824_at) &#x0003e; 434, then Class 0.</p></list-item></list><p>The three rules have 100%, 92% and 88% confidence, respectively. One can employ the four or alternative three rules to classify the test set. When another sample instead of the first one is left out, gene pair D83542_at&#x02014;S71824_at will generate four similar decision rules. These rules indicate that if both D83542_at and S71824_at are highly expressed in one CNS tumor patient, then the patient will be very likely to succumb to the disease. Similar rules can be derived by the other chosen gene pairs.</p></sec><sec sec-type="methods"><title>Colon tumor dataset</title><p>Using the same learning algorithm for the dataset, we screen the genes and gene pairs with comparatively high prediction performance. The results are presented in <xref ref-type="table" rid="t3-cin-2009-123">Table 3</xref> and <xref ref-type="table" rid="t4-cin-2009-123">Table 4</xref>. As before, decision rules can be induced by the selected genes or gene pairs.</p></sec><sec sec-type="methods"><title>Lung cancer dataset</title><p>In the dataset, when <italic>&#x003b1;</italic> is set to 0.8, no any gene is detected; when <italic>&#x003b1;</italic> equals to 0.75, eight genes are detected; when <italic>&#x003b1;</italic> is reduced to 0.7, no more genes are found. To make the decision rules induced by gene more reliable, we exclude the genes with missing values. When <italic>&#x003b1;</italic> is set to 0.9, 0.85 or 0.8, no any gene pair is found; when <italic>&#x003b1;</italic> is reduced to 0.75, eight gene pairs are detected. The results are presented in <xref ref-type="table" rid="t5-cin-2009-123">Table 5</xref> and <xref ref-type="table" rid="t6-cin-2009-123">Table 6</xref>.</p></sec><sec sec-type="methods"><title>DLBCL dataset</title><p>In the dataset, when <italic>&#x003b1;</italic> is set to 0.7, there are four genes selected; when <italic>&#x003b1;</italic> increases to 0.75, no any gene is found. With respect to gene pairs, when <italic>&#x003b1;</italic> is set to 0.9 or 0.85, no any gene pair is found; when <italic>&#x003b1;</italic> decreases to 0.8, there are 22 gene pairs chosen. The results are presented in <xref ref-type="table" rid="t7-cin-2009-123">Table 7</xref> and <xref ref-type="table" rid="t8-cin-2009-123">Table 8</xref>. <xref ref-type="table" rid="t8-cin-2009-123">Table 8</xref> shows only 20 out of the 22 gene pairs. The other two gene pairs are omitted because of their overly low prediction accuracy.</p></sec></sec><sec><title>Comparison of Prediction Performance</title><sec sec-type="methods"><title>CNS tumor dataset</title><p>The dataset is dataset C mentioned in<xref ref-type="bibr" rid="b19-cin-2009-123">19</xref> that is used to analyze the outcome of the treatment for central nervous system embryonal tumor patients. In this dataset, we gain the 83% and 90% best prediction accuracy using one and two genes respectively. In,<xref ref-type="bibr" rid="b19-cin-2009-123">19</xref> Pomeroy et al use a k-NNs algorithm to construct outcome predictor based on gene expression. The reported statistically significant gene size for k-NN models ranges from 2 to 21 genes, with the best prediction made by an 8-gene model that made 13/60 classification errors. Several other prediction algorithms including weighted voting, SVMs, and IBM SPLASH are also tested in.<xref ref-type="bibr" rid="b19-cin-2009-123">19</xref> In,<xref ref-type="bibr" rid="b20-cin-2009-123">20</xref> Zhang et al propose a hybrid approach, which combines discernibility matrix, the filter strategy and the wrapper method to select gene sets. Then they adopt the classifiers C4.5 and NaiveBayes to evaluate the prediction performance of the gene sets. Their prediction accuracy by LOOCV is 75% for C4.5 using 20 genes and 86.67% for Naive-Bayes using 29 genes. In,<xref ref-type="bibr" rid="b12-cin-2009-123">12</xref> Tan et al use decision trees (Single C4.5, Bagging C4.5, AdaBoost C4.5) to perform prediction tasks on cancerous microarray data including the CNS tumor dataset. They first employ Fayyad and Irani&#x02019;s<xref ref-type="bibr" rid="b21-cin-2009-123">21</xref> discretization method to screen 74 genes for the actual learning process. Their highest prediction accuracy is 88% by tenfold cross-validation. The comparison of our methods with the others is summarized in <xref ref-type="table" rid="t9-cin-2009-123">Table 9</xref>. The table shows that our results are better than almost all the other compared results from previous studies.</p><sec sec-type="methods"><title>Colon tumor dataset</title><p>The dataset is first studied by Alon et al.<xref ref-type="bibr" rid="b22-cin-2009-123">22</xref> They propose two-way clustering approach that classify genes into functional groups and classify tissues based on their gene expression similarity. Since their original work, the dataset has been frequently investigated by other investigators. In this dataset, we reach the 84% and 90% highest prediction accuracy using one and two genes respectively. <xref ref-type="table" rid="t10-cin-2009-123">Table 10</xref> compares the prediction results of our work with some other studies. The table demonstrates that whereas we use the least genes, our prediction accuracy is superior to or matches the others.</p></sec></sec><sec sec-type="methods"><title>Lung cancer dataset</title><p>In this dataset, we obtain the 85% and 82% highest prediction accuracy using one and two genes respectively. With respect to this dataset, we only find that Zhang et al report their study results<xref ref-type="bibr" rid="b20-cin-2009-123">20</xref> apart from the original paper.<xref ref-type="bibr" rid="b23-cin-2009-123">23</xref> <xref ref-type="table" rid="t11-cin-2009-123">Table 11</xref> presents the comparison between our method and that provided in.<xref ref-type="bibr" rid="b20-cin-2009-123">20</xref> Although their best prediction accuracy by the HFW feature selection approach is a little higher than ours, the numbers of the genes used by them far exceed ours. As for the other feature selection approaches including FCBF, CFS-SF and ReliefF, the prediction performance caused by them is inferior to ours.</p></sec><sec sec-type="methods"><title>DLBCL dataset</title><p>In this dataset, we achieve the 78% and 90% best prediction accuracy using one and two genes respectively. <xref ref-type="table" rid="t12-cin-2009-123">Table 12</xref> gives the comparison between our method and that provided in<xref ref-type="bibr" rid="b20-cin-2009-123">20</xref> and<xref ref-type="bibr" rid="b24-cin-2009-123">24</xref> Obviously, our results dominate the others.</p></sec></sec><sec sec-type="methods"><title>Analysis of Biological Relevance</title><sec sec-type="methods"><title>CNS tumor dataset</title><p>In this dataset, we identify six genes with comparatively high prediction performance individually. The six genes are U28963_at, X99050_rna1_at, D83542_at, S71824_at, U37673_ at, and D86974_at. According to the decision rules induced by the genes, we suspect that they are all over-expressed in the patients who succumb to their disease. As expected, three out of the six genes are picked as the markers of survival by Pomeroy et al.<xref ref-type="bibr" rid="b19-cin-2009-123">19</xref> The three genes are referred to as GPS2 (U28963_at), beta-NAP (U37673_at) and KIAA0220 gene (D86974_at) respectively. Moreover, beta-NAP and KIAA0220 gene are the members of the 8-gene model by which k-NN makes optimal prediction. In addition, three genes named Human polyposis locus (DP1 gene), NSCL1 and VLCAD which compose the gene pairs with strong prediction power are also identified as markers of survival by Pomeroy et al.<xref ref-type="bibr" rid="b19-cin-2009-123">19</xref></p><p>GPS2 encodes a protein involved in G protein-mitogen-activated protein kinase (MAPK) signaling cascades. The function of this gene may be signal repression. Zhang et al indicate that GPS2 interacts with another protein RFX4_v3 to modulate transactivation of genes involved in brain morphogenesis.<xref ref-type="bibr" rid="b25-cin-2009-123">25</xref> Therefore, the dysregulation of GPS2 may be closely correlated with the pathogenesis of CNS tumor. Beta-NAP, a cerebellar degeneration antigen, is a neuron-specific vesicle coat protein.<xref ref-type="bibr" rid="b26-cin-2009-123">26</xref> NSCL1 is the gene expressed predominantly in the developing nervous system.<xref ref-type="bibr" rid="b27-cin-2009-123">27</xref> Our rules indicate that if the gene is over-expressed, the patients will be more likely to succumb to the CNS tumor. It coincides with the observation reported in.<xref ref-type="bibr" rid="b27-cin-2009-123">27</xref></p><sec sec-type="methods"><title>Colon tumor dataset</title><p>In this dataset, we identify 21 genes which can result to relatively efficient prediction individually. Some of these genes have been proved to tightly link with the pathogenesis of colon tumor or other tumors. Desmin is identified as one of three known hub cancer genes in colon cancer-specific gene network.<xref ref-type="bibr" rid="b28-cin-2009-123">28</xref> Our rules indicate that the gene is down-regulated in colon tumor samples. The same conclusion is provided in.<xref ref-type="bibr" rid="b29-cin-2009-123">29</xref> The gene CRP encodes a member of the cysteine-rich protein (CSRP) family. This gene family includes a group of LIM domain proteins, which may be involved in regulatory processes important for development and cellular differentiation. The LIM/double zincfinger motif found in this gene product occurs in proteins with critical functions in gene regulation, cell growth, and somatic differentiation. This gene has been reported to be associated with several cancers.<xref ref-type="bibr" rid="b30-cin-2009-123">30</xref>&#x02013;<xref ref-type="bibr" rid="b32-cin-2009-123">32</xref> MONAP belongs to angiogenesis-related genes. Its overexpression is associated with the pathogenesis and progression of a variety of cancers.<xref ref-type="bibr" rid="b33-cin-2009-123">33</xref>&#x02013;<xref ref-type="bibr" rid="b37-cin-2009-123">37</xref> Our rules imply that gene MONAP is up-regulated in colon tumor samples. It is consistent with the established notion. Moreover, just as Desmin, MONAP is also identified as one of three known hub cancer genes in colon cancer-specific gene network.<xref ref-type="bibr" rid="b28-cin-2009-123">28</xref> hnRNP belongs to the subfamily of ubiquitously expressed heterogeneous nuclear ribonucleoproteins which are associated with pre-mRNAs in the nucleus and appear to influence pre-mRNA processing and other aspects of mRNA metabolism and transport. Thus its dysregulation may cause the occurrence of cancers. Hevin encodes the protein which is implicated in tumor cell growth, differentiation and metastasis, and may play the role of tumor-suppressor.<xref ref-type="bibr" rid="b38-cin-2009-123">38</xref>&#x02013;<xref ref-type="bibr" rid="b44-cin-2009-123">44</xref> Our rules show that if Hevin is down-regulated in the colon tissue samples, then the samples are more likely from the colon tumor patients. It rightly defends the argument that Hevin is the repressor of tumors. EF1R is associated with several functions including translation elongation, actin filament depolymerization, apoptosis, and ubiquitin-mediated protein degradation, etc. Its role in oncogenesis has been investigated by some researchers.<xref ref-type="bibr" rid="b45-cin-2009-123">45</xref>&#x02013;<xref ref-type="bibr" rid="b49-cin-2009-123">49</xref> Calgizzarin encodes the protein which belongs to the group of S100 proteins involved in the Ca<sup>2+</sup> signaling network, and regulates intracellular activities such as cell growth and motility, cell cycle progression, transcription, and cell differentiation<xref ref-type="bibr" rid="b50-cin-2009-123">50</xref>,<xref ref-type="bibr" rid="b51-cin-2009-123">51</xref> Chromosomal rearrangements and altered expression of this gene have been implicated in tumor metastasis. In,<xref ref-type="bibr" rid="b52-cin-2009-123">52</xref> calgizzarin is characterized as a proteomic marker of colorectal cancer due to its significant up-regulation in colorectal carcinoma. The same observation is provided in.<xref ref-type="bibr" rid="b53-cin-2009-123">53</xref>&#x02013;<xref ref-type="bibr" rid="b55-cin-2009-123">55</xref> Tanaka et al detect that the expression of human calgizzarin is remarkably elevated in colorectal cancers compared with that in normal colorectal mucosa by a large scale random cDNA sequencing and Northern blot analysis.<xref ref-type="bibr" rid="b56-cin-2009-123">56</xref> Our rules express the same tendency that calgizzarin is over-expressed in colon tumors. Likewise, our rules demonstrate that TPM1 is down-regulated in colon tumor that coincides with the finding reported in.<xref ref-type="bibr" rid="b57-cin-2009-123">57</xref> Our rules exhibit that PCBD1 is up-regulated in colon tumor, but very few literatures reports the same result. Additionally, there are several genes tightly associated with colon tumor among the marked gene pairs. In our rules, if MIF (macrophage migration inhibitory factor) is up-regulated, then the sample tends to come from tumor tissue. A number of investigations have demonstrated that MIF promotes colon tumor and the other cancers.<xref ref-type="bibr" rid="b58-cin-2009-123">58</xref>&#x02013;<xref ref-type="bibr" rid="b63-cin-2009-123">63</xref> Thus, our rules conform to the documented evidence. CDH3 has been found to be involved in a broad spectrum of cancers including colorectal cancer.<xref ref-type="bibr" rid="b64-cin-2009-123">64</xref>&#x02013;<xref ref-type="bibr" rid="b71-cin-2009-123">71</xref> The gene is identified as accurate prognostic indicator of several tumors due to its marked up-regulation in these tumors.<xref ref-type="bibr" rid="b66-cin-2009-123">66</xref>,<xref ref-type="bibr" rid="b68-cin-2009-123">68</xref>,<xref ref-type="bibr" rid="b71-cin-2009-123">71</xref>,<xref ref-type="bibr" rid="b72-cin-2009-123">72</xref> Our rules show that it is over-expressed in colon tumor as well.</p><p>In summary, the majority of important genes relevant to the pathogenesis of colon tumor are marked by our method. The other identified up-regulated genes include Hsp60, Human serine kinase mRNA, IPL1, HYPOTHETICAL PROTEIN IN TRPE 3&#x02019;REGION and COL11A2 while down-regulated genes encompass MYL9, ACTIN, MaxiK, MGP, GLUT4, MYOSIN HEAVY CHAIN and HCC-1. Some of them have definite biological meaning while the others remain to be explored. Here what we want to emphasize is that the genes distinguishing tumor from normal tissues well involve not only muscle-specific ones but also non-muscle-specific portion. This is in agreement with the finding reported in.<xref ref-type="bibr" rid="b22-cin-2009-123">22</xref> It also reflects the complexity of cancerous pathogenesis.</p></sec></sec><sec sec-type="methods"><title>Lung cancer dataset</title><p>In this dataset, we identify eight genes with comparatively strong prediction power individually. Our rules reveal that the reduced expression of each gene is correlated with the poor prognosis of the cancer. Owing to five out of the eight genes have no annotation available in raw dataset, we only learn about the other three genes: TCEAL1, GEMIN5 and TMPO. TCEAL1, also named as p21, which belongs to the Cip/Kip family of cyclin dependent kinases, has been identified as a gene whose product is tightly associated with development and metastasis of several cancers.<xref ref-type="bibr" rid="b73-cin-2009-123">73</xref>&#x02013;<xref ref-type="bibr" rid="b77-cin-2009-123">77</xref> Direct and indirect evidence has proved that a decrease in the expression levels of the gene might enhance tumor formation, progression and bad prognosis. GEMIN5 encodes the protein which is part of a large macromolecular complex localized to both the cytoplasm and the nucleus that plays a role in the cytoplasmic assembly of small nuclear ribonucleoproteins (snRNPs). In,<xref ref-type="bibr" rid="b78-cin-2009-123">78</xref> Lee et al suggest that Gemin5 overexpression inhibts tumor cell motility so as to may play a role of suppressing metastatic progression. This conforms to our rules. We have not found any evidence indicating that the expression levels of TMPO were correlated with prognosis of cancers. But there are investigations showing that the gene is deregulated in various human tumors.<xref ref-type="bibr" rid="b79-cin-2009-123">79</xref>,<xref ref-type="bibr" rid="b80-cin-2009-123">80</xref></p><p>In addition, we marked eight gene pairs with good prediction performance. Apart from the non-annotated genes, the involved genes encompass SMAC, PFDN2, FLJ10829, LOC51646, FLJ10326, FLJ12438, GYS10.145 and MSH5. Our rules imply that the decreased expression of these genes indicate a poor prognosis of NSCLC patients- relapse or metastasis. SMAC encodes an inhibitor of apoptosis protein (IAP)-binding protein. A wide variety of investigations have revealed the low expression levels of SMAC correlate with a worse prognosis in many tumor types including NSCLC.<xref ref-type="bibr" rid="b81-cin-2009-123">81</xref>&#x02013;<xref ref-type="bibr" rid="b92-cin-2009-123">92</xref> At the same time, some researchers propose the idea of treating cancers by enhancing SMAC expression in tumor cells.<xref ref-type="bibr" rid="b83-cin-2009-123">83</xref>,<xref ref-type="bibr" rid="b85-cin-2009-123">85</xref>&#x02013;<xref ref-type="bibr" rid="b87-cin-2009-123">87</xref>,<xref ref-type="bibr" rid="b89-cin-2009-123">89</xref> MSH5 encodes a member of the mutS family of proteins that are involved in DNA mismatch repair or meiotic recombination (MMR) processes. It is a strong candidate for lung cancer susceptibility as deficiency of MMR has been documented to have a role in lung cancer.<xref ref-type="bibr" rid="b93-cin-2009-123">93</xref> Hence, it is quite possible that the downregulation of the gene results to unfavorable clinical outcome of tumors.</p></sec><sec sec-type="methods"><title>DLBCL dataset</title><p>In this dataset, we marked four genes with relatively excellent prediction ability individually. The four genes are EZF, IGF2, CEBPE and BTF1. Our rules indicate that elevated expression of EZF, CEBPE or BTF1 may cause a worse prognosis of DLBCL while abundant expression of IGF2 implies a better prognosis. In,<xref ref-type="bibr" rid="b93-cin-2009-123">93</xref> IGF2 is also identified as a positive indicator of DLBCL prognosis. Whereas previous investigation indicates that these genes are involved in cancerous pathogenesis, further biological insights remain to be clarified.</p><p>Some genes lying in the gene pairs we selected in the dataset maybe have important biological relevance. DBP is responsible for high, tissue-specific expression of albumin in fully differentiated hepatocytes, which is expressed by adult not fetal liver cells, and is quickly down-regulated in proliferating hepatocytes.<xref ref-type="bibr" rid="b94-cin-2009-123">94</xref> Our rules indicate that if the gene is down-regulated in one DLBCL patient, then the patient is inclined to have a favorable prognosis. That sounds reasonable. TGM2 encodes the protein which is the enzyme that catalyzes the crosslinking of proteins and appears to be involved in apoptosis. Oudejans et al point out that differences in apoptosis resistance occurring between DLBCL samples link up with distinct clinical outcome.<xref ref-type="bibr" rid="b95-cin-2009-123">95</xref> Since the abundant expression of TGM2 activates the induction of the apoptosis, the upregulation of the gene might mean an excellent prognosis. Our rules reflect the tendency. In addition, in,<xref ref-type="bibr" rid="b96-cin-2009-123">96</xref> Mishra et al suggest that TGM2 modification of p53 oncoprotein could be an additional mechanism whereby TGM2 could facilitate apoptosis. In,<xref ref-type="bibr" rid="b97-cin-2009-123">97</xref> Mangala et al hold that TGM2-induced alterations in the extracellular matrix could effectively inhibit the process of metastasis. In,<xref ref-type="bibr" rid="b98-cin-2009-123">98</xref> Xu et al argue that TGM2 acts as an inhibitor of tumor progression in combination with another gene. PDCD4 encodes a protein localized to the nucleus in proliferating cells which is thought to play a role in apoptosis but the specific role has not yet been determined. Our rules imply that decreased expression of the gene is associated with a good prognosis. It appears to contradict with some previous reports,<xref ref-type="bibr" rid="b99-cin-2009-123">99</xref>&#x02013;<xref ref-type="bibr" rid="b103-cin-2009-123">103</xref> whereas Lankat-Buttgereit et al point out that the function of Pdcd4 might be cell type specific and a role for Pdcd4 in apoptosis or as a tumor suppressor might be limited to certain cell types.<xref ref-type="bibr" rid="b104-cin-2009-123">104</xref> The other identified genes like HRES-1, DTNA,VIPR1, BTF1, HAB1, PTPRN2, EIF2B, IQGAP2 etc., overall possess strong class discriminative power, while their biological mechanism indicating the clinical outcome of DLBCL or other tumors remain unclear.</p></sec></sec><sec><title>Conclusion</title><p>Using gene expression patterns to conduct classification or prediction of cancer is often faced with the dilemma: genes (features) far outnumber samples (instances), which will bring about weak prediction efficiency or effect if the model is not chosen reasonably. Another concern is the interpretability of the prediction model when biologists and clinician care for your investigation. Here we employ feature selection to overcome the first difficulty and decision rules to handle the second trouble. We propose one way of feature selection on the basis of the depended degree, a concept from rough set theory. As the canonical definition of the depended degree is too stringent to perform feature selection well, we extend its definition under soft computing consideration. We define the concept of <italic>&#x003b1;</italic> depended degree, whereby we are capable of screening highly discriminative features. Additionally, our work is in accordance with the principle of Occam&#x02019;s razor: when deciding among many models which make equivalent predictions, choose the simplest one. For this purpose, we only use single genes or gene pairs to build decision rules, which are used to execute prediction of cancer. Results demonstrate that our models work well in that the picked single genes and gene pairs overall give rise to excellent prediction, and meanwhile some biologically significant genes are identified. In general, our method is simpler and more interpretable than most of previously proposed approaches, since our model is based on rules and our rules are created via very few genes. Moreover, our model is robust as we are able to tune our parameters to meet different datasets. Indeed, through comparison, we discover our method outperforms or at least match other algorithms in simplicity and efficacy. It is not strange at all that one or two-gene models are able to result in accurate cancerous prediction because the single genes or gene pairs possibly are the biological or clinical indicators of some specific cancer or general cancer. It appears that one or two gene prediction models are overly simple in that the routine belief is that cancerous pathogenesis is involved in complex systems composed of multi-genes. Whereas our models do not violate the habitual notion in that we have various genes or gene pairs which can cause accurate prediction individually so as to be regarded as candidate markers of cancer. In contrast, some prediction models are not applicable for they contain too many parameters (genes) so that overfitting happens easily. Similar idea is expressed in<xref ref-type="bibr" rid="b4-cin-2009-123">4</xref>,<xref ref-type="bibr" rid="b7-cin-2009-123">7</xref>,<xref ref-type="bibr" rid="b13-cin-2009-123">13</xref>,<xref ref-type="bibr" rid="b15-cin-2009-123">15</xref>,<xref ref-type="bibr" rid="b105-cin-2009-123">105</xref> as well. Another advantage of our models is that significant biomarkers can be identified with ease thanks to the operation of few genes once while it is hard to assess which gene is more important by multi-gene models for they run on the basis of a group of genes.</p><p>We test our method on several gene expression datasets including CNS tumor, colon tumor, lung cancer and DLBCL. In each dataset, we identify several important genes with documented biological relevance to the malignancy or the cell type. In the CNS tumor dataset, some significant genes like GPS2, beta-NAP, KIAA0220 gene, NSCL1 etc., are identified. In the colon tumor dataset, we succeed in choosing the genes highly related to colon tumor or other tumors. They include Desmin, CRP, MONAP, hnRNP, Hevin, EF1R, calgizzarin, TPM1, PCBD1, MIF etc., wherein calgizzarin has been emphasized as a proteomic marker of colorectal cancer.<xref ref-type="bibr" rid="b52-cin-2009-123">52</xref> In the lung dataset, TCEAL1, GEMIN5, TMPO, SMAC, MSH5 etc. genes associated with the pathogenesis and progression of a variety of cancers are marked by us. In the DLBCL dataset, IGF2, DBP, TGM2, PDCD4 etc., are identified. Their close relationship with tumor occurrence, progression, metastasis and relapse has been widely explored.</p><p>Generally speaking, most of the genes associated with tumors encode the proteins involved in cell growth, motility and differentiation, apoptosis, angiogenesis, metabolism, chromosomal rearrangement and translocation, and immune reaction. It is worth noting that whereas there may exist a few particular markers for some specific tumor, a majority of tumor markers might be shared by several tumors. In addition, it is possible that the repressor of some tumor acts as the promoter of another tumor. And it is not impossible that the enhancer of some tumor in one stage transforms into the inhibitor of the same tumor during the other stage.</p><p>Another issue concerned with molecular prediction of cancer is whether the prediction performance of one gene or gene set is proportional to its biological interest. We identify some genes which own strong prediction power while their biological or clinical involvements remain unobvious. Whether these genes are indeed correlated to the pathogenesis of cancer, or merely coincidence? This is an important problem, deserving further investigation.</p><p>In summary, our method uses very few genes to build rule classifiers of cancer. These classifiers can carry out comparatively accurate prediction. The efficacy of our method has been manifested to be satisfactory by testing on four gene expression datasets. Our follow-up study is to examine our method by more microarray data, including multi-class datasets. In addition, we plan to design more powerful and robust rule classifiers in conjunction with other machine learning algorithms.</p></sec><sec sec-type="materials|methods"><title>Methods and Materials</title><sec><title>Rough sets</title><p>In reality, when we are faced with a heap of data, we often want to learn about them with already known knowledge. However, a majority of data cannot be precisely defined by known knowledge. Thus, in rough set theory, Pawlak describes ill-defined data by designing two concepts: upper approximations and lower approximations, based on the equivalence relation, which is also referred to as one <italic>knowledge</italic> on the studied object set.</p><p><bold>Definition 1</bold> Let <italic>U</italic> be a universe of discourse, <italic>X</italic> &#x02286; <italic>U</italic>, and <italic>R</italic> is an equivalence relation on <italic>U. U/R</italic> represents the set of the equivalence class of <italic>U</italic> induced by <italic>R. R</italic> <italic><sub>*</sub></italic> <italic>X</italic>, <italic>R * X</italic>, <italic>br</italic>(<italic>R</italic>, <italic>X</italic>), <italic>pos</italic>(<italic>R</italic>, <italic>X</italic>) and <italic>neg</italic>(<italic>R</italic>, <italic>X</italic>) represent the <italic>lower approximation</italic>, <italic>upper approximation</italic>, <italic>boundary region</italic>, <italic>positive region</italic> and <italic>negative region</italic> of <italic>X</italic> on <italic>R</italic> in <italic>U</italic>, respectively, where</p><disp-formula><mml:math id="M1"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mo>*</mml:mo></mml:msub><mml:mi>X</mml:mi><mml:mo>=</mml:mo><mml:mo>&#x0222a;</mml:mo><mml:mo>{</mml:mo><mml:mi>Y</mml:mi><mml:mo>&#x02208;</mml:mo><mml:mi>U</mml:mi><mml:mo>/</mml:mo><mml:mi>R</mml:mi><mml:mo>|</mml:mo><mml:mi>Y</mml:mi><mml:mo>&#x02286;</mml:mo><mml:mi>X</mml:mi><mml:mo>}</mml:mo><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mo>*</mml:mo></mml:msup><mml:mi>X</mml:mi><mml:mo>=</mml:mo><mml:mo>&#x0222a;</mml:mo><mml:mo>{</mml:mo><mml:mi>Y</mml:mi><mml:mo>&#x02208;</mml:mo><mml:mi>U</mml:mi><mml:mo>/</mml:mo><mml:mi>R</mml:mi><mml:mo>|</mml:mo><mml:mi>Y</mml:mi><mml:mo>&#x02229;</mml:mo><mml:mi>X</mml:mi><mml:mo>&#x02260;</mml:mo><mml:mo>&#x02205;</mml:mo><mml:mo>}</mml:mo><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>R</mml:mi><mml:mo>,</mml:mo><mml:mi>X</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mo>*</mml:mo></mml:msub><mml:mi>X</mml:mi><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>b</mml:mi><mml:mi>r</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>R</mml:mi><mml:mo>,</mml:mo><mml:mi>X</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mo>*</mml:mo></mml:msup><mml:mi>X</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mo>*</mml:mo></mml:msub><mml:mi>X</mml:mi><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>g</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>R</mml:mi><mml:mo>,</mml:mo><mml:mi>X</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi>U</mml:mi><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mo>*</mml:mo></mml:msup><mml:mi>X</mml:mi><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula><p>If <italic>R</italic> <italic><sup>*</sup></italic> <italic>X</italic> = <italic>R</italic> <italic><sub>*</sub></italic> <italic>X</italic>, then <italic>X</italic> is called <italic>definable</italic> or the <italic>precise set</italic> on <italic>R</italic>; otherwise <italic>X</italic> is called <italic>indefinable</italic> or the <italic>rough set</italic> on <italic>R</italic>.<xref ref-type="bibr" rid="b6-cin-2009-123">6</xref></p><p>The data studied by rough set theory are mainly organized in the form of decision tables. One decision table can be represented as <italic>S</italic>= ( <italic>U</italic>, <italic>A</italic> = <italic>C</italic> &#x0222a; <italic>D</italic>), where <italic>U</italic> is the set of samples, <italic>C</italic> the condition attribute set and <italic>D</italic> the decision attribute set. In the decision table, we define the function <italic>I</italic><italic><sub>a</sub></italic> that maps a member (sample) of <italic>U</italic> to the value of the member on the attribute <italic>a</italic> (<italic>a &#x02208; A</italic>), and an equivalence relation <italic>R</italic>(<italic>A</italic>&#x02019;) induced by the attribute subset <italic>A</italic>&#x02019; &#x02286; <italic>A</italic> as: for <italic>x</italic>, <italic>y &#x02208; U</italic>, <italic>xR</italic>(<italic>A</italic>&#x02019;) <italic>y</italic> if and only if <italic>I</italic><italic><sub>a</sub></italic>(<italic>x</italic>) = <italic>I</italic><italic><sub>a</sub></italic>(<italic>y</italic>) for each <italic>a &#x02208; A</italic>&#x02019;.</p><p>In,<xref ref-type="bibr" rid="b17-cin-2009-123">17</xref> Pawlak defines a decision logic language (<italic>DLL</italic>) for decision table <italic>S</italic>= ( <italic>U</italic>, <italic>A</italic> = <italic>C</italic> &#x0222a; <italic>D</italic>) as: each (<italic>a</italic>, <italic>v</italic>) is an atomic formula, where <italic>a</italic> &#x02208; <italic>A</italic> and <italic>v &#x02208; V</italic><italic><sub>a</sub></italic> (set of all the values of a); if &#x003d5; and &#x003c8; are formulas, then so are &#x000ac;&#x003d5;, &#x003d5;&#x02227;&#x003c8;, &#x003d5;&#x02228;&#x003c8;, &#x003d5;&#x02192;&#x003c8;, and &#x003d5;&#x02194;&#x003c8;. The semantics of <italic>DLL</italic> are defined through the model of decision tables. The <italic>satisfiability</italic> of a formula &#x003d5; by an object <italic>x</italic> in <italic>S</italic>, denoted by <italic>x</italic> &#x0255e; <sub>S</sub>&#x003d5; or for short <italic>x</italic> &#x0255e; &#x003d5; if <italic>S</italic> is understood, is defined by the following conditions:</p><list list-type="order"><list-item><p><italic>x</italic> &#x0255e; (<italic>a</italic>, <italic>v</italic>) if and only if <italic>I</italic><italic><sub>a</sub></italic>(<italic>x</italic>) = <italic>v</italic>,</p></list-item><list-item><p><italic>x</italic> &#x0255e; &#x000ac;&#x003d5; if and only if not <italic>x</italic> &#x0255e; &#x003d5;,</p></list-item><list-item><p><italic>x</italic> &#x0255e; &#x003d5;&#x02227;&#x003c8; if and only if <italic>x</italic> &#x0255e; &#x003d5; and <italic>x</italic> &#x0255e; &#x003c8;,</p></list-item><list-item><p><italic>x</italic> &#x0255e; &#x003d5;&#x02228;&#x003c8; if and only if <italic>x</italic> &#x0255e; &#x003d5; or <italic>x</italic> &#x0255e; &#x003c8;,</p></list-item><list-item><p><italic>x</italic> &#x0255e; &#x003d5;&#x02192;&#x003c8; if and only if <italic>x</italic> &#x0255e; &#x000ac;&#x003d5;&#x02228;&#x003c8;,</p></list-item><list-item><p><italic>x</italic> &#x0255e; &#x003d5;&#x02194;&#x003c8; if and only if <italic>x</italic> &#x0255e; &#x003d5; &#x02192; &#x003c8; and <italic>x</italic> &#x0255e; &#x003c8;&#x02192;&#x003d5;.</p></list-item></list><p>We call the set <italic>m</italic><italic><sub>S</sub></italic>(&#x003d5;) = {<italic>x</italic> &#x02208; <italic>U</italic> | <italic>x</italic> &#x0255e; <italic><sub>S</sub></italic>&#x003d5;} the <italic>meaning</italic> of formula &#x003d5; in decision table <italic>S. m</italic><italic><sub>S</sub></italic>(&#x003d5;) is simply written as <italic>m</italic>(&#x003d5;) if <italic>S</italic> is understood. On the other hand, we call &#x003d5; a <italic>description</italic> of object set <italic>m</italic>(&#x003d5;). Obviously, the following properties hold:</p><list list-type="alpha-lower"><list-item><p><italic>m</italic>((<italic>a</italic>, <italic>v</italic>)) = {<italic>x</italic> &#x02208; <italic>U</italic> | <italic>I</italic><italic><sub>a</sub></italic>(<italic>x</italic>) = <italic>v</italic>},</p></list-item><list-item><p><italic>m</italic>(&#x000ac;&#x003d5;) = &#x0223c;<italic>m</italic>(&#x003d5;),</p></list-item><list-item><p><italic>m</italic>(&#x003d5;&#x02227;&#x003c8;) = <italic>m</italic>(&#x003d5;) &#x02229; <italic>m</italic>(&#x003c8;),</p></list-item><list-item><p><italic>m</italic>(&#x003d5;&#x02228;&#x003c8;) = <italic>m</italic>(&#x003d5;) &#x0222a; <italic>m</italic>(&#x003c8;),</p></list-item><list-item><p><italic>m</italic>(&#x003d5;&#x02192;&#x003c8;) = &#x0223c;<italic>m</italic>(&#x003d5;) &#x0222a; <italic>m</italic>(&#x003c8;),</p></list-item><list-item><p><italic>m</italic>(&#x003d5;&#x02194;&#x003c8;) = (<italic>m</italic>(&#x003d5;) &#x02229; <italic>m</italic>(&#x003c8;)) &#x0222a; (&#x0223c;<italic>m</italic>(&#x003d5;) &#x02229; &#x0223c;<italic>m</italic>(&#x003c8;)).</p></list-item></list><p>In rough set theory, the <italic>depended degree</italic> of an attribute subset <italic>P</italic> by an attribute subset <italic>Q</italic> is denoted by &#x003b3; <italic><sub>p</sub></italic>(<italic>Q)</italic> and is defined as</p><disp-formula><mml:math id="M2"><mml:mrow><mml:msub><mml:mrow><mml:mi>&#x003b3;</mml:mi></mml:mrow><mml:mi>P</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>Q</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>|</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mtext>POS</mml:mtext></mml:mrow></mml:mrow><mml:mi>P</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>Q</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mo>|</mml:mo><mml:mi>U</mml:mi><mml:mo>|</mml:mo></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula><p>where 

<inline-formula><mml:math id="M3"><mml:mrow><mml:mo>|</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mtext>POS</mml:mtext></mml:mrow></mml:mrow><mml:mi>P</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>Q</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>|</mml:mo><mml:mo>=</mml:mo><mml:mo>|</mml:mo><mml:munder><mml:mo>&#x0222a;</mml:mo><mml:mrow><mml:mi>X</mml:mi><mml:mo>&#x02208;</mml:mo><mml:mi>U</mml:mi><mml:mo>/</mml:mo><mml:mi>R</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>Q</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:munder><mml:mrow><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>P</mml:mi><mml:mo>,</mml:mo><mml:mi>X</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>|</mml:mo></mml:mrow></mml:math></inline-formula> represents the size of the union of the positive region of each equivalence class in <italic>U/R</italic>(<italic>Q</italic>) on <italic>P</italic> in <italic>U</italic>, and <italic>U</italic> represents the size of <italic>U</italic> (set of samples).</p><p>If <italic>Q</italic> is the decision attribute <italic>D</italic>, and <italic>P</italic> a subset of condition attributes, then &#x003b3; <italic><sub>p</sub></italic>(<italic>D</italic>) indicates the depended degree of the condition attribute subset <italic>P</italic> by the decision attribute <italic>D</italic>. It means that, to what degree, <italic>P</italic> can discriminate the distinct classes of <italic>D</italic>. Thus, &#x003b3; <italic><sub>p</sub></italic>(<italic>D</italic>) rightly reflects the classification power of the subset <italic>P</italic> of condition attributes. The greater &#x003b3; <italic><sub>p</sub></italic>(<italic>D</italic>) is, the stronger classification ability <italic>P</italic> inclines to possess.</p><p>Rough set theory tries to discover the simplest <italic>decision rules</italic> with the equivalent explaining power and classification performance as more complicated rules. One decision rule with the form of &#x0201c;<italic>A</italic> &#x021d2; <italic>B</italic>&#x0201d; indicates that &#x0201c;if <italic>A</italic>, then <italic>B</italic>&#x0201d;, where <italic>A</italic> is the description of condition attributes and <italic>B</italic> the description of decision attributes. The <italic>confidence</italic> of a decision rule <italic>A</italic> &#x021d2; <italic>B</italic> is defined as:</p><disp-formula><mml:math id="M4"><mml:mrow><mml:mtext>confidence&#x02009;</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>A</mml:mi><mml:mo>&#x021d2;</mml:mo><mml:mi>B</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mtext>support&#x02009;</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>A</mml:mi><mml:mo>&#x02227;</mml:mo><mml:mi>B</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mtext>support&#x02009;</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>A</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula><p>where support (<italic>A</italic>) denotes the proportion of the samples satisfying <italic>A</italic> and support (<italic>A</italic> &#x02227; <italic>B</italic>) the proportion of the samples satisfying <italic>A</italic> and <italic>B</italic> simultaneously. According to the <italic>DLL</italic>, the <italic>confidence</italic> of a decision rule <italic>A</italic> &#x021d2; <italic>B</italic> is rewritten as:</p><disp-formula><mml:math id="M5"><mml:mrow><mml:mtext>confidence&#x02009;</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>A</mml:mi><mml:mo>&#x021d2;</mml:mo><mml:mi>B</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>|</mml:mo><mml:mi>m</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>A</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x02229;</mml:mo><mml:mi>m</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>B</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mo>|</mml:mo><mml:mi>m</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>A</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>|</mml:mo></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula><p>The confidence of a decision rule implies the reliable degree of the rule. If one decision rule has 100% confidence, we call it the <italic>consistent decision rule</italic>.</p><p>In the previous studies of classifying cancer by gene expression profiles using rough set theory, the measure of depended degree is often set as the basis of ranking genes.<xref ref-type="bibr" rid="b9-cin-2009-123">9</xref>,<xref ref-type="bibr" rid="b10-cin-2009-123">10</xref> However, as the canonical definition of depended degree is overly stringent, sometimes it is not able to rightly express the discriminatory power of features. Hence, here we extend the definition of depended degree under soft computing consideration.</p><p><bold>Definition 2</bold> Let <italic>U</italic> be a universe of discourse, <italic>X</italic> &#x02286; <italic>U</italic>, 0 &#x02264; <italic>&#x003b1;</italic> &#x02264; 1 and <italic>R</italic> is an equivalence relation on <italic>U. pos</italic>(<italic>R</italic>, <italic>X</italic>, <italic>&#x003b1;</italic>) representing the <italic>&#x003b1; positive region</italic> of <italic>X</italic> on <italic>R</italic> in <italic>U</italic>, is defined as:</p><disp-formula><mml:math id="M6"><mml:mrow><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>R</mml:mi><mml:mo>,</mml:mo><mml:mi>X</mml:mi><mml:mo>,</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo>&#x0222a;</mml:mo><mml:mo>{</mml:mo><mml:mi>Y</mml:mi><mml:mo>&#x02208;</mml:mo><mml:mi>U</mml:mi><mml:mo>/</mml:mo><mml:mi>R</mml:mi><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mi>Y</mml:mi><mml:mo>&#x02229;</mml:mo><mml:mi>X</mml:mi><mml:mo>|</mml:mo><mml:mo>/</mml:mo><mml:mo>|</mml:mo><mml:mi>Y</mml:mi><mml:mo>|</mml:mo><mml:mo>&#x02265;</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mo>}</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula><p>Correspondingly, the <italic>&#x003b1; depended degree</italic> of an attribute subset <italic>P</italic> by an attribute subset <italic>Q</italic>, denoted by &#x003b3; <italic><sub>p</sub></italic>(<italic>Q</italic>, <italic>&#x003b1;</italic>), is defined as:</p><disp-formula><mml:math id="M7"><mml:mrow><mml:msub><mml:mrow><mml:mi>&#x003b3;</mml:mi></mml:mrow><mml:mi>P</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>Q</mml:mi><mml:mo>,</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>|</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mtext>POS</mml:mtext></mml:mrow></mml:mrow><mml:mi>P</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>Q</mml:mi><mml:mo>,</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mo>|</mml:mo><mml:mi>U</mml:mi><mml:mo>|</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula><p>where 

<inline-formula><mml:math id="M8"><mml:mrow><mml:mo>|</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mtext>POS</mml:mtext></mml:mrow></mml:mrow><mml:mi>P</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>Q</mml:mi><mml:mo>,</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>|</mml:mo><mml:mo>=</mml:mo><mml:mo>|</mml:mo><mml:munder><mml:mo>&#x0222a;</mml:mo><mml:mrow><mml:mi>X</mml:mi><mml:mo>&#x02208;</mml:mo><mml:mi>U</mml:mi><mml:mo>/</mml:mo><mml:mi>R</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>Q</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:munder><mml:mrow><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>P</mml:mi><mml:mo>,</mml:mo><mml:mi>X</mml:mi><mml:mo>,</mml:mo><mml:mi>&#x003b1;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>|</mml:mo></mml:mrow></mml:math></inline-formula> represents the size of the union of the <italic>&#x003b1; positive region</italic> of each equivalence class in <italic>U</italic>/<italic>R</italic> (<italic>Q</italic>) on <italic>P</italic> in <italic>U</italic>.</p><p>Obviously, the definition of <italic>&#x003b1;</italic> depended degree is a generalization of the definition of depended degree as when <italic>&#x003b1;</italic> equals to 1, both definitions are equivalent. We choose <italic>&#x003b1;</italic> depended degree instead of depended degree as the basis of screening features. Once <italic>&#x003b1;</italic> value is determined, we only choose the genes or gene pairs with 1 of &#x003b3; <italic><sub>p</sub></italic>(<italic>D</italic>, <italic>&#x003b1;</italic>) value to build classification (decision) rules. Suppose g is one of the selected genes and <italic>U</italic> sample set. <italic>U/R</italic>(<italic>g</italic>) = {<italic>c</italic><sub>1</sub>(<italic>g</italic>), <italic>c</italic><sub>2</sub>(<italic>g</italic>), &#x02026;, <italic>c</italic><italic><sub>n</sub></italic>(<italic>g</italic>)} represents the set of the equivalence class of samples induced by <italic>R</italic>(<italic>g</italic>). Two samples <italic>s</italic><sub>1</sub> and <italic>s</italic><sub>2</sub> belong to the same equivalence class of <italic>U/R</italic>(<italic>g</italic>) if and only if they have the same value on <italic>g</italic>. In addition, we represent the set of the equivalence class of samples induced by <italic>R</italic>(<italic>D</italic>) as <italic>U/R</italic>(<italic>D</italic>) = {<italic>d</italic><sub>1</sub>(<italic>D</italic>), <italic>d</italic><sub>2</sub>(<italic>D</italic>), &#x02026;, <italic>d</italic><italic><sub>m</sub></italic>(<italic>D</italic>)}, where <italic>D</italic> is the class (decision) attribute. Two samples <italic>s</italic><sub>1</sub> and <italic>s</italic><sub>2</sub> belong to the same equivalence class of <italic>U/ R</italic>(<italic>D</italic>) if and only if they have the same value on <italic>D</italic>. For each <italic>c</italic><sub>i</sub>(<italic>g</italic>) (<italic>i</italic> = 1, 2, &#x02026;, <italic>n</italic>), if there exists some <italic>d</italic><italic><sub>j</sub></italic>(<italic>D</italic>) ( <italic>j</italic> &#x02208; {1, 2,&#x02026;, <italic>m</italic>}), satisfying |<italic>c</italic><italic><sub>i</sub></italic>(<italic>g</italic>) &#x02229; <italic>d</italic><italic><sub>j</sub></italic>(<italic>D</italic>)|/ |c<italic><sub>i</sub></italic>(<italic>g</italic>)| &#x02265; <italic>&#x003b1;</italic>, then we generate the classification rule: <italic>A</italic>(<italic>c</italic><italic><sub>i</sub></italic>(<italic>g</italic>)) &#x021d2; <italic>B</italic>(<italic>d</italic><italic><sub>j</sub></italic>(<italic>D</italic>)), where <italic>A</italic>(<italic>c</italic><italic><sub>i</sub></italic>(<italic>g</italic>)) is the formula describing the sample set <italic>c</italic><italic><sub>i</sub></italic>(<italic>g</italic>) by <italic>g</italic> value and <italic>B</italic>(<italic>d</italic><italic><sub>j</sub></italic>(<italic>D</italic>)) is the formula describing the sample set <italic>d</italic><italic><sub>j</sub></italic>(<italic>D</italic>) by the class value. In the case of gene pairs, we construct classification rules through the same strategy. Here what we want to emphasize is that only the single genes or gene pairs chosen by all the leave-one-out training sets are used for building classification rules.</p><p>The confidences of the rules generated by our approach depend on <italic>&#x003b1;</italic>. The following theorem states the relationship between <italic>&#x003b1;</italic> and the confidences of the induced rules.</p><p><bold>Theorem 1</bold> The confidence of each induced decision rule by our way is no less than <italic>&#x003b1;</italic>.</p><p>Proof. For any condition attribute subset <italic>P</italic> of size one or two, if &#x003b3; <italic><sub>p</sub></italic>(<italic>D</italic>, <italic>&#x003b1;</italic>) = 1, then <italic>P</italic> will be chosen by our way. Suppose the decision rule <italic>A</italic> &#x021d2; <italic>B</italic> is produced by <italic>P</italic>. Then by our way, we have <italic>m</italic>(<italic>A</italic>) &#x02208; <italic>U/R</italic>(<italic>P</italic>), <italic>m</italic>(<italic>B</italic>) &#x02208; <italic>U/R</italic>(<italic>D</italic>) and |<italic>m</italic>(<italic>A</italic>) &#x02229; <italic>m</italic>(<italic>B</italic>)|/|<italic>m</italic>(<italic>A</italic>)| &#x02265; <italic>&#x003b1;</italic>. As confidence ( <italic>A</italic>&#x021d2; <italic>B</italic>) = |<italic>m</italic>( <italic>A</italic>) &#x02229; <italic>m</italic>( <italic>B</italic>)| / | <italic>m</italic>( <italic>A</italic>)| , the conclusion is founded.</p><p>Therefore, by tuning <italic>&#x003b1;</italic> value, we can not only control the size of the set of selected single genes or gene pairs, but also ensure the confidence of derived decision rules.</p><p>For the cancer classification problem, every microarray data collected can be represented as a decision table with the form of <xref ref-type="table" rid="t13-cin-2009-123">Table 13</xref>. In the microarray data decision table, there are <italic>m</italic> samples and <italic>n</italic> genes. Every sample is assigned to one class label. <italic>g</italic>(<italic>x</italic>, <italic>y</italic>) represents the expression level of gene <italic>y</italic> in sample <italic>x</italic>.</p></sec><sec sec-type="methods"><title>Dataset</title><sec sec-type="methods"><title>CNS tumor dataset</title><p>The dataset is about patient outcome prediction for central nervous system embryonal tumor.<xref ref-type="bibr" rid="b19-cin-2009-123">19</xref> In this dataset, there are 60 observations, each of which is described by the gene expression levels of 7129 genes and a class attribute with two distinct labels&#x02014;Class 1 (survivors) versus Class 0 (failures). Survivors are patients who are alive after treatment while the failures are those who succumbed to their disease. Among 60 patient samples, 21 are labeled as &#x0201c;Class 1&#x0201d; and 39 are labeled as &#x0201c;Class 0&#x0201d;.</p></sec><sec sec-type="methods"><title>Colon tumor dataset</title><p>The dataset contains 62 samples collected from colon-cancer patients.<xref ref-type="bibr" rid="b22-cin-2009-123">22</xref> Among them, 40 tumor biopsies are from tumors (labeled as &#x0201c;negative&#x0201d;) and 22 normal (labeled as &#x0201c;positive&#x0201d;) biopsies are from healthy parts of the colons of the same patients. Each sample is described by 2000 genes.</p></sec><sec sec-type="methods"><title>Lung cancer dataset</title><p>The dataset contains 39 NSCLC (Non-Small Cell Lung Cancer) samples, 24 of which are from patients with metastasis (labeled as &#x0201c;relapse&#x0201d;) and 15 are from the patients with disease-free based on both clinical and radiological testing (labeled as &#x0201c;non-relapse&#x0201d;).<xref ref-type="bibr" rid="b23-cin-2009-123">23</xref> The total number of genes is 2880.</p></sec><sec sec-type="methods"><title>DLBCL dataset</title><p>The dataset is about patient outcome prediction for DLBCL.<xref ref-type="bibr" rid="b24-cin-2009-123">24</xref> The total of 58 DLBCL samples are from 32 cured patients (labeled as &#x02018;cured&#x02019;) and 26 refractory patients (labeled as &#x02018;fatal&#x02019;). The gene expression profile contains 6817 genes.</p><p><xref ref-type="table" rid="t14-cin-2009-123">Table 14</xref> summarizes the four gene expression datasets.</p></sec></sec><sec sec-type="methods"><title>Data preprocessing</title><p>As there exist a few missing attribute values in the lung cancer dataset, we first fill each of them with the mean of all the attribute values from the same class of samples as the sample containing the missing value.</p><p>Because rough set theory is suitable for handling discrete attributes, we discretize all the training set decision tables. We utilize the entropy-based discretization method, proposed by Fayyad et al.<xref ref-type="bibr" rid="b21-cin-2009-123">21</xref> This algorithm recursively applies an entropy minimization heuristic to discretize the continuous-valued attributes. The stop of the recursive step for this algorithm depends on the minimum description length (MDL) principle. We implement the discretization in the Weka package.<xref ref-type="bibr" rid="b106-cin-2009-123">106</xref> Every continuous-valued attribute is discretized into a one-category, two-category or three-category attribute. <xref ref-type="table" rid="t15-cin-2009-123">Table 15</xref> shows the discretized decision table for the CNS tumor with the first sample left out. We execute our algorithm for the feature selection and decision rule induction using this kind of tables.</p></sec><sec><title>Validation</title><p>We employ leave-one-out cross-validation approach. For the dataset containing <italic>n</italic> samples, each sample is left out in turn, and the learning algorithm is trained on all the remaining <italic>n-1</italic> samples. Then the training result is tested on the left-out sample. The final estimate is the average of <italic>n</italic> test results.</p></sec></sec></body><back><ack><title>Acknowledgements</title><p>This work was partly supported by KAKENHI (Grant-in-Aid for Scientific Research) on Priority Areas &#x0201c;comparative genomics&#x0201d; from the Ministry of Education, Culture, Sports, Science and Technology of Japan.</p></ack><fn-group><fn><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-cin-2009-123"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schena</surname><given-names>M</given-names></name><name><surname>Shalon</surname><given-names>D</given-names></name><name><surname>Davis</surname><given-names>RW</given-names></name><name><surname>Brown</surname><given-names>PO</given-names></name></person-group><article-title>Quantitative monitoring of gene expression patterns with a complementary DNA microarray</article-title><source>Science</source><year>1995</year><volume>270</volume><issue>5235</issue><fpage>467</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">7569999</pub-id></mixed-citation></ref><ref id="b2-cin-2009-123"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Slonim</surname><given-names>DK</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><etal/></person-group><article-title>Molecular classification of cancer: class discovery and class prediction by gene expression monitoring</article-title><source>Science</source><year>1999</year><volume>286</volume><issue>5439</issue><fpage>531</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10521349</pub-id></mixed-citation></ref><ref id="b3-cin-2009-123"><label>3</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>EP</given-names></name><name><surname>Jordan</surname><given-names>MI</given-names></name><name><surname>Karp</surname><given-names>RM</given-names></name></person-group><article-title>Feature selection for high-dimensional genomic microarray data</article-title><conf-name>the Eighteenth International Conference on Machine Learning</conf-name><conf-date>2001</conf-date><conf-loc>Williams College, MA</conf-loc><publisher-name>Morgan Kaufmann Publishers Inc</publisher-name><publisher-loc>San Francisco, U.S.A</publisher-loc><year>2001</year><fpage>601</fpage><lpage>8</lpage></mixed-citation></ref><ref id="b4-cin-2009-123"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>R</given-names></name></person-group><article-title>Supervised analysis when the number of candidate feature (p) greatly exceeds the number of cases (n)</article-title><source>ACM SIGKDD Explorations Newsletter</source><year>2003</year><volume>5</volume><issue>2</issue><fpage>31</fpage><lpage>6</lpage></mixed-citation></ref><ref id="b5-cin-2009-123"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinlan</surname><given-names>J</given-names></name></person-group><article-title>Induction of decision trees</article-title><source>Machine Learning</source><year>1986</year><volume>1</volume><fpage>81</fpage><lpage>106</lpage></mixed-citation></ref><ref id="b6-cin-2009-123"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlak</surname><given-names>Z</given-names></name></person-group><article-title>Rough sets</article-title><source>International Journal of Computer and Information Sciences</source><year>1982</year><volume>11</volume><fpage>341</fpage><lpage>56</lpage></mixed-citation></ref><ref id="b7-cin-2009-123"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>L</given-names></name></person-group><article-title>Identifying good diagnostic gene groups from gene expression profiles using the concept of emerging patterns</article-title><source>Bioinformatics</source><year>2002</year><volume>18</volume><issue>5</issue><fpage>725</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">12050069</pub-id></mixed-citation></ref><ref id="b8-cin-2009-123"><label>8</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Miao</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name></person-group><article-title>Efficient gene selection with rough sets from gene expression data</article-title><conf-name>the 3rd International Conference on Rough Sets and Knowledge Technology</conf-name><year>2008</year><fpage>164</fpage><lpage>71</lpage></mixed-citation></ref><ref id="b9-cin-2009-123"><label>9</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name></person-group><article-title>Gene selection using rough set theory</article-title><conf-name>the 1st International Conference on Rough Sets and Knowledge Technology</conf-name><year>2006</year><fpage>778</fpage><lpage>85</lpage></mixed-citation></ref><ref id="b10-cin-2009-123"><label>10</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Momin</surname><given-names>BF</given-names></name><name><surname>Mitra</surname><given-names>S</given-names></name></person-group><article-title>Reduct generation and classification of gene expression data</article-title><conf-name>First International Conference on Hybrid Information Technology</conf-name><year>2006</year><fpage>699</fpage><lpage>708</lpage></mixed-citation></ref><ref id="b11-cin-2009-123"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>M</given-names></name><name><surname>Mitra</surname><given-names>S</given-names></name><name><surname>Banka</surname><given-names>H</given-names></name></person-group><article-title>Evolutinary-rough feature selection in gene expression data</article-title><source>IEEE Transaction on Systems, Man, and Cybernetics, Part C: Application and Reviews</source><year>2007</year><issue>37</issue><fpage>622</fpage><lpage>32</lpage></mixed-citation></ref><ref id="b12-cin-2009-123"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>AC</given-names></name><name><surname>Gilbert</surname><given-names>D</given-names></name></person-group><article-title>Ensemble machine learning on gene expression data for cancer classification</article-title><source>Appl Bioinformatics</source><year>2003</year><volume>2</volume><issue>3 Suppl</issue><fpage>S75</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">15130820</pub-id></mixed-citation></ref><ref id="b13-cin-2009-123"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Downing</surname><given-names>JR</given-names></name><name><surname>Yeoh</surname><given-names>AE</given-names></name><name><surname>Wong</surname><given-names>L</given-names></name></person-group><article-title>Simple rules underlying gene expression profiles of more than six subtypes of acute lymphoblastic leukemia (ALL) patients</article-title><source>Bioinformatics</source><year>2003</year><volume>19</volume><issue>1</issue><fpage>71</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12499295</pub-id></mixed-citation></ref><ref id="b14-cin-2009-123"><label>14</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Cong</surname><given-names>G</given-names></name><name><surname>Tan</surname><given-names>KLKH</given-names></name><name><surname>Tung</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name></person-group><article-title>Mining top-k covering rule groups for gene expression data</article-title><conf-name>the ACM SIGMOD International Conference on Management of Data</conf-name><year>2005</year><fpage>670</fpage><lpage>81</lpage></mixed-citation></ref><ref id="b15-cin-2009-123"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geman</surname><given-names>D</given-names></name><name><surname>d&#x02019;Avignon</surname><given-names>C</given-names></name><name><surname>Naiman</surname><given-names>DQ</given-names></name><name><surname>Winslow</surname><given-names>RL</given-names></name></person-group><article-title>Classifying gene expression profiles from pairwise mRNA comparisons</article-title><source>Stat Appl Genet Mol Biol</source><year>2004</year><volume>3</volume><comment>Article 19</comment></mixed-citation></ref><ref id="b16-cin-2009-123"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>GJ</given-names></name><name><surname>Jensen</surname><given-names>RV</given-names></name><name><surname>Hsiao</surname><given-names>LL</given-names></name><etal/></person-group><article-title>Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><issue>17</issue><fpage>4963</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12208747</pub-id></mixed-citation></ref><ref id="b17-cin-2009-123"><label>17</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pawlak</surname><given-names>Z</given-names></name></person-group><source>Rough sets-Theoretical aspects of reasoning about data</source><volume>9</volume><publisher-loc>Dordrecht; Boston</publisher-loc><publisher-name>Kluwer Academic Publishers</publisher-name><year>1991</year></mixed-citation></ref><ref id="b18-cin-2009-123"><label>18</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name></person-group><article-title>Redundancy based feature selection for microarray data</article-title><conf-name>the Tenth ACM SIGKDD Conference on Knowledge Discovery and Data Mining</conf-name><year>2004</year><fpage>737</fpage><lpage>42</lpage></mixed-citation></ref><ref id="b19-cin-2009-123"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Gaasenbeek</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prediction of central nervous system embryonal tumour outcome based on gene expression</article-title><source>Nature</source><year>2002</year><volume>415</volume><issue>6870</issue><fpage>436</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">11807556</pub-id></mixed-citation></ref><ref id="b20-cin-2009-123"><label>20</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>LJ</given-names></name><name><surname>Li</surname><given-names>ZJ</given-names></name><name><surname>Hu</surname><given-names>XH</given-names></name></person-group><article-title>A Hybrid Gene Selection Method for Cancer Classification</article-title><conf-name>VLDB Workshop on Data Mining in Bioinformatics</conf-name><conf-date>2007</conf-date><conf-loc>Vienna, Austria</conf-loc><year>2007</year></mixed-citation></ref><ref id="b21-cin-2009-123"><label>21</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Fayyad</surname><given-names>UM</given-names></name><name><surname>Irani</surname><given-names>KB</given-names></name></person-group><article-title>Multi-interval discretization of continuous-valued attributes for classification learning</article-title><conf-name>the 13th International Joint Conference of Artificial Intelligence</conf-name><year>1993</year><fpage>1022</fpage><lpage>7</lpage></mixed-citation></ref><ref id="b22-cin-2009-123"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alon</surname><given-names>U</given-names></name><name><surname>Barkai</surname><given-names>N</given-names></name><name><surname>Notterman</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays</article-title><source>Proc Natl Acad Sci U S A</source><year>1999</year><volume>96</volume><issue>12</issue><fpage>6745</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">10359783</pub-id></mixed-citation></ref><ref id="b23-cin-2009-123"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wigle</surname><given-names>DA</given-names></name><name><surname>Jurisica</surname><given-names>I</given-names></name><name><surname>Radulovich</surname><given-names>N</given-names></name><etal/></person-group><article-title>Molecular profiling of non-small cell lung cancer and correlation with disease-free survival</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><issue>11</issue><fpage>3005</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12036904</pub-id></mixed-citation></ref><ref id="b24-cin-2009-123"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shipp</surname><given-names>MA</given-names></name><name><surname>Ross</surname><given-names>KN</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><etal/></person-group><article-title>Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning</article-title><source>Nat Med</source><year>2002</year><volume>8</volume><issue>1</issue><fpage>68</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">11786909</pub-id></mixed-citation></ref><ref id="b25-cin-2009-123"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Harry</surname><given-names>GJ</given-names></name><name><surname>Blackshear</surname><given-names>PJ</given-names></name><name><surname>Zeldin</surname><given-names>DC</given-names></name></person-group><article-title>G-protein pathway suppressor 2 (GPS2) interacts with the regulatory factor X4 variant 3 (RFX4_v3) and functions as a transcriptional co-activator</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><issue>13</issue><fpage>8580</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">18218630</pub-id></mixed-citation></ref><ref id="b26-cin-2009-123"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>LS</given-names></name><name><surname>McKeever</surname><given-names>MO</given-names></name><name><surname>Okano</surname><given-names>HJ</given-names></name><name><surname>Darnell</surname><given-names>RB</given-names></name></person-group><article-title>Beta-NAP, a cerebellar degeneration antigen, is a neuron-specific vesicle coat protein</article-title><source>Cell</source><year>1995</year><volume>82</volume><issue>5</issue><fpage>773</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">7671305</pub-id></mixed-citation></ref><ref id="b27-cin-2009-123"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipkowitz</surname><given-names>S</given-names></name><name><surname>Gobel</surname><given-names>V</given-names></name><name><surname>Varterasian</surname><given-names>ML</given-names></name><name><surname>Nakahara</surname><given-names>K</given-names></name><name><surname>Tchorz</surname><given-names>K</given-names></name><name><surname>Kirsch</surname><given-names>IR</given-names></name></person-group><article-title>A comparative structural characterization of the human NSCL-1 and NSCL-2 genes. Two basic helix-loop-helix genes expressed in the developing nervous system</article-title><source>J Biol Chem</source><year>1992</year><volume>267</volume><issue>29</issue><fpage>21065</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">1328219</pub-id></mixed-citation></ref><ref id="b28-cin-2009-123"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><etal/></person-group><article-title>Constructing disease-specific gene networks using pair-wise relevance metric: application to colon cancer identifies interleukin 8, desmin and enolase 1 as the central elements</article-title><source>BMC Syst Biol</source><year>2008</year><volume>2</volume><fpage>72</fpage><pub-id pub-id-type="pmid">18691435</pub-id></mixed-citation></ref><ref id="b29-cin-2009-123"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klieveri</surname><given-names>L</given-names></name><name><surname>Fehres</surname><given-names>O</given-names></name><name><surname>Griffini</surname><given-names>P</given-names></name><name><surname>Van Noorden</surname><given-names>CJ</given-names></name><name><surname>Frederiks</surname><given-names>WM</given-names></name></person-group><article-title>Promotion of colon cancer metastases in rat liver by fish oil diet is not due to reduced stroma formation</article-title><source>Clin Exp Metastasis</source><year>2000</year><volume>18</volume><issue>5</issue><fpage>371</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">11467768</pub-id></mixed-citation></ref><ref id="b30-cin-2009-123"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Williamson</surname><given-names>M</given-names></name><name><surname>Bott</surname><given-names>S</given-names></name><etal/></person-group><article-title>Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><issue>45</issue><fpage>6560</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">17486081</pub-id></mixed-citation></ref><ref id="b31-cin-2009-123"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirasawa</surname><given-names>Y</given-names></name><name><surname>Arai</surname><given-names>M</given-names></name><name><surname>Imazeki</surname><given-names>F</given-names></name><etal/></person-group><article-title>Methylation status of genes upregulated by demethylating agent 5-aza-2&#x02019;-deoxycytidine in hepatocellular carcinoma</article-title><source>Oncology</source><year>2006</year><volume>71</volume><issue>1&#x02013;2</issue><fpage>77</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">17341888</pub-id></mixed-citation></ref><ref id="b32-cin-2009-123"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Fukushima</surname><given-names>N</given-names></name><name><surname>Matsubayashi</surname><given-names>H</given-names></name><name><surname>Goggins</surname><given-names>M</given-names></name></person-group><article-title>Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><issue>8</issue><fpage>1531</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">14716296</pub-id></mixed-citation></ref><ref id="b33-cin-2009-123"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schauer</surname><given-names>IG</given-names></name><name><surname>Ressler</surname><given-names>SJ</given-names></name><name><surname>Rowley</surname><given-names>DR</given-names></name></person-group><article-title>Keratinocyte-derived chemokine induces prostate epithelial hyperplasia and reactive stroma in a novel transgenic mouse model</article-title><source>Prostate</source><year>2009</year><volume>69</volume><issue>4</issue><fpage>373</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">19021203</pub-id></mixed-citation></ref><ref id="b34-cin-2009-123"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bendrik</surname><given-names>C</given-names></name><name><surname>Dabrosin</surname><given-names>C</given-names></name></person-group><article-title>Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo</article-title><source>J Immunol</source><year>2009</year><volume>182</volume><issue>1</issue><fpage>371</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19109168</pub-id></mixed-citation></ref><ref id="b35-cin-2009-123"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negaard</surname><given-names>HF</given-names></name><name><surname>Iversen</surname><given-names>N</given-names></name><name><surname>Bowitz-Lothe</surname><given-names>IM</given-names></name><etal/></person-group><article-title>Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors</article-title><source>Leukemia</source><year>2009</year><volume>23</volume><issue>1</issue><fpage>162</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18800145</pub-id></mixed-citation></ref><ref id="b36-cin-2009-123"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chikazawa</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Fukata</surname><given-names>S</given-names></name><name><surname>Karashima</surname><given-names>T</given-names></name><name><surname>Shuin</surname><given-names>T</given-names></name></person-group><article-title>Expression of angiogenesis-related genes regulates different steps in the process of tumor growth and metastasis in human urothelial cell carcinoma of the urinary bladder</article-title><source>Pathobiology</source><year>2008</year><volume>75</volume><issue>6</issue><fpage>335</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">19096229</pub-id></mixed-citation></ref><ref id="b37-cin-2009-123"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lurje</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Schultheis</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer</article-title><source>Ann Oncol</source><year>2008</year><volume>19</volume><issue>10</issue><fpage>1734</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">18550579</pub-id></mixed-citation></ref><ref id="b38-cin-2009-123"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>MM</given-names></name><name><surname>Sage</surname><given-names>EH</given-names></name></person-group><article-title>Hevin/SC1, a matricellular glycoprotein and potential tumor-suppressor of the SPARC/BM-40/Osteonectin family</article-title><source>Int J Biochem Cell Biol</source><year>2004</year><volume>36</volume><issue>6</issue><fpage>991</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15094114</pub-id></mixed-citation></ref><ref id="b39-cin-2009-123"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Framson</surname><given-names>PE</given-names></name><name><surname>Sage</surname><given-names>EH</given-names></name></person-group><article-title>SPARC and tumor growth: where the seed meets the soil?</article-title><source>J Cell Biochem</source><year>2004</year><volume>92</volume><issue>4</issue><fpage>679</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">15211566</pub-id></mixed-citation></ref><ref id="b40-cin-2009-123"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>CP</given-names></name><name><surname>Poon</surname><given-names>RT</given-names></name><name><surname>Cheung</surname><given-names>ST</given-names></name><name><surname>Yu</surname><given-names>WC</given-names></name><name><surname>Fan</surname><given-names>ST</given-names></name></person-group><article-title>SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma</article-title><source>J Pathol</source><year>2006</year><volume>210</volume><issue>4</issue><fpage>459</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">17029219</pub-id></mixed-citation></ref><ref id="b41-cin-2009-123"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esposito</surname><given-names>I</given-names></name><name><surname>Kayed</surname><given-names>H</given-names></name><name><surname>Keleg</surname><given-names>S</given-names></name><etal/></person-group><article-title>Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer</article-title><source>Neoplasia</source><year>2007</year><volume>9</volume><issue>1</issue><fpage>8</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">17325739</pub-id></mixed-citation></ref><ref id="b42-cin-2009-123"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bendik</surname><given-names>I</given-names></name><name><surname>Schraml</surname><given-names>P</given-names></name><name><surname>Ludwig</surname><given-names>CU</given-names></name></person-group><article-title>Characterization of MAST9/Hevin, a SPARC-like protein, that is down-regulated in non-small cell lung cancer</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><issue>4</issue><fpage>626</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9485012</pub-id></mixed-citation></ref><ref id="b43-cin-2009-123"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claeskens</surname><given-names>A</given-names></name><name><surname>Ongenae</surname><given-names>N</given-names></name><name><surname>Neefs</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation</article-title><source>Br J Cancer</source><year>2000</year><volume>82</volume><issue>6</issue><fpage>1123</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">10735494</pub-id></mixed-citation></ref><ref id="b44-cin-2009-123"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>Plymate</surname><given-names>SR</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adeno-carcinoma</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><issue>2</issue><fpage>232</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9443398</pub-id></mixed-citation></ref><ref id="b45-cin-2009-123"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Mi</surname><given-names>Z</given-names></name><etal/></person-group><article-title>EF1A1-actin interactions alter mRNA stability to determine differential osteopontin expression in HepG2 and Hep3B cells</article-title><source>Exp Cell Res</source><year>2009</year><volume>315</volume><issue>2</issue><fpage>304</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">19026636</pub-id></mixed-citation></ref><ref id="b46-cin-2009-123"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umeda</surname><given-names>D</given-names></name><name><surname>Yano</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Tachibana</surname><given-names>H</given-names></name></person-group><article-title>Green tea polyphenol epigallocatechin-3-gallate signaling pathway through 67-kDa laminin receptor</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><issue>6</issue><fpage>3050</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18079119</pub-id></mixed-citation></ref><ref id="b47-cin-2009-123"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rho</surname><given-names>SB</given-names></name><name><surname>Park</surname><given-names>YG</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name></person-group><article-title>A novel cervical cancer suppressor 3 (CCS-3) interacts with the BTB domain of PLZF and inhibits the cell growth by inducing apoptosis</article-title><source>FEBS Lett</source><year>2006</year><volume>580</volume><issue>17</issue><fpage>4073</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">16828757</pub-id></mixed-citation></ref><ref id="b48-cin-2009-123"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frum</surname><given-names>R</given-names></name><name><surname>Busby</surname><given-names>SA</given-names></name><name><surname>Ramamoorthy</surname><given-names>M</given-names></name><etal/></person-group><article-title>HDM2-binding partners: interaction with translation elongation factor EF1alpha</article-title><source>J Proteome Res</source><year>2007</year><volume>6</volume><issue>4</issue><fpage>1410</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17373842</pub-id></mixed-citation></ref><ref id="b49-cin-2009-123"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gopalkrishnan</surname><given-names>RV</given-names></name><name><surname>Su</surname><given-names>ZZ</given-names></name><name><surname>Goldstein</surname><given-names>NI</given-names></name><name><surname>Fisher</surname><given-names>PB</given-names></name></person-group><article-title>Translational infidelity and human cancer: role of the PTI-1 oncogene</article-title><source>Int J Biochem Cell Biol</source><year>1999</year><volume>31</volume><issue>1</issue><fpage>151</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">10216950</pub-id></mixed-citation></ref><ref id="b50-cin-2009-123"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schafer</surname><given-names>BW</given-names></name><name><surname>Heizmann</surname><given-names>CW</given-names></name></person-group><article-title>The S100 family of EF-hand calcium-binding proteins: functions and pathology</article-title><source>Trends Biochem Sci</source><year>1996</year><volume>21</volume><issue>4</issue><fpage>134</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">8701470</pub-id></mixed-citation></ref><ref id="b51-cin-2009-123"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heizmann</surname><given-names>CW</given-names></name><name><surname>Fritz</surname><given-names>G</given-names></name><name><surname>Schafer</surname><given-names>BW</given-names></name></person-group><article-title>S100 proteins: structure, functions and pathology</article-title><source>Front Biosci</source><year>2002</year><volume>7</volume><fpage>d1356</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">11991838</pub-id></mixed-citation></ref><ref id="b52-cin-2009-123"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melle</surname><given-names>C</given-names></name><name><surname>Ernst</surname><given-names>G</given-names></name><name><surname>Schimmel</surname><given-names>B</given-names></name><etal/></person-group><article-title>Different expression of calgizzarin (S100A11) in normal colonic epithelium, adenoma and colorectal carcinoma</article-title><source>Int J Oncol</source><year>2006</year><volume>28</volume><issue>1</issue><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">16327996</pub-id></mixed-citation></ref><ref id="b53-cin-2009-123"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stulik</surname><given-names>J</given-names></name><name><surname>Koupilova</surname><given-names>K</given-names></name><name><surname>Osterreicher</surname><given-names>J</given-names></name><etal/></person-group><article-title>Protein abundance alterations in matched sets of macroscopically normal colon mucosa and colorectal carcinoma</article-title><source>Electrophoresis</source><year>1999</year><volume>20</volume><issue>18</issue><fpage>3638</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">10612291</pub-id></mixed-citation></ref><ref id="b54-cin-2009-123"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichling</surname><given-names>T</given-names></name><name><surname>Goss</surname><given-names>KH</given-names></name><name><surname>Carson</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Transcriptional profiles of intestinal tumors in Apc(Min) mice are unique from those of embryonic intestine and identify novel gene targets dysregulated in human colorectal tumors</article-title><source>Cancer Re</source><year>2005</year><volume>65</volume><issue>1</issue><fpage>166</fpage><lpage>76</lpage></mixed-citation></ref><ref id="b55-cin-2009-123"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaurand</surname><given-names>P</given-names></name><name><surname>DaGue</surname><given-names>BB</given-names></name><name><surname>Pearsall</surname><given-names>RS</given-names></name><name><surname>Threadgill</surname><given-names>DW</given-names></name><name><surname>Caprioli</surname><given-names>RM</given-names></name></person-group><article-title>Profiling proteins from azoxymethane-induced colon tumors at the molecular level by matrix-assisted laser desorption/ionization mass spectrometry</article-title><source>Proteomics</source><year>2001</year><volume>1</volume><issue>10</issue><fpage>1320</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11721643</pub-id></mixed-citation></ref><ref id="b56-cin-2009-123"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Adzuma</surname><given-names>K</given-names></name><name><surname>Iwami</surname><given-names>M</given-names></name><name><surname>Yoshimoto</surname><given-names>K</given-names></name><name><surname>Monden</surname><given-names>Y</given-names></name><name><surname>Itakura</surname><given-names>M</given-names></name></person-group><article-title>Human calgizzarin; one colorectal cancer-related gene selected by a large scale random cDNA sequencing and northern blot analysis</article-title><source>Cancer Lett</source><year>1995</year><volume>89</volume><issue>2</issue><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">7889529</pub-id></mixed-citation></ref><ref id="b57-cin-2009-123"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varga</surname><given-names>AE</given-names></name><name><surname>Stourman</surname><given-names>NV</given-names></name><name><surname>Zheng</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Silencing of the Tropomyosin-1 gene by DNA methylation alters tumor suppressor function of TGF-beta</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><issue>32</issue><fpage>5043</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">15897890</pub-id></mixed-citation></ref><ref id="b58-cin-2009-123"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>XX</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Macrophage migration inhibitory factor promotes colorectal cancer</article-title><source>Mol Med</source><year>2009</year><volume>15</volume><issue>1&#x02013;2</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">19009023</pub-id></mixed-citation></ref><ref id="b59-cin-2009-123"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Law</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma</article-title><source>Ann Surg</source><year>2005</year><volume>242</volume><issue>1</issue><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">15973102</pub-id></mixed-citation></ref><ref id="b60-cin-2009-123"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legendre</surname><given-names>H</given-names></name><name><surname>Decaestecker</surname><given-names>C</given-names></name><name><surname>Nagy</surname><given-names>N</given-names></name><etal/></person-group><article-title>Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers</article-title><source>Mod Pathol</source><year>2003</year><volume>16</volume><issue>5</issue><fpage>491</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">12748256</pub-id></mixed-citation></ref><ref id="b61-cin-2009-123"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Tsui</surname><given-names>HT</given-names></name><name><surname>Poon</surname><given-names>RT</given-names></name><etal/></person-group><article-title>Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma</article-title><source>Int J Cancer</source><year>2003</year><volume>107</volume><issue>1</issue><fpage>22</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12925952</pub-id></mixed-citation></ref><ref id="b62-cin-2009-123"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>JM</given-names></name><name><surname>Coletta</surname><given-names>PL</given-names></name><name><surname>Cuthbert</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Macrophage migration inhibitory factor promotes intestinal tumorigenesis</article-title><source>Gastroenterology</source><year>2005</year><volume>129</volume><issue>5</issue><fpage>1485</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">16285950</pub-id></mixed-citation></ref><ref id="b63-cin-2009-123"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Ye</surname><given-names>C</given-names></name><etal/></person-group><article-title>Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer</article-title><source>Cancer Lett</source><year>2008</year><volume>261</volume><issue>2</issue><fpage>147</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">18171602</pub-id></mixed-citation></ref><ref id="b64-cin-2009-123"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>K</given-names></name><name><surname>Hirata</surname><given-names>S</given-names></name><name><surname>Irie</surname><given-names>A</given-names></name><etal/></person-group><article-title>Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><issue>20</issue><fpage>6487</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">18927288</pub-id></mixed-citation></ref><ref id="b65-cin-2009-123"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>R</given-names></name><name><surname>Dowejko</surname><given-names>A</given-names></name><name><surname>Driemel</surname><given-names>O</given-names></name><name><surname>Bosserhoff</surname><given-names>AK</given-names></name><name><surname>Reichert</surname><given-names>TE</given-names></name></person-group><article-title>Truncated P-cadherin is produced in oral squamous cell carcinoma</article-title><source>Febs J</source><year>2008</year><volume>275</volume><issue>16</issue><fpage>4198</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">18637117</pub-id></mixed-citation></ref><ref id="b66-cin-2009-123"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben Hamida</surname><given-names>A</given-names></name><name><surname>Labidi</surname><given-names>IS</given-names></name><name><surname>Mrad</surname><given-names>K</given-names></name><etal/></person-group><article-title>Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin</article-title><source>BMC Cancer</source><year>2008</year><volume>8</volume><fpage>28</fpage><pub-id pub-id-type="pmid">18230143</pub-id></mixed-citation></ref><ref id="b67-cin-2009-123"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocha</surname><given-names>AS</given-names></name><name><surname>Soares</surname><given-names>P</given-names></name><name><surname>Machado</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Mucoepidermoid carcinoma of the thyroid: a tumour histotype characterised by P-cadherin neoex-pression and marked abnormalities of E-cadherin/catenins complex</article-title><source>Virchows Arch</source><year>2002</year><volume>440</volume><issue>5</issue><fpage>498</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">12021924</pub-id></mixed-citation></ref><ref id="b68-cin-2009-123"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paredes</surname><given-names>J</given-names></name><name><surname>Albergaria</surname><given-names>A</given-names></name><name><surname>Oliveira</surname><given-names>JT</given-names></name><name><surname>Jeronimo</surname><given-names>C</given-names></name><name><surname>Milanezi</surname><given-names>F</given-names></name><name><surname>Schmitt</surname><given-names>FC</given-names></name></person-group><article-title>P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><issue>16</issue><fpage>5869</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">16115928</pub-id></mixed-citation></ref><ref id="b69-cin-2009-123"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>IS</given-names></name><name><surname>Madan</surname><given-names>P</given-names></name><name><surname>Getsios</surname><given-names>S</given-names></name><name><surname>Bertrand</surname><given-names>MA</given-names></name><name><surname>MacCalman</surname><given-names>CD</given-names></name></person-group><article-title>Cadherin switching in ovarian cancer progression</article-title><source>Int J Cancer</source><year>2003</year><volume>106</volume><issue>2</issue><fpage>172</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12800191</pub-id></mixed-citation></ref><ref id="b70-cin-2009-123"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo Muzio</surname><given-names>L</given-names></name><name><surname>Campisi</surname><given-names>G</given-names></name><name><surname>Farina</surname><given-names>A</given-names></name><etal/></person-group><article-title>P-cadherin expression and survival rate in oral squamous cell carcinoma: an immunohistochemical study</article-title><source>BMC Cancer</source><year>2005</year><volume>5</volume><fpage>63</fpage><pub-id pub-id-type="pmid">15967043</pub-id></mixed-citation></ref><ref id="b71-cin-2009-123"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reed</surname><given-names>CE</given-names></name><name><surname>Graham</surname><given-names>A</given-names></name><name><surname>Hoda</surname><given-names>RS</given-names></name><etal/></person-group><article-title>A simple two-gene prognostic model for adenocarcinoma of the lung</article-title><source>J Thorac Cardiovasc Surg</source><year>2008</year><volume>135</volume><issue>3</issue><fpage>627</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">18329483</pub-id></mixed-citation></ref><ref id="b72-cin-2009-123"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>R</given-names></name><name><surname>Bosserhoff</surname><given-names>AK</given-names></name></person-group><article-title>Functional implication of truncated P-cadherin expression in malignant melanoma</article-title><source>Exp Mol Pathol</source><year>2006</year><volume>81</volume><issue>3</issue><fpage>224</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">16919267</pub-id></mixed-citation></ref><ref id="b73-cin-2009-123"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makino</surname><given-names>H</given-names></name><name><surname>Tajiri</surname><given-names>T</given-names></name><name><surname>Miyashita</surname><given-names>M</given-names></name><etal/></person-group><article-title>Differential expression of TCEAL1 in esophageal cancers by custom cDNA microarray analysis</article-title><source>Dis Esophagus</source><year>2005</year><volume>18</volume><issue>1</issue><fpage>37</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">15773840</pub-id></mixed-citation></ref><ref id="b74-cin-2009-123"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>YF</given-names></name><name><surname>Yuan</surname><given-names>ST</given-names></name><name><surname>Li</surname><given-names>HC</given-names></name><etal/></person-group><article-title>ERbeta exerts multiple stimulative effects on human breast carcinoma cells</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><issue>34</issue><fpage>5799</fpage><lpage>806</lpage><pub-id pub-id-type="pmid">15208676</pub-id></mixed-citation></ref><ref id="b75-cin-2009-123"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sohda</surname><given-names>M</given-names></name><name><surname>Ishikawa</surname><given-names>H</given-names></name><name><surname>Masuda</surname><given-names>N</given-names></name><etal/></person-group><article-title>Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer</article-title><source>Int J Cancer</source><year>2004</year><volume>110</volume><issue>6</issue><fpage>838</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">15170665</pub-id></mixed-citation></ref><ref id="b76-cin-2009-123"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YB</given-names></name><name><surname>Ki</surname><given-names>SW</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Horinouchi</surname><given-names>S</given-names></name></person-group><article-title>Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells</article-title><source>J Antibiot (Tokyo)</source><year>2000</year><volume>53</volume><issue>10</issue><fpage>1191</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">11132966</pub-id></mixed-citation></ref><ref id="b77-cin-2009-123"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>AM</given-names></name><name><surname>Sousa</surname><given-names>H</given-names></name><name><surname>Pinto</surname><given-names>D</given-names></name><etal/></person-group><article-title>Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer</article-title><source>Eur J Cancer</source><year>2006</year><volume>42</volume><issue>7</issue><fpage>958</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">16542834</pub-id></mixed-citation></ref><ref id="b78-cin-2009-123"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Horak</surname><given-names>CE</given-names></name><name><surname>Khanna</surname><given-names>C</given-names></name><etal/></person-group><article-title>Alterations in Gemin5 expression contribute to alternative mRNA splicing patterns and tumor cell motility</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><issue>3</issue><fpage>639</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">18245461</pub-id></mixed-citation></ref><ref id="b79-cin-2009-123"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parise</surname><given-names>P</given-names></name><name><surname>Finocchiaro</surname><given-names>G</given-names></name><name><surname>Masciadri</surname><given-names>B</given-names></name><etal/></person-group><article-title>Lap2alpha expression is controlled by E2F and deregulated in various human tumors</article-title><source>Cell Cycle</source><year>2006</year><volume>5</volume><issue>12</issue><fpage>1331</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">16760672</pub-id></mixed-citation></ref><ref id="b80-cin-2009-123"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>PJ</given-names></name><name><surname>Eckhard</surname><given-names>CP</given-names></name><name><surname>Gonser</surname><given-names>S</given-names></name><name><surname>Otto</surname><given-names>H</given-names></name><name><surname>Folkers</surname><given-names>G</given-names></name><name><surname>Beck-Sickinger</surname><given-names>AG</given-names></name></person-group><article-title>On the role of thymopoietins in cell proliferation. Immunochemical evidence for new members of the human thymopoietin family</article-title><source>Biol Chem</source><year>1999</year><volume>380</volume><issue>6</issue><fpage>653</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">10430029</pub-id></mixed-citation></ref><ref id="b81-cin-2009-123"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><etal/></person-group><article-title>Inhibition of fibroblast growth factor 2-induced apoptosis involves survivin expression, protein kinase C alpha activation and subcellular translocation of Smac in human small cell lung cancer cells</article-title><source>Acta Biochim Biophys Sin (Shanghai)</source><year>2008</year><volume>40</volume><issue>4</issue><fpage>297</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">18401527</pub-id></mixed-citation></ref><ref id="b82-cin-2009-123"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempkensteffen</surname><given-names>C</given-names></name><name><surname>Hinz</surname><given-names>S</given-names></name><name><surname>Christoph</surname><given-names>F</given-names></name><etal/></person-group><article-title>Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value</article-title><source>J Cancer Res Clin Oncol</source><year>2008</year><volume>134</volume><issue>5</issue><fpage>543</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">17922292</pub-id></mixed-citation></ref><ref id="b83-cin-2009-123"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizutani</surname><given-names>Y</given-names></name><name><surname>Nakanishi</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><etal/></person-group><article-title>Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><issue>3</issue><fpage>448</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">15572731</pub-id></mixed-citation></ref><ref id="b84-cin-2009-123"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Mahotka</surname><given-names>C</given-names></name><name><surname>Heikaus</surname><given-names>S</given-names></name><etal/></person-group><article-title>Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas</article-title><source>Br J Cancer</source><year>2004</year><volume>91</volume><issue>7</issue><fpage>1349</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">15328523</pub-id></mixed-citation></ref><ref id="b85-cin-2009-123"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulda</surname><given-names>S</given-names></name><name><surname>Wick</surname><given-names>W</given-names></name><name><surname>Weller</surname><given-names>M</given-names></name><name><surname>Debatin</surname><given-names>KM</given-names></name></person-group><article-title>Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo</article-title><source>Nat Med</source><year>2002</year><volume>8</volume><issue>8</issue><fpage>808</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">12118245</pub-id></mixed-citation></ref><ref id="b86-cin-2009-123"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Mashima</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><etal/></person-group><article-title>Predominant suppression of apopto-some by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><issue>4</issue><fpage>831</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12591734</pub-id></mixed-citation></ref><ref id="b87-cin-2009-123"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogler</surname><given-names>M</given-names></name><name><surname>Giagkousiklidis</surname><given-names>S</given-names></name><name><surname>Genze</surname><given-names>F</given-names></name><name><surname>Gschwend</surname><given-names>JE</given-names></name><name><surname>Debatin</surname><given-names>KM</given-names></name><name><surname>Fulda</surname><given-names>S</given-names></name></person-group><article-title>Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><issue>48</issue><fpage>7190</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">16091752</pub-id></mixed-citation></ref><ref id="b88-cin-2009-123"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>HL</given-names></name><name><surname>Liu</surname><given-names>PS</given-names></name><name><surname>Zheng</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro</article-title><source>Pharmacol Res</source><year>2007</year><volume>56</volume><issue>6</issue><fpage>483</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">18029193</pub-id></mixed-citation></ref><ref id="b89-cin-2009-123"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Checinska</surname><given-names>A</given-names></name><name><surname>Hoogeland</surname><given-names>BS</given-names></name><name><surname>Rodriguez</surname><given-names>JA</given-names></name><name><surname>Giaccone</surname><given-names>G</given-names></name><name><surname>Kruyt</surname><given-names>FA</given-names></name></person-group><article-title>Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: a small molecule Smac mimic sensitizes for chemotherapy-induced apoptosis by enhancing caspase-3 activation</article-title><source>Exp Cell Res</source><year>2007</year><volume>313</volume><issue>6</issue><fpage>1215</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">17291493</pub-id></mixed-citation></ref><ref id="b90-cin-2009-123"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNeish</surname><given-names>IA</given-names></name><name><surname>Lopes</surname><given-names>R</given-names></name><name><surname>Bell</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Survivin interacts with Smac/ DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis</article-title><source>Exp Cell Res</source><year>2005</year><volume>302</volume><issue>1</issue><fpage>69</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">15541727</pub-id></mixed-citation></ref><ref id="b91-cin-2009-123"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Velazquez</surname><given-names>M</given-names></name><name><surname>Melendez-Zajgla</surname><given-names>J</given-names></name><name><surname>Maldonado</surname><given-names>V</given-names></name></person-group><article-title>Apoptosis induced by cAMP requires Smac/DIABLO transcriptional upregulation</article-title><source>Cell Signal</source><year>2007</year><volume>19</volume><issue>6</issue><fpage>1212</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">17320350</pub-id></mixed-citation></ref><ref id="b92-cin-2009-123"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekimura</surname><given-names>A</given-names></name><name><surname>Konishi</surname><given-names>A</given-names></name><name><surname>Mizuno</surname><given-names>K</given-names></name><etal/></person-group><article-title>Expression of Smac/DIABLO is a novel prognostic marker in lung cancer</article-title><source>Oncol Rep</source><year>2004</year><volume>11</volume><issue>4</issue><fpage>797</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">15010875</pub-id></mixed-citation></ref><ref id="b93-cin-2009-123"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Broderick</surname><given-names>P</given-names></name><name><surname>Webb</surname><given-names>E</given-names></name><etal/></person-group><article-title>Common 5p15.33 and 6p21.33 variants influence lung cancer risk</article-title><source>Nat Genet</source><year>2008</year><volume>40</volume><issue>12</issue><fpage>1407</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18978787</pub-id></mixed-citation></ref><ref id="b94-cin-2009-123"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inaba</surname><given-names>T</given-names></name><name><surname>Roberts</surname><given-names>WM</given-names></name><name><surname>Shapiro</surname><given-names>LH</given-names></name><etal/></person-group><article-title>Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia</article-title><source>Science</source><year>1992</year><volume>257</volume><issue>5069</issue><fpage>531</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">1386162</pub-id></mixed-citation></ref><ref id="b95-cin-2009-123"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muris</surname><given-names>JJ</given-names></name><name><surname>Meijer</surname><given-names>CJ</given-names></name><name><surname>Ossenkoppele</surname><given-names>GJ</given-names></name><name><surname>Vos</surname><given-names>W</given-names></name><name><surname>Oudejans</surname><given-names>JJ</given-names></name></person-group><article-title>Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B-cell lymphoma</article-title><source>Hematol Oncol</source><year>2006</year><volume>24</volume><issue>3</issue><fpage>97</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">16715473</pub-id></mixed-citation></ref><ref id="b96-cin-2009-123"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>S</given-names></name><name><surname>Murphy</surname><given-names>LJ</given-names></name></person-group><article-title>The p53 oncoprotein is a substrate for tissue transglutaminase kinase activity</article-title><source>Biochem Biophys Res Commun</source><year>2006</year><volume>339</volume><issue>2</issue><fpage>726</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">16313886</pub-id></mixed-citation></ref><ref id="b97-cin-2009-123"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangala</surname><given-names>LS</given-names></name><name><surname>Arun</surname><given-names>B</given-names></name><name><surname>Sahin</surname><given-names>AA</given-names></name><name><surname>Mehta</surname><given-names>K</given-names></name></person-group><article-title>Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion</article-title><source>Mol Cancer</source><year>2005</year><volume>4</volume><fpage>33</fpage><pub-id pub-id-type="pmid">16153302</pub-id></mixed-citation></ref><ref id="b98-cin-2009-123"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Begum</surname><given-names>S</given-names></name><name><surname>Hearn</surname><given-names>JD</given-names></name><name><surname>Hynes</surname><given-names>RO</given-names></name></person-group><article-title>GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis</article-title><source>Proc Natl Acad Sci U S A</source><year>2006</year><volume>103</volume><issue>24</issue><fpage>9023</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16757564</pub-id></mixed-citation></ref><ref id="b99-cin-2009-123"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goke</surname><given-names>R</given-names></name><name><surname>Barth</surname><given-names>P</given-names></name><name><surname>Schmidt</surname><given-names>A</given-names></name><name><surname>Samans</surname><given-names>B</given-names></name><name><surname>Lankat-Buttgereit</surname><given-names>B</given-names></name></person-group><article-title>Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1)</article-title><source>Am J Physiol Cell Physiol</source><year>2004</year><volume>287</volume><issue>6</issue><fpage>C1541</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15317660</pub-id></mixed-citation></ref><ref id="b100-cin-2009-123"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>TH</given-names></name><name><surname>Hwang</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Aerosol delivery of urocanic acid-modified chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle, and angiogenesis in lungs of K-ras null mice</article-title><source>Mol Cancer Ther</source><year>2006</year><volume>5</volume><issue>4</issue><fpage>1041</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16648576</pub-id></mixed-citation></ref><ref id="b101-cin-2009-123"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>T</given-names></name><name><surname>Jansen</surname><given-names>AP</given-names></name><name><surname>Baker</surname><given-names>AR</given-names></name><name><surname>Hegamyer</surname><given-names>G</given-names></name><name><surname>Hagan</surname><given-names>JP</given-names></name><name><surname>Colburn</surname><given-names>NH</given-names></name></person-group><article-title>Translation inhibitor Pdcd4 is targeted for degradation during tumor promotion</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><issue>5</issue><fpage>1254</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">18296647</pub-id></mixed-citation></ref><ref id="b102-cin-2009-123"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>HS</given-names></name></person-group><article-title>Downregulation of tumor suppressor Pdcd4 promotes invasion and activates both beta-catenin/Tcf and AP-1-dependent transcription in colon carcinoma cells</article-title><source>Oncogene</source><year>2008</year><volume>27</volume><issue>11</issue><fpage>1527</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">17828298</pub-id></mixed-citation></ref><ref id="b103-cin-2009-123"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>HS</given-names></name><name><surname>Matthews</surname><given-names>CP</given-names></name><name><surname>Clair</surname><given-names>T</given-names></name><etal/></person-group><article-title>Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion</article-title><source>Mol Cell Biol</source><year>2006</year><volume>26</volume><issue>4</issue><fpage>1297</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">16449643</pub-id></mixed-citation></ref><ref id="b104-cin-2009-123"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lankat-Buttgereit</surname><given-names>B</given-names></name><name><surname>Lenschen</surname><given-names>B</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Goke</surname><given-names>R</given-names></name></person-group><article-title>The action of Pdcd4 may be cell type specific: evidence that reduction of dUTPase levels might contribute to its tumor suppressor activity in Bon-1 cells</article-title><source>Apoptosis</source><year>2008</year><volume>13</volume><issue>1</issue><fpage>157</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">17955371</pub-id></mixed-citation></ref><ref id="b105-cin-2009-123"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holte</surname><given-names>RC</given-names></name></person-group><article-title>Very simple classification rules perform well on most commonly used datasets</article-title><source>Machine Learning</source><year>1993</year><fpage>63</fpage><lpage>91</lpage></mixed-citation></ref><ref id="b106-cin-2009-123"><label>106</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Witten</surname><given-names>IH</given-names></name><name><surname>Frank</surname><given-names>E</given-names></name></person-group><source>Data mining: practical machine learning tools and techniques</source><edition>second edition</edition><publisher-name>Morgan Kaufmann</publisher-name><year>2005</year></mixed-citation></ref><ref id="b107-cin-2009-123"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Makedon</surname><given-names>FS</given-names></name><name><surname>Ford</surname><given-names>JC</given-names></name><name><surname>Pearlman</surname><given-names>J</given-names></name></person-group><article-title>HykGene: a hybrid approach for selecting marker genes for phenotype classification using microarray gene expression data</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><issue>8</issue><fpage>1530</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15585531</pub-id></mixed-citation></ref><ref id="b108-cin-2009-123"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antoniadis</surname><given-names>A</given-names></name><name><surname>Lambert-Lacroix</surname><given-names>S</given-names></name><name><surname>Leblanc</surname><given-names>F</given-names></name></person-group><article-title>Effective dimension reduction methods for tumor classification using gene expression data</article-title><source>Bioinformatics</source><year>2003</year><volume>19</volume><issue>5</issue><fpage>563</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">12651713</pub-id></mixed-citation></ref><ref id="b109-cin-2009-123"><label>109</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Miao</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name></person-group><article-title>Gene Selection with Rough Sets for Cancer Classification</article-title><conf-name>Fourth International Conference on Fuzzy Systems and Knowledge Discovery</conf-name><year>2007</year><fpage>167</fpage><lpage>72</lpage></mixed-citation></ref><ref id="b110-cin-2009-123"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name></person-group><article-title>Minimum redundancy feature selection from microarray gene expression data</article-title><source>J Bioinform Comput Biol</source><year>2005</year><volume>3</volume><issue>2</issue><fpage>185</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">15852500</pub-id></mixed-citation></ref><ref id="b111-cin-2009-123"><label>111</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name></person-group><article-title>Redundancy Based Feature Selection for Microarray Data</article-title><conf-name>the tenth ACM SIGKDD international conference on Knowledge discovery and data mining</conf-name><conf-date>2004</conf-date><year>2004</year><fpage>737</fpage><lpage>42</lpage></mixed-citation></ref></ref-list></back><floats-group><table-wrap id="t1-cin-2009-123" position="float"><label>Table 1</label><caption><p>6 genes with high prediction accuracy in the CNS tumor dataset.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Probe ID</th><th align="center" rowspan="1" colspan="1">Correctly-classified sample number (accuracy)</th><th align="center" rowspan="1" colspan="1">&#x003b1;</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">U28963_at</td><td align="center" rowspan="1" colspan="1">47 (78%)</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">X99050_rna1_at</td><td align="center" rowspan="1" colspan="1">45 (75%)</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">D83542_at</td><td align="center" rowspan="1" colspan="1">46 (77%)</td><td align="center" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">S71824_at</td><td align="center" rowspan="1" colspan="1">50 (83%)</td><td align="center" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">U37673_at</td><td align="center" rowspan="1" colspan="1">40 (67%)</td><td align="center" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">D86974_at</td><td align="center" rowspan="1" colspan="1">45 (75%)</td><td align="center" rowspan="1" colspan="1">0.7</td></tr></tbody></table></table-wrap><table-wrap id="t2-cin-2009-123" position="float"><label>Table 2</label><caption><p>11 gene pairs with high prediction accuracy in the CNS tumor dataset.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">1st &#x02013; 2nd Probe ID</th><th align="center" rowspan="1" colspan="1">Correctly-classified sample number (accuracy)</th><th align="center" rowspan="1" colspan="1">&#x003b1;</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">D83542_at&#x02013;S71824_at</td><td align="center" rowspan="1" colspan="1">54 (90%)</td><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">D31763_at&#x02013;U08998_at</td><td align="center" rowspan="1" colspan="1">54 (90%)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">D83542_at&#x02013;X99050_rna1_at</td><td align="center" rowspan="1" colspan="1">49 (82%)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">D83542_at&#x02013;D86974_at</td><td align="center" rowspan="1" colspan="1">52 (87%)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">L33243_at&#x02013;U36448_at</td><td align="center" rowspan="1" colspan="1">52 (87%)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">M73547_at&#x02013;U74324_at</td><td align="center" rowspan="1" colspan="1">51 (85%)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">M96739_at&#x02013;U36448_at</td><td align="center" rowspan="1" colspan="1">54 (90%)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">S71824_at&#x02013;D86974_at</td><td align="center" rowspan="1" colspan="1">51 (85%)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">U37143_at&#x02013;D43682_s_at</td><td align="center" rowspan="1" colspan="1">48 (80%)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">U79277_at&#x02013;D43682_s_at</td><td align="center" rowspan="1" colspan="1">47 (78%)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">X99050_rna1_at&#x02013;D86974_at</td><td align="center" rowspan="1" colspan="1">49 (82%)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr></tbody></table></table-wrap><table-wrap id="t3-cin-2009-123" position="float"><label>Table 3</label><caption><p>21 genes with high prediction accuracy in the colon tumor dataset.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">GenBank accession no.</th><th align="center" rowspan="1" colspan="1">Correctly-classified sample number (accuracy)</th><th align="center" rowspan="1" colspan="1">&#x003b1;</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">M63391</td><td align="center" rowspan="1" colspan="1">52 (84%)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">M76378</td><td align="center" rowspan="1" colspan="1">50 (81%)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">J02854</td><td align="center" rowspan="1" colspan="1">50 (81%)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">M26383</td><td align="center" rowspan="1" colspan="1">52 (84%)</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">M76378</td><td align="center" rowspan="1" colspan="1">50 (81%)</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">T60155</td><td align="center" rowspan="1" colspan="1">48 (77%)</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">M22382</td><td align="center" rowspan="1" colspan="1">50 (81%)</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">X12671</td><td align="center" rowspan="1" colspan="1">49 (79%)</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">M76378</td><td align="center" rowspan="1" colspan="1">50 (81%)</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">T96873</td><td align="center" rowspan="1" colspan="1">47 (76%)</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">X86693</td><td align="center" rowspan="1" colspan="1">47 (76%)</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">J05032</td><td align="center" rowspan="1" colspan="1">50 (81%)</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">U25138</td><td align="center" rowspan="1" colspan="1">48 (77%)</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">T60778</td><td align="center" rowspan="1" colspan="1">47 (76%)</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">M91463</td><td align="center" rowspan="1" colspan="1">48 (77%)</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">R87126</td><td align="center" rowspan="1" colspan="1">51 (82%)</td><td align="left" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">T51571</td><td align="center" rowspan="1" colspan="1">46 (74%)</td><td align="left" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">T92451</td><td align="center" rowspan="1" colspan="1">48 (77%)</td><td align="left" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">U09564</td><td align="center" rowspan="1" colspan="1">48 (77%)</td><td align="left" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">R97912</td><td align="center" rowspan="1" colspan="1">45 (73%)</td><td align="left" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">L41559</td><td align="center" rowspan="1" colspan="1">45 (73%)</td><td align="left" rowspan="1" colspan="1">0.7</td></tr></tbody></table></table-wrap><table-wrap id="t4-cin-2009-123" position="float"><label>Table 4</label><caption><p>16 gene pairs with high prediction accuracy in the colon tumor-dataset.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">1st &#x02013; 2nd GenBank accession no.</th><th align="center" rowspan="1" colspan="1">Correctly-classified sample number (accuracy)</th><th align="center" rowspan="1" colspan="1">&#x003b1;</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">T51571&#x02013;J02854</td><td align="center" rowspan="1" colspan="1">56 (90%)</td><td align="left" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">J02854&#x02013;L41559</td><td align="center" rowspan="1" colspan="1">56 (90%)</td><td align="left" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">M76378&#x02013;M63391</td><td align="center" rowspan="1" colspan="1">52 (84%)</td><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">M63391&#x02013;M76378</td><td align="center" rowspan="1" colspan="1">52 (84%)</td><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">M63391&#x02013;Z49269</td><td align="center" rowspan="1" colspan="1">45 (73%)</td><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">M63391&#x02013;X86693</td><td align="center" rowspan="1" colspan="1">53 (85%)</td><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">Z50753&#x02013;H40095</td><td align="center" rowspan="1" colspan="1">55 (89%)</td><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">R87126&#x02013;H81068</td><td align="center" rowspan="1" colspan="1">55 (89%)</td><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">X12671&#x02013;J02854</td><td align="center" rowspan="1" colspan="1">56 (90%)</td><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">X12671&#x02013;M26383</td><td align="center" rowspan="1" colspan="1">54 (87%)</td><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">M76378&#x02013;M26383</td><td align="center" rowspan="1" colspan="1">55 (89%)</td><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">H40095&#x02013;M36634</td><td align="center" rowspan="1" colspan="1">54 (87%)</td><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">R97912&#x02013;J02854</td><td align="center" rowspan="1" colspan="1">55 (89%)</td><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">R97912&#x02013;M26383</td><td align="center" rowspan="1" colspan="1">54 (87%)</td><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">R06601&#x02013;X63629</td><td align="center" rowspan="1" colspan="1">54 (87%)</td><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">M36634&#x02013;H08393</td><td align="center" rowspan="1" colspan="1">56 (90%)</td><td align="left" rowspan="1" colspan="1">0.85</td></tr></tbody></table></table-wrap><table-wrap id="t5-cin-2009-123" position="float"><label>Table 5</label><caption><p>8 genes with high prediction accuracy in the lung cancer dataset.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Unigene ID</th><th align="center" rowspan="1" colspan="1">Correctly-classified sample number (accuracy)</th><th align="center" rowspan="1" colspan="1">&#x003b1;</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">505266<xref ref-type="table-fn" rid="tfn1-cin-2009-123">a</xref></td><td align="center" rowspan="1" colspan="1">32 (82%)</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Hs.95243</td><td align="center" rowspan="1" colspan="1">32 (82%)</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Hs.25882</td><td align="center" rowspan="1" colspan="1">32 (82%)</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Hs.275198</td><td align="center" rowspan="1" colspan="1">32 (82%)</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">36491<xref ref-type="table-fn" rid="tfn1-cin-2009-123">a</xref></td><td align="center" rowspan="1" colspan="1">32 (82%)</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Hs.170225</td><td align="center" rowspan="1" colspan="1">33 (85%)</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Hs.17258</td><td align="center" rowspan="1" colspan="1">29 (74%)</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Hs.11556</td><td align="center" rowspan="1" colspan="1">31 (79%)</td><td align="center" rowspan="1" colspan="1">0.75</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-cin-2009-123"><label>a</label><p>The Unigene ID is not available.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t6-cin-2009-123" position="float"><label>Table 6</label><caption><p>8 gene pairs with high prediction accuracy in the lung cancer dataset.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">1st &#x02013; 2nd Unigene ID</th><th align="center" rowspan="1" colspan="1">Correctly-classified sample number (accuracy)</th><th align="center" rowspan="1" colspan="1">&#x003b1;</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Hs.169611&#x02013;Hs.285701</td><td align="center" rowspan="1" colspan="1">31 (79%)</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Hs.285701&#x02013;Hs.132415</td><td align="center" rowspan="1" colspan="1">29 (74%)</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Hs.285701&#x02013;Hs.57655</td><td align="center" rowspan="1" colspan="1">30 (77%)</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Hs.57655&#x02013;Hs.8595</td><td align="center" rowspan="1" colspan="1">31 (79%)</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Hs.184542&#x02013;Hs.58323</td><td align="center" rowspan="1" colspan="1">31 (79%)</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Hs.262823&#x02013;Hs.8595</td><td align="center" rowspan="1" colspan="1">31 (79%)</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Hs.262480&#x02013;Hs.772</td><td align="center" rowspan="1" colspan="1">32 (82%)</td><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Hs.112193&#x02013;505266<sup>a</sup></td><td align="center" rowspan="1" colspan="1">31 (79%)</td><td align="center" rowspan="1" colspan="1">0.75</td></tr></tbody></table></table-wrap><table-wrap id="t7-cin-2009-123" position="float"><label>Table 7</label><caption><p>4 genes with high prediction accuracy in the DLBCL dataset.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Probe ID</th><th align="center" rowspan="1" colspan="1">Correctly-classified sample number (accuracy)</th><th align="center" rowspan="1" colspan="1">&#x003b1;</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">U70663_at</td><td align="center" rowspan="1" colspan="1">44 (76%)</td><td align="center" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">M17863_s_at</td><td align="center" rowspan="1" colspan="1">44 (76%)</td><td align="center" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">U48865_s_at</td><td align="center" rowspan="1" colspan="1">43 (74%)</td><td align="center" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">U90543_at</td><td align="center" rowspan="1" colspan="1">45 (78%)</td><td align="center" rowspan="1" colspan="1">0.7</td></tr></tbody></table></table-wrap><table-wrap id="t8-cin-2009-123" position="float"><label>Table 8</label><caption><p>20 gene pairs with high prediction accuracy in the DLBCL dataset.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">1st &#x02013; 2nd Probe ID</th><th align="center" rowspan="1" colspan="1">Correctly-classified sample number (accuracy)</th><th align="center" rowspan="1" colspan="1">&#x003b1;</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">AFFX-BioC-3_at&#x02013;M95925_at</td><td align="center" rowspan="1" colspan="1">46 (79%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">AFFX-BioC-3_at&#x02013;U70663_at</td><td align="center" rowspan="1" colspan="1">48 (83%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">AFFX-M27830_5_at &#x02013; X70811_at</td><td align="center" rowspan="1" colspan="1">49 (84%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">AFFX-M27830_5_at &#x02013; U46744_at</td><td align="center" rowspan="1" colspan="1">49 (84%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">AC002450_at&#x02013;M95925_at</td><td align="center" rowspan="1" colspan="1">47 (81%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">AC002450_at&#x02013;U48213_at</td><td align="center" rowspan="1" colspan="1">47 (81%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">AC002450_at&#x02013;HG4020-HT4290_s_at</td><td align="center" rowspan="1" colspan="1">48 (83%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">M95925_at&#x02013;X70811_at</td><td align="center" rowspan="1" colspan="1">46 (79%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">U23028_at&#x02013;U70663_at</td><td align="center" rowspan="1" colspan="1">47 (81%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">U23028_at&#x02013;X70811_at</td><td align="center" rowspan="1" colspan="1">48 (83%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">U51903_at&#x02013;U70663_at</td><td align="center" rowspan="1" colspan="1">48 (83%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">U51903_at&#x02013;X70811_at</td><td align="center" rowspan="1" colspan="1">47 (81%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">U66702_at&#x02013;U70663_at</td><td align="center" rowspan="1" colspan="1">47 (81%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">U66702_at&#x02013;HG4020-HT4290_s_at</td><td align="center" rowspan="1" colspan="1">48 (83%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">U66702_at&#x02013;U90543_at</td><td align="center" rowspan="1" colspan="1">52 (90%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">U70663_at&#x02013;U83908_at</td><td align="center" rowspan="1" colspan="1">47 (81%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">U70663_at&#x02013;X83412_at</td><td align="center" rowspan="1" colspan="1">46 (79%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">U70663_at&#x02013;X77777_s_at</td><td align="center" rowspan="1" colspan="1">47 (81%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">U70663_at&#x02013;X16660_cds1_s_at</td><td align="center" rowspan="1" colspan="1">46 (79%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">U70663_at&#x02013;U46744_at</td><td align="center" rowspan="1" colspan="1">47 (81%)</td><td align="center" rowspan="1" colspan="1">0.8</td></tr></tbody></table></table-wrap><table-wrap id="t9-cin-2009-123" position="float"><label>Table 9</label><caption><p>Comparison of best prediction accuracy for the CNS tumor dataset.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Methods (feature selection + classification)<xref ref-type="table-fn" rid="tfn2-cin-2009-123">b</xref></th><th align="center" rowspan="1" colspan="1"># Selected genes</th><th align="center" rowspan="1" colspan="1"># Correctly-classified samples (accuracy)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>&#x003b1;</italic> depended degree + decision rules</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">50 (83%)</td></tr><tr><td align="left" rowspan="1" colspan="1">[this work]</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">54 (90%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Signal to noise ratios + k-NNs<xref ref-type="bibr" rid="b19-cin-2009-123">19</xref></td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">47 (78%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Signal to noise ratios + Weighted voting<xref ref-type="bibr" rid="b19-cin-2009-123">19</xref></td><td align="center" rowspan="1" colspan="1">1&#x02013;200</td><td align="center" rowspan="1" colspan="1">46 (77%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Signal to noise ratios + SVMs<xref ref-type="bibr" rid="b19-cin-2009-123">19</xref></td><td align="center" rowspan="1" colspan="1">150</td><td align="center" rowspan="1" colspan="1">45 (75%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Signal to noise ratios + SPLASH<xref ref-type="bibr" rid="b19-cin-2009-123">19</xref></td><td align="center" rowspan="1" colspan="1">1&#x02013;200</td><td align="center" rowspan="1" colspan="1">45 (75%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Signal to noise ratios + TrkC<xref ref-type="bibr" rid="b19-cin-2009-123">19</xref></td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">40 (67%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Signal to noise ratios + Staging<xref ref-type="bibr" rid="b19-cin-2009-123">19</xref></td><td align="center" rowspan="1" colspan="1">1&#x02013;200</td><td align="center" rowspan="1" colspan="1">41 (68%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Signal to noise ratios + staging, k-NNs and TrkC<xref ref-type="bibr" rid="b19-cin-2009-123">19</xref></td><td align="center" rowspan="1" colspan="1">1&#x02013;200</td><td align="center" rowspan="1" colspan="1">48 (80%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Signal to noise ratios + SVM, k-NNs and TrkC<xref ref-type="bibr" rid="b19-cin-2009-123">19</xref></td><td align="center" rowspan="1" colspan="1">1&#x02013;200</td><td align="center" rowspan="1" colspan="1">48 (80%)</td></tr><tr><td align="left" rowspan="1" colspan="1">HFW + C4.5<xref ref-type="bibr" rid="b20-cin-2009-123">20</xref></td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">45 (75%)</td></tr><tr><td align="left" rowspan="1" colspan="1">HFW + NaiveBayes<xref ref-type="bibr" rid="b20-cin-2009-123">20</xref></td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">52 (86.67%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Discretization + Single C4.5<xref ref-type="bibr" rid="b12-cin-2009-123">12</xref></td><td align="center" rowspan="1" colspan="1">74<xref ref-type="table-fn" rid="tfn3-cin-2009-123">c</xref></td><td align="center" rowspan="1" colspan="1">51 (85%)<xref ref-type="table-fn" rid="tfn4-cin-2009-123">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Discretization + Bagging C4.5<xref ref-type="bibr" rid="b12-cin-2009-123">12</xref></td><td align="center" rowspan="1" colspan="1">74<xref ref-type="table-fn" rid="tfn3-cin-2009-123">c</xref></td><td align="center" rowspan="1" colspan="1">53 (88%)<xref ref-type="table-fn" rid="tfn4-cin-2009-123">d</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Discretization + AdaBoost C4.5<xref ref-type="bibr" rid="b12-cin-2009-123">12</xref></td><td align="center" rowspan="1" colspan="1">74<xref ref-type="table-fn" rid="tfn3-cin-2009-123">c</xref></td><td align="center" rowspan="1" colspan="1">53 (88%)<xref ref-type="table-fn" rid="tfn4-cin-2009-123">d</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn2-cin-2009-123"><label>b</label><p>The methods include two sections: feature selection methods and classification methods. The decision trees classification methods are also involved in feature selection.</p></fn><fn id="tfn3-cin-2009-123"><label>c</label><p>74 is the number of the genes withheld for the actual learning process instead of the number of the genes contained in the decision trees, which is not provided in.<xref ref-type="bibr" rid="b12-cin-2009-123">12</xref></p></fn><fn id="tfn4-cin-2009-123"><label>d</label><p>Tenfold cross-validation accuracy is provided.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t10-cin-2009-123" position="float"><label>Table 10</label><caption><p>Comparison of best prediction accuracy for the colon tumor dataset.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Methods (feature selection + classification)</th><th align="center" rowspan="1" colspan="1"># Selected genes</th><th align="center" rowspan="1" colspan="1"># Correctly-classified samples (accuracy)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>&#x003b1;</italic> depended degree + decision rules</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">52 (84%)</td></tr><tr><td align="left" rowspan="1" colspan="1">[this work]</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">56 (90%)</td></tr><tr><td align="left" rowspan="1" colspan="1">HykGene + k-NNs, SVMs, C4.5, NB<xref ref-type="bibr" rid="b107-cin-2009-123">107</xref></td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">57 (92%)</td></tr><tr><td align="left" rowspan="1" colspan="1">MAVE + logistic discrimination<xref ref-type="bibr" rid="b108-cin-2009-123">108</xref></td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">52 (84%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Clustering and rough sets attribute reduction + k-NNs<xref ref-type="bibr" rid="b109-cin-2009-123">109</xref></td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">49 (79%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Clustering and rough sets attribute reduction + NB<xref ref-type="bibr" rid="b109-cin-2009-123">109</xref></td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">51 (82%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Clustering and rough sets attribute reduction + C5.0<xref ref-type="bibr" rid="b109-cin-2009-123">109</xref></td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">56 (90%)</td></tr><tr><td align="left" rowspan="1" colspan="1">MRMR + NB<xref ref-type="bibr" rid="b110-cin-2009-123">110</xref></td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">58 (94%)</td></tr><tr><td align="left" rowspan="1" colspan="1">RBF + C4.5<xref ref-type="bibr" rid="b111-cin-2009-123">111</xref></td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">58 (94%)</td></tr><tr><td align="left" rowspan="1" colspan="1">ReliefF + C4.5<xref ref-type="bibr" rid="b111-cin-2009-123">111</xref></td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">53 (85%)</td></tr><tr><td align="left" rowspan="1" colspan="1">CFS-SF + C4.5<xref ref-type="bibr" rid="b111-cin-2009-123">111</xref></td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">55 (89%)</td></tr></tbody></table></table-wrap><table-wrap id="t11-cin-2009-123" position="float"><label>Table 11</label><caption><p>Comparison of best prediction accuracy for the lung cancer dataset.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Methods (feature selection + classification)</th><th align="center" rowspan="1" colspan="1"># Selected genes</th><th align="center" rowspan="1" colspan="1"># Correctly-classified samples (accuracy)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>&#x003b1;</italic> depended degree + decision rules</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">33 (85%)</td></tr><tr><td align="left" rowspan="1" colspan="1">[this work]</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">32 (82%)</td></tr><tr><td align="left" rowspan="1" colspan="1">HFW + C4.5<xref ref-type="bibr" rid="b20-cin-2009-123">20</xref></td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">35 (90%)</td></tr><tr><td align="left" rowspan="1" colspan="1">HFW + NaiveBayes<xref ref-type="bibr" rid="b20-cin-2009-123">20</xref></td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">35 (90%)</td></tr><tr><td align="left" rowspan="1" colspan="1">FCBF + C4.5<xref ref-type="bibr" rid="b20-cin-2009-123">20</xref></td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">31 (79%)</td></tr><tr><td align="left" rowspan="1" colspan="1">FCBF + NaiveBayes<xref ref-type="bibr" rid="b20-cin-2009-123">20</xref></td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">24 (62%)</td></tr><tr><td align="left" rowspan="1" colspan="1">CFS-SF + C4.5<xref ref-type="bibr" rid="b20-cin-2009-123">20</xref></td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">26 (67%)</td></tr><tr><td align="left" rowspan="1" colspan="1">CFS-SF + NaiveBayes<xref ref-type="bibr" rid="b20-cin-2009-123">20</xref></td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">24 (62%)</td></tr><tr><td align="left" rowspan="1" colspan="1">ReliefF + C4.5<xref ref-type="bibr" rid="b20-cin-2009-123">20</xref></td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">24 (62%)</td></tr><tr><td align="left" rowspan="1" colspan="1">ReliefF + NaiveBayes<xref ref-type="bibr" rid="b20-cin-2009-123">20</xref></td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">25 (64%)</td></tr></tbody></table></table-wrap><table-wrap id="t12-cin-2009-123" position="float"><label>Table 12</label><caption><p>Comparison of best prediction accuracy for the DLBCL dataset.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Methods (feature selection + classification)</th><th align="center" rowspan="1" colspan="1"># Selected genes</th><th align="center" rowspan="1" colspan="1"># Correctly-classified samples (accuracy)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">&#x003b1; depended degree + decision rules</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">48 (78%)</td></tr><tr><td align="left" rowspan="1" colspan="1">[this work]</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">52 (90%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Signal to noise ratios + Weighted voting<xref ref-type="bibr" rid="b24-cin-2009-123">24</xref></td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">44 (76%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Signal to noise ratios + k-NNs<xref ref-type="bibr" rid="b24-cin-2009-123">24</xref></td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">41 (71%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gradient descent algorithm + SVMs<xref ref-type="bibr" rid="b24-cin-2009-123">24</xref></td><td align="center" rowspan="1" colspan="1">unknown<xref ref-type="table-fn" rid="tfn5-cin-2009-123">e</xref></td><td align="center" rowspan="1" colspan="1">45 (78%)</td></tr><tr><td align="left" rowspan="1" colspan="1">HFW + C4.5<xref ref-type="bibr" rid="b20-cin-2009-123">20</xref></td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">44 (76%)</td></tr><tr><td align="left" rowspan="1" colspan="1">HFW + NaiveBayes<xref ref-type="bibr" rid="b20-cin-2009-123">20</xref></td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">50 (86%)</td></tr><tr><td align="left" rowspan="1" colspan="1">FCBF + C4.5<xref ref-type="bibr" rid="b20-cin-2009-123">20</xref></td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">27 (47%)</td></tr><tr><td align="left" rowspan="1" colspan="1">FCBF + NaiveBayes<xref ref-type="bibr" rid="b20-cin-2009-123">20</xref></td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">31 (53%)</td></tr><tr><td align="left" rowspan="1" colspan="1">ReliefF + C4.5<xref ref-type="bibr" rid="b20-cin-2009-123">20</xref></td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">25 (43%)</td></tr><tr><td align="left" rowspan="1" colspan="1">ReliefF + NaiveBayes<xref ref-type="bibr" rid="b20-cin-2009-123">20</xref></td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">31 (53%)</td></tr></tbody></table><table-wrap-foot><fn id="tfn5-cin-2009-123"><label>e</label><p>No related data is provided.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t13-cin-2009-123" position="float"><label>Table 13</label><caption><p>Microarray data decision table.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Samples</th><th colspan="4" align="center" rowspan="1">Condition attributes (genes)

<hr/></th><th align="center" rowspan="1" colspan="1">Decision attributes (classes)
<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Gene 1</th><th align="center" rowspan="1" colspan="1">Gene 2</th><th align="center" rowspan="1" colspan="1">&#x02026;</th><th align="center" rowspan="1" colspan="1">Gene <italic>n</italic></th><th align="center" rowspan="1" colspan="1">Class label</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"><italic>g</italic> (1, 1)</td><td align="center" rowspan="1" colspan="1"><italic>g</italic> (1, 2)</td><td align="center" rowspan="1" colspan="1"><italic>&#x02026;</italic></td><td align="center" rowspan="1" colspan="1"><italic>g</italic> (1, <italic>n</italic>)</td><td align="center" rowspan="1" colspan="1"><italic>Class</italic> (1)</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1"><italic>g</italic> (2, 1)</td><td align="center" rowspan="1" colspan="1"><italic>g</italic> (2, 2)</td><td align="center" rowspan="1" colspan="1"><italic>&#x02026;</italic></td><td align="center" rowspan="1" colspan="1"><italic>g</italic> (2, <italic>n</italic>)</td><td align="center" rowspan="1" colspan="1"><italic>Class</italic> (2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1"><italic>&#x02026;</italic></td><td align="center" rowspan="1" colspan="1"><italic>&#x02026;</italic></td><td align="center" rowspan="1" colspan="1"><italic>&#x02026;</italic></td><td align="center" rowspan="1" colspan="1"><italic>&#x02026;</italic></td><td align="center" rowspan="1" colspan="1"><italic>&#x02026;</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1"><italic>&#x02026;</italic></td><td align="center" rowspan="1" colspan="1"><italic>&#x02026;</italic></td><td align="center" rowspan="1" colspan="1"><italic>&#x02026;</italic></td><td align="center" rowspan="1" colspan="1"><italic>&#x02026;</italic></td><td align="center" rowspan="1" colspan="1"><italic>&#x02026;</italic></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>m</italic></td><td align="center" rowspan="1" colspan="1"><italic>g</italic> (<italic>m</italic>, 1)</td><td align="center" rowspan="1" colspan="1"><italic>g</italic> (<italic>m</italic>, 2)</td><td align="center" rowspan="1" colspan="1"><italic>&#x02026;</italic></td><td align="center" rowspan="1" colspan="1"><italic>g</italic> (<italic>m, n</italic>)</td><td align="center" rowspan="1" colspan="1"><italic>Class</italic> (<italic>m</italic>)</td></tr></tbody></table></table-wrap><table-wrap id="t14-cin-2009-123" position="float"><label>Table 14</label><caption><p>Summary of the four gene expression datasets.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Dataset</th><th align="center" rowspan="1" colspan="1"># Original genes</th><th align="center" rowspan="1" colspan="1">Class</th><th align="center" rowspan="1" colspan="1"># Samples</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CNS Tumor</td><td align="center" rowspan="1" colspan="1">7129</td><td align="center" rowspan="1" colspan="1">Class 1/Class 0</td><td align="center" rowspan="1" colspan="1">60 (21/39)</td></tr><tr><td align="left" rowspan="1" colspan="1">Colon Tumor</td><td align="center" rowspan="1" colspan="1">2000</td><td align="center" rowspan="1" colspan="1">negative/positive</td><td align="center" rowspan="1" colspan="1">62 (40/22)</td></tr><tr><td align="left" rowspan="1" colspan="1">Lung Cancer</td><td align="center" rowspan="1" colspan="1">2880</td><td align="center" rowspan="1" colspan="1">relapse/non-relapse</td><td align="center" rowspan="1" colspan="1">39 (24/15)</td></tr><tr><td align="left" rowspan="1" colspan="1">DLBCL</td><td align="center" rowspan="1" colspan="1">6817</td><td align="center" rowspan="1" colspan="1">cured/fatal</td><td align="center" rowspan="1" colspan="1">58 (32/26)</td></tr></tbody></table></table-wrap><table-wrap id="t15-cin-2009-123" position="float"><label>Table 15</label><caption><p>Discretized CNS tumor decision table with the first sample left out.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Samples</th><th colspan="7" align="center" rowspan="1">Condition attributes (genes)<xref ref-type="table-fn" rid="tfn6-cin-2009-123">f</xref><hr/></th><th align="center" rowspan="1" colspan="1">Decision attributes (classes)

<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Gene 1</th><th align="center" rowspan="1" colspan="1">&#x02026;</th><th align="center" rowspan="1" colspan="1">Gene 11</th><th align="center" rowspan="1" colspan="1">&#x02026;</th><th align="center" rowspan="1" colspan="1">Gene 18</th><th align="center" rowspan="1" colspan="1">&#x02026;</th><th align="center" rowspan="1" colspan="1">Gene 7129</th><th align="center" rowspan="1" colspan="1">Class label</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02018;All&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;(-inf-187]&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;(&#x02212;330-inf]&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;All&#x02019;</td><td align="center" rowspan="1" colspan="1">Class 1</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">&#x02018;All&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;(-inf-187]&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;(&#x02212;330-inf]&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;All&#x02019;</td><td align="center" rowspan="1" colspan="1">Class 1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">&#x02018;All&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;(-inf-187]&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;(&#x02212;330-inf]&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;All&#x02019;</td><td align="center" rowspan="1" colspan="1">Class 1</td></tr><tr><td align="left" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">&#x02018;All&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;(-inf-187]&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;(&#x02212;330-inf]&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;All&#x02019;</td><td align="center" rowspan="1" colspan="1">Class 0</td></tr><tr><td align="left" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">&#x02018;All&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;(187-inf]&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;(&#x02212;330-inf]&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;All&#x02019;</td><td align="center" rowspan="1" colspan="1">Class 0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">&#x02018;All&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;(-inf-187]&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;(-inf&#x02212;330]&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;All&#x02019;</td><td align="center" rowspan="1" colspan="1">Class 0</td></tr><tr><td align="left" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">&#x02018;All&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;(-inf-187]&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;(&#x02212;330-inf]&#x02019;</td><td align="center" rowspan="1" colspan="1">&#x02026;</td><td align="center" rowspan="1" colspan="1">&#x02018;All&#x02019;</td><td align="center" rowspan="1" colspan="1">Class 0</td></tr></tbody></table><table-wrap-foot><fn id="tfn6-cin-2009-123"><label>f</label><p>&#x02018;All&#x02019; represents that one gene has the same value in all samples; &#x02018;(-inf-x]&#x02019; represents &#x02018;&#x02264;x&#x02019;; &#x02018;(x-inf]&#x02019; represents &#x02018;&#x02264;x&#x02019;.</p></fn></table-wrap-foot></table-wrap></floats-group></article>

</pmc-articleset>
